O bs te tr ics C li ni c W orksh ee t (con ti n ue d)
Transcription
O bs te tr ics C li ni c W orksh ee t (con ti n ue d)
Medical Access Program Provider Handbook April 2016 TABLE OF CONTENTS Section 1: INTRODUCTION Section 2: ENROLLMENT AND DISCHARGE Section 3: COVERAGE VERIFICATION Section 4: CO-PAYMENTS, GROUPS AND PLANS Section 5: SERVICES AND AUTHORIZATIONS Section 6: HEALTH SERVICES Section 7: CCC CLINICAL PROTOCOLS Section 8: CONTRACTED PROVIDERS Section 9: CLAIMS Section 10: SPECIALTY CARE Section 11: PHARMACY SERVICES Section 12: COMMUNITY CARE — WOMEN’S HEALTH CENTER Section 13: QUICK REFERENCE: CONTACTS AND HELPFUL NUMBERS Section 14: FREQUENTLY ASKED QUESTIONS 1. INTRODUCTION Disclaimer Information in the Provider Handbook is current as of the date of release with revisions. All efforts are made to maintain the accuracy of the information found within. It is the responsibility of the provider to verify that the most current revision documents of the handbook are used for the provision of services. Medical Access Program Handbook The member manual contains useful information on the MAP Program and can be accessed using the link below Medical Access Program Handbook MAP Website http://www.medicalaccessprogram.net/ Central Health Eligibility Website http://www.cheligibility.net 2. ENROLLMENT ENROLLMENT ELIGIBILITY OFFICES COVERAGE MAP RENEWAL AND/OR EXPIRED COVERAGE CHANGE OF ADDRESS LOST MAP ID CARD CUSTOMER SERVICE CALL CENTER DISCHARGE FROM PRACTICE ENROLLMENT ELIGIBILITY OFFICES Visit the Central Health Eligibility website for a current listing of MAP eligibility offices, addresses, and phone numbers. http://www.cheligibility.net/en/sites/ COVERAGE MAP enrollees are given a pink identification card, which states the effective and expiration dates of coverage, co-payments, and other important information. The length of issuance for MAP coverage may range from one month to one year and is dependent on the enrollee’s circumstances as determined during the enrollment process. The MAP card does not guarantee coverage. Services, supplies, or equipment provided without active MAP coverage will not be reimbursed. :> To verify coverage, visit the Provider Self Service website at https://www9.medicaider.com/medicaid/manager/login.asp MAP RENEWAL and/or EXPIRED COVERAGE Enrollees are encouraged to call our Customer Service Call Center at (512) 978-8130 two to three (2-3) weeks in advance of her or his MAP expiration date to schedule an enrollment/eligibility appointment. CHANGE OF ADDRESS An enrollee should be referred to the Customer Service Call Center at (512) 978-8130 to report a change of address. LOST MAP ID CARD An enrollee should be referred to the Customer Service Call Center at (512) 9788130 to obtain a replacement MAP identification card. CUSTOMER SERVICE PHONE LINE The Medical Access Program Customer Service Call Center is available to enrollees and providers for benefit information, general information, setting eligibility appointments or reporting changes. The phone number is (512) 9788130. PROVIDER PRACTICE DISCHARGE NOTIFICATION PROCESS There are situations in which a Provider may discharge a MAP Enrollee from their medical practice. If a provider has decided to discharge a patient from their practice, the provider should contact the MAP Customer Service number at 512978-8130 for instructions on how to notify all applicable parties during the discharge process. 3. COVERAGE VERIFICATION COVERAGE VERIFICATION How to read a MAP identification card The MAP card does not guarantee coverage. To verify coverage, visit the Provider Self Service at www.medicaider.com/medicaid/manager/start.asp. 1 2 4 6 8 3 5 7 9 10 3 7 9 MAP Card Legend 1. ID#: Enrollee’s Master Record Number. In this case, the MR# is 474238. 2. Group: This is the Group Identifier for the enrollee’s level of coverage issued. 3. Plan: This is the enrollee’s coverage plan type. 4. EFF: This is the effective date of the enrollee’s coverage. The format is MM/DD/YYYY. EXP: This is the expiration date of the enrollee’s coverage. The format is MM/DD/YYYY. 5. 6. This is where you will see the enrollee’s name. The format is first name, middle name, last name. 7. DOB: This is where you will see the enrollee’s date of birth. The format is M/D/YYYY. 8. CO-PAY: OP ($1o) IP ($3o) ER ($25): This is the co-pay amounts to be requested from the enrollee at time of service. In some exceptional cases an enrollee’s co-pay may be zero ($0). These cases will be documented at the time of an enrollment/eligibility interview and the zero co-pay printed on the ID card. For further information regarding co-payments, groups, and plans see section 4. 9. Dental: This is the co-pay amount to be requested from the enrollee at time of service. 10. RX: This is the co-pay amount to be requested from the enrollee per eligible prescription. In some exceptional cases an enrollee’s co-pay may be zero ($0). These cases will be documented at the time of an enrollment/eligibility interview and the zero co-pay printed on the ID card. Central Health Provider Self Service Registration & Instructions Provider Self Service Registration Section I Registering for Provider Self Service Step 1 To use the Provider Self-Service website, you must first register on the provider eligibility registration webpage. Generally, the turnaround time for the registration process is three business days. Using the most current version of Internet Explorer web browser, go to www.medicalaccessprogram.net. To access the website and its range of functions, you must use Internet Explorer version 9.0 or higher. Once you are on the main page for the Medical Access Program website, you must choose the tab labeled For Providers. Step 2 On the “For Providers” page, you will see a link called “Online Agreement and fill out the pre- registration form”. Click on the link, this will lead to the provider eligibility registration page. Step 3 Please read the Online Access Agreement for Provider Self Service and scroll to the bottom of the page to register. Please enter the requested information in the appropriate boxes. Once the information is entered completely, please click on the Submit button found at the bottom of the page. Once you submit your information, you will receive an email indicating there was a successful submission. You should receive two emails within three business days of a successful submission. One email will include: Your user name The CHASSIS Software Web Address Technical Support Provider Self-Service Instructions Reminders Second email will include: Your temporary password A reminder to change the temporary password upon first use Provider Self Service Instructions Section II Logging into CHASSIS Software Step 1 In order to access the Provider Self Service, you must use Internet Explorer verion 9.0 or higher. Go to the Provider Self Service log in page found in the email sent to you after registering. Type in your username and password. Step 2 Once you are on the Provider Self Service page, make sure the radio button, “Verify Eligibility” is selected. Step 3 Enter the client’s information into the provided fields. You must use a combination of information in order to obtain results. The combinations are listed below and are also found on the webpage itself. 1. 2. 3. 4. Last name, first name, birth date or Social Security Number and birth date or Social Security Number and last name or Master Record # (unique number assigned by an organization to identify a person) The date or date range of service is required in every search. Step 4 Viewing the client’s enrollment information Upper Right Hand: Client Information Master Record: Listed as the ID # on the MAP card; also known as an enrollment number, Name, Birth Date, Gender, Address, Phone Upper Left Hand: Search Information The information entered to reach this screen. Lower Portion of the screen: Program Eligibility Segment Dates: Effective Date, End Date, Certification Date Program: Details the type of medical benefits coverage the enrollee currently has along with the co-pay responsibilities of the enrollee Riders: Rider A indicates Dental benefits, Rider B indicates Prescription Drug benefits along with copays Fee Scale: Not Used PCP: Primary Care Provider enrollee is assigned Other: Not Used Step 5 Based on the search criteria entered if there is no match in the database the screen below will appear. When this screen is displayed there are two possible reasons why: 1. The client does not have current medical coverage during the date(s) of service entered or 2. The criteria entered on the Eligibility Verification Report page may have been entered incorrectly. Please return to the Eligibility Verification Report page using the Back button found on the lower portion of the screen in blue. Enter the correct information. Provider Self Service Instructions Section III Resetting Your Password Step 1 If you incorrectly enter your password on the first log on, you will receive this error message “Invalid User Name or Password”. Step 2 If you enter your password incorrectly a second time, a statement and hyperlink that states “Forgot your password?” “E-mail it to me” will appear on the screen. Click on the “Email it to me” hyperlink. Your password will be emailed to the email address you provided during the registration process. If you enter your password incorrectly a third time, you will lock yourself out of your Provider Self Service account. Then you will need to email [email protected] to request a reset of your account password. 4. CO-PAYMENTS, GROUPS, AND PLANS CO-PAYMENTS, GROUPS and PLANS The MAP card does not guarantee coverage. To verify coverage, visit the Provider Self Service website at www.medicaider.com/medicaid/manager/start.asp. GROUP CBRACKFQ CBRACKFQ PLAN CBRACKFQ CPENDSSI Out-patient Contract PCPs Contract Specialty Providers Urgent care In-patient Emergency Room Dental office visit Partial Dentures Full Dentures $1o co-pay or $o co-pay if noted on MAP card $1o co-pay or $o co-pay if noted on MAP card $3o co-pay or $o co-pay if noted on MAP card $25 co-pay or $o co-pay if noted on MAP card $1o co-pay or $o co-pay if noted on MAP card $35 per partial or $o co-pay if noted on MAP card $5o per plate or $o co-pay if noted on MAP card $3o co-pay or $o co-pay if noted on MAP card $25 co-pay or $o co-pay if noted on MAP card $1o co-pay or $o co-pay if noted on MAP card $35 per partial or $o co-pay if noted on MAP card $5o per plate or $o co-pay if noted on MAP card $7 co-pay for 1-3o day supply or $14 co-pay for 31-9o* day supply or $o co-pay if noted on MAP card $7 co-pay for 1-3o day supply or $14 co-pay for 31-9o* day supply or $o co-pay if noted on MAP card *90-day supply on selected drugs only *90-day supply on selected drugs only $1o co-pay for 1-30 day supply or $20 co-pay for 31-90* day supply or $o co-pay if noted on MAP card $1o co-pay for 1-30 day supply or $20 co-pay for 31-90* day supply or $o co-pay if noted on MAP card Pharmacy Formulary Non-Formulary 5. SERVICES AND AUTHORIZATIONS Medical Access Program SERVICES AND AUTHORIZATIONS Services Prior Authorizations Vasectomy Referrals Services and Authorization Matrix Seton Health Plan Pre-Certification Form Seton Health Plan Coverage Guidelines for Varicose Vein Referral Seton Health Plan Polysomnography — Sleep Study Authorization For m MAP Exclusions Services Community Care Collaborative (CCC) arranges for healthcare services for Travis County residents who are not eligible for other private or public insurance programs. To ensure a complement of services, Community Care Collaborative continues to evaluate services for MAP enrollees. Through contractual agreements, the Medical Access Program (MAP) provides access to health care through networks of established providers. The CCC is directly responsible for primary care services, dental services, and selected specialty services. The CCC contracts with Seton Health Plan (SHP) for hospital-based and specialty, diagnostic, durable medical equipment services, and home health services as well as utilization management which includes prior authorizations. :> See document entitled “Services and Authorizations Matrix.” :> Please visit www.setonhealthplan.com/providers/ for the latest version. Prior Authorizations Prior authorization is the process used to authorize designated medically necessary services. The majority of services do not require authorization. The primary care office submits the prior authorization request, which provides the medical information related to the services requested. The request is reviewed, and is authorized (approved) or denied. An authorization number is issued when a request is authorized. :> MAP Authorization Form: See documents entitled: D “Pre-Certification Form” D “Polysomnography — Sleep Study Authorization Form” D “Varicose Vein Referral (Coverage Guidelines)” :> Please visit www.setonhealthplan.com/providers/ for the latest version. Vasectomy Referrals Vasectomy is a covered service for MAP clients. MAP clients must be referred to The Urology Team for a vasectomy Referral Process: Primary Care Provider identifies an eligible MAP client who desires to have the procedure performed. MAP client is issued the Vasectomy Voucher by the Primary Care Provider. MAP client is responsible for calling The Urology Team at PH: (512) 231-1444 to schedule an appointment. MAP client is to present the Vasectomy Voucher at the time of the scheduled appointment at The Urology Team office. MAP Vasectomy Voucher: Services and Authorizations Matrix Services Acupuncture MAP NB Ambulance, Emergent ground D Ambulance, Non-emergent, ground P Ambulance, Non-emergent, air P Behavioral Health, Inpatient including substance abuse NB Behavioral Health, Outpatient - Office Visits for BH or Substance Abuse NB Behavioral Health, Outpatient - Intensive Outpatient Program NB Behavioral Health - Psychological Testing NB Behavioral Health - ECT (Electroconvulsive Therapy) NB Biofeedback NB Chemotherapy CPT code: 90870 D Chiropractic NB Cognitive Training / Retraining NB Cosmetic Surgery Notes P/NB Certain procedures are covered for medical necessity; prior authorization required in all cases Cyberknife and related pre-treatment imaging/services P Consultation and follow-up visit with Ron Wilson MD require authorization. Treatment provided by charity (from Cyberknife vendor), three per quarter. Dental: including general dentistry & orthognathic services, dental trauma, oral surgery, and dentures D MAP Dental Services: contact 512-978-9895 for RBJ Dental Clinic; 512-978-9880 for Northeast Dental Clinic; 512-978-9865 for South Austin Clinic Dialysis Emergency Services, hospital ER NB D Experimental / Investigational NB Genetic Counseling P/D Private Office/Clinic Genetic Testing NB Includes the following tests: BRCA1&2 (ovarian and breast cancer); MLH1&2 (hereditary nonpolyposis colorectal cancer-HNPCC); APC (familial adenomatous polyposis-FAP); Oncotype DX test; Codes: S3818-S3820, S3822-S3823, S3828-S3831, S3833-S3834, S3854; NOT COVERED APOE epilson 4-(susceptibility to Alzheimer's), S3852 Hearing Aids NB Health Education - (Diabetes; Nutrition) Home Health Care / Home Infusion Hospice Vasectomy See comment Diabetic education and nutrition responsibility of contracted primary care providers. P NB D Ancillary supplies/equipment may be covered under MAP if no other funding program available. Provider referral required to the Urology Team. Use the Vasectomy Voucher. Hospital Services Inpatient Scheduled (Elective) P P Rehab Facility NB Trauma / ER Admit P/N Observation (Trauma / ER) D Recuperative Care P Skilled Nursing Facility NB Observation and Outpatient Surgery (elective) *** Biopsy - w/ or w/o image guided D See "biopsy codes, etc." list for codes Cataract removal w/ IOLens D CPT codes: 66820-66821, 66825, 66830, 66840, 66850, 66852, 66982-66985 Services MAP Notes Cholecystectomy, laparoscopic D CPT codes: 47562-47564; outpatient only Circumcision D CPT codes: 54150-54163 DaVinci Robot assisted surgery P Available at SMCA &SMCW Hernia Repair D CPT codes: 39501, 39503, 39540-43337, 49491-49496, 49500-49501, 49505, 49507, 4952049521, 49525, 49540, 49550, 49553, 49555, 49557, 49560-49561, 49565-49568, 49570, 49572, 49580, 49582, 49585, 49587, 49590, 49650-49659 Lumbar Puncture D CPT code: 62270 Port-a-cath insertion / removal: includes Insert tunneled CV cath D CPT codes: 36555-36558, 36560-36561, 36566, 36568-36569, 36570-36571, 36576, 36578, 36580-36585, 36595-36596, 76937 Infertility (diagnostic testing for definitive diagnosis) NB Infertility Treatment NB 1) No authorization through SHP. 2) Medication needs to be arranged through Patient Pharmacy Assistance Programs (PPAP). 3) Coverage of outpatient infusions limited to UMCB Shivers Specialty Clinic. Specialty Injectable / infusion Medications see note Laser Assisted Uvulopalatoplasty P Laser (Excimer) Treatment P Lymphedema Management / Therapy Neuropsychological Testing Oral Surgery / TMJ CPT codes: 96920-96922 P/see comment Only benefit when provided at SHF rehab department NB CPT codes: 96118-96120 D Orthodontia (pre / post surgical) NB Transplants NB Varicose Vein Treatment ~ Including but not limited to: Chemotherapy agents, Botox, Bisphosphonates (Boniva, Fosamax, Reclast, etc.); Osteoclast Inhibitors (Prolia) Depo-Provera, IGG, Lupron Depot, DMAD (Remicade; Orencia; Humira, etc.); Viscosupplements: (Supartz, Synvisc, Euflexxa, Hyalgan, Orthovisc, etc.) Synagis, Tysabri, Xolair, Provenge; 17 Alpha hydroxyprogesterone caproate (17P) P Outpatient Therapeutic Studies Arthrogram P CPT code: 21116, 23350, 24220, 25246, 27093-27096, 27370, 27648, 70328-70332, 73040, 73085, 73115, 73525, 73542, 73580, 73615 Bronchoscopy D CPT codes: 31622-31656 Cardiac Cath / EP studies/Ablation D CPT codes: 93451-93461, 93503-93533, 93600-93662 Colonoscopy; Sigmoidoscopy D CPT codes: 45355, 45378-45387, 45391-45392, 45330-45345 Doppler Study - Arterial/venous D CPT codes: 93922-93924, 93971, 93886-93888, 93926-93990 Echocardiogram; EKG; Holter Monitor D CPT codes: EKG - 93010, 93300, 93305; Holter Monitor - 93224-93227, 93230-93237; Echocardiograms - 93025, 93303-93304, 93306, 93308, 93312-93314, 93318, 93320-93321, 93350 EEG D CPT codes: 95816, 95819 EGD D CPT codes: 43200-43259 Hysterosalpingography (HSG) / Sonohysterography (SIS) P CPT codes: 58340, 74740 Stress Test - Cardiac (ETT) D CPT codes: 93015-93024 Visual Field Testing D CPT codes: 92081-92083; NB for charity patient who resides outside Travis County Pain Management Procedures P-limited coverage Limited to: Acute back pain (not chronic pain); Dx: herniated disc with radiculopathy; unresponsive to conservative treatment (i.e. PT, NSAIDs); Treatment limited to epidural steroid injection (ESI) maximum of 3 per 12 month period MAP Prolotherapy NB Sleep Study P Notes CPT code: 95811 Radiology / Imaging Imaging Services Not Listed D Anesthesia for Imaging D Angiography / Venography D Barium Enema D CPT codes: 74270-74280 Bone Density Study (Dexa Scan) D CPT codes: 77071-77084; only available at SSW Ca Scoring (Heart Saver CT) NB CT Myelogram P CT Scan P CT Cardiac Angiography P CT Colonoscopy (Virtual Colonoscopy) CPT code: 01922 NB CPT codes: 62284, 62290-62291 Not a covered benefit of Medicare, therefore not covered Image Guided Biopsy D IVP (Intravenous Pyelogram) D CPT codes: 74400-74415, 74420 Mammography (screening) D Community resources available; CPT codes: 77051-77057 CPT codes: 78000-79999 Nuclear Medicine (NM) Bone Scan D MRA P MRI P MRI - Breast P MRI - Open P Not available at SFH (try SNW - have large semi-open) Nuclear Med Stress Test D CPT codes: 78451-78454 Perfusion Studies; spect D CPT codes: 78451-78454, 78472-78473, 78494, 78496 PET Scan P Not available at SFH (ARA) Thyroid Scan/Uptake D CPT codes: 78012-78099 Upper GI D CPT codes: 74246-74249 Other NM not listed P Includes, but not limited to, CPT codes: 79000-79999 Radiation Therapy D Referral to Specialist (private office and specialty clinics) D/P CPT codes: 78300-78320, 78350-78351, 78399 Direct access to UMCB & DCMCCT Marnie Paul Specialty Clinics; Prior-authorization required for private practice; See Ophthalmologist grid for treatment of eye disorders Rehab Services Cardiac Rehab PT, OT, ST (therapy) Wound Care DME (quantity limits apply) D P>8vists D **D<$250 P>$250 Blood glucose monitor w/ voice synthesis P E2100; MAP members access through Pharmacy benefit Compression Support Hose / Stockings (over the counter) D Over the Counter; A6530-A6541; Limit 2 pair per year Continuous Glucose Monitor (CGS) and supplies P Services MAP Notes Custom items: DME, orthotics and prosthetics, shoe inserts P Diabetic Shoes and Inserts (over the counter) D A5500, A5512 Disposable Supplies, including wound care supplies D No custom DME items Insulin Pumps and Supplies P Lymphedema Pumps & Stockings P Orthotics P** Prosthetics P When no other funding source available Apnea Monitor D E0618-E0619 Bedside Commode D E0163-E0168 Bili lights (phototherapy) D E0202 BIPAP P E0470-E0472; Approved for 3 months initial usage, then compliance report for continued rental of CPAP/ BIPAP Rental items requiring authorization regardless of dollar amount: Breast Pump NB E0602-E0604; Available through community resources Compressors (high volume) D E0575, E0580, E0585 CPAP P E0601 CPM; Dynamic splinting; PMD P E0935, E1800-E1840 Enteral Therapy, supplies and formula, nutrition P** B4034-B4036, B4150-B4160 Feeding pump (Enteral Therapy) P** B9000-B9006, B9998-B9999; if valid authorization on file for pump, then authorization includes the B4034-B4036 listed above Hospital Beds and Accessories P E0250-E0270, E0277-E0300 Humidifier, w/ equipment (Nebulizer) D E0550-E0562 Jaw motion rehab system (CPM) P E1700-E1702 Oxygen and Related Respiratory Equipment P E0424-E0500, E1353-E1390, E1392, E1405-E1406 Patient Lifts P E0621-E0636 Powered air flotation bed / mattress (low air loss) NB E0193 Powered / Nonpowered overlay for mattress P E0371-E0373 Pressure-relief pads; alternating; air; water mattress P E0180-E0187, E0194-E0199 Pulse Oximeter P CPT codes: 94760-94762; Not covered: E0445 & A4606 (as excluded by Medicare) Safety enclosure frame / canopy for use with hospital bed P E0316 Suction Machine P E0600, E2000 TENS D E0720-E0730 Neuromuscular and bone growth stimulators P E0744-E0765 Wheelchairs P E1050-E1298, K0001-K0014 Wound V.A.C. (Negative pressure wound therapy) Arrange thru E2402 facility PT Dept. Notes: ** Subject to plan limitations *** Outpatient surgery/procedure performed in facility - not to include office procedure Abbreviations: D - Direct access no authorization required for this service. P - Plan approval required by phone/fax with medical information NB - Not a benefit SFH - Seton Family of Hospitals Prior-Authorization Form * Plan Name SmartHealth 500 SmartHealth HDHP 1300 *Request Date: *Phone # and Ext (Include area code): *Patient Name: Referral Type: □ Routine Medical Management Dept. □ Urgent (Service in next 72hrs) Phone #: (512) 324-3135 Fax #: (512) 380-4253 Seton Care Plus MAP Charity (attach demographic sheet City/County Community Clinic with address/phone number(s), etc) * (CCHC/COTHER) TERM DATE: *Submitted by (Name): *Return Fax # (include area code): *Patient’s ID Number: *DOB: NPI: *Requesting Provider or Clinic name: *Requested Specialist or Service: *Requested # of visits: *ICD-10 Codes: NPI: *Proposed Date of Service: *Diagnosis Description: *Description: *CPT or HCPCS Codes: NPI: *Facility Name (for Inpatient or Outpatient Services): *□ Inpatient □ Outpatient □ Observation □ In Office □ Imaging □ DME/Home Health □ Therapy *Reason for referral (please attach pertinent clinical/progress notes or provide clinical narrative, including duration of problem, types of treatment, pertinent physical findings, pertinent testing results): *Workman’s Compensation: *Other Insurance Coverage: YES YES Coordination of Benefits (Other Insurance) YES NO *MVA Date of Injury: Subrogation: NO Subscriber Name of Name and ID #: Insurance: NO TO BE COMPLETED BY SETON HEALTH PLAN MEDICAL MANAGEMENT SERVICES Authorization Number: Number of Visits or Services Approved: Comments/Questions: Authorization Dates: * In order to process request, all required fields with asterisks must be completed. NOTICE OF CONFIDENTIALITY – This document is intended solely for the use of the individual identity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or individual responsible for delivering the message to the intended recipient, you are hereby advised that any dissemination, distribution or copying of this information is strictly prohibited. If you have received this communication in error, please advise us immediately by telephone and destroy these papers 12.1.2015 Seton Health Plan Coverage Guidelines Varicose Vein Referral Policy: 1) Seton Health Plan (SHP) will review Medical Assistance Program (MAP) patient referrals for varicose vein evaluations. 2) Primary care physician will submit varicose vein evaluation requests to SHP and include supporting documentation (i.e. conservative measures taken, physical findings and related test results). 3) SHP will approve an evaluation visit at Austin Radiology Associates (ARA) if the following criteria have been met: > No significant symptomatic improvement in response to 3-month trial of fitted elastic support hose AND > Objective complications — symptoms causing clinically significant functional impairment as indicated by 1 or more of the following: AND o Leg pain o Leg fatigue o Leg edema > Ultrasound lower extremities to RIO DVT OR > 1 or more of the following complications or recurrent symptoms: o Bleeding from a varicosity that has eroded skin o Large superficial varices around skin ulcer o Persistent or recurrent venous stasis ulcer 4) Initial evaluation authorization for ARA will include the following: > 99241 — Consult x 2 > 93970 — Duplex Doppler 5) If ARA determines that intervention is required they will contact SHP to obtain authorization. Procedure codes for EVLT will depend on patient’s condition and may include the following codes: 36478; 37799; 37765; 37766; 36470; 36471; 36479 Pre-Certification Form Medical Management Dept. Phone #: (512) 324-3135 Fax #: (512) 324-1936 Polysomnography- Sleep Study Authorization Form This form should be completed by the person who has a thorough knowledge of the patient’s current clinical presentation and his/her treatment history. Please complete ALL parts as clearly and as specifically as possible. Omissions, generalities, and illegibility will result in the form being returned as an incomplete request. Plan Name Seton Care Plus Charity *Request Date: *Patient Name: *DOB: *Submitted by: MAP CitylCounty Community Clinic (CCHC) *Phone #: *Fax: *Patient’s ID Number: Diagnosis and ICD 10 code: *PCP or Requesting Provider Name: REQUEST FOR INITIAL POLYSOMNOGRAM — SPLIT NIGHT (CPAP applied half night if AASM criteria met) (Both Sections Need To Be Completed) u Patient awakens with a sense of gasping, choking, or suffocations u An observer of the patient’s sleep reports repeated pauses in breathing, lasting more than 10 seconds, gasping or choking during sleep u Awakening of the patient in a state of terror later attributed to the inability to move air through his/her upper airway u Patient has to fight off sleep while engaging in activities or actually falls asleep unintentionally in the absence of such apparent causes as use of potentially sedating medications, etc. Epworth Sleepiness Scale (Required) How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? This refers to your usual way of life in recent times. Even if you have not done some of these things recently, try to work out how they would have affected you. Use the following scale to choose the most appropriate number for each situation: 0 = would never doze; 1 = slight chance of dozing; 2= moderate chance of dozing; 3- high chance of dozing Situation Chance of dozing (score 0 — 3) Sitting and reading Watching TV Sitting, inactive in public placed (e.g. theater or meeting) As a passenger in a car for an hour without a break Lying down at rest in the afternoon when circumstances permit Sitting and talking to someone Sitting quietly after a lunch without alcohol In a car, while stopped for a few minutes in traffic TOTAL o OTHER CLINICAL FINDINGS: o REQUEST FOR REPEAT SLEEP STUDY E E E Indication is following a recent positive first night sleep study, where titration was not performed . Copy of previous sleep study submitted with this request Other indication: Please provide details as to why another sleep study is required: Requesting Provider Signature and Date: SHP AUTHORIZATION NUMBER: COMMENTS: Conum/internal guidelines/current guidelines/Polysomnography Request Form 2_22.2011 DRAFT AUTH DATES: MAP EXCLUSIONS Services and related items excluded from coverage by the Medical Assistance Program (MAP) include but are not limited to the following list. MAP does not cover items on this list. The list of MAP benefits and exclusions are also listed on the MAP Handbook located at: https://www.dropbox.com/s/gpngym7stmf2je2/MAP%20Handbook%20English%20Feb%2 015%202016.pdf?dl=0 1. All services that have been denied through pre-authorization by the Medical Assistance Program; 2. Services not provided within the MAP designated network, unless pre-authorized; 3. Services and supplies to any individual who is a resident or inmate in a public institution; 4. In-patient hospital and related services for a patient in an institution for tuberculosis, mental disease, or a nursing section of a public institution for the intellectually disabled; 5. Services provided for any work-related illness, injury or complication thereof arising out of the course of employment for which Worker’s Compensation Benefits or any other similar regulation of the United States are provided or should be provided according to the laws of the state, territory or subdivision thereof governing the employer under which such illness or injury occurred; 6. Services or supplies provided in connection with cosmetic surgery except as required for the repair of accidental injury if the initial treatment is received within 12 months of the accident in which the injury was sustained, or for improvement of the functioning of a malformed body member, or when prior authorization is obtained for other medically necessary purposes; 7. Services, supplies and medications for which benefits are available under a manufacturer’s Patient Benefit Program, or any other contract policy or insurance which would have been available in the absence of the Medical Assistance Program; 8. Services payable by any health, accident, or other insurance coverage; or by any private or other governmental benefit system, or any legally liable third party; 9. Services, supplies or medications considered experimental or investigational, i.e., services and items which have not been approved for marketing by the Food and Drug Administration Services; 10. Supplies or medication related to infertility; 11. Any services to include, but not be limited to, drugs, surgery, medical or psychiatric care or treatment for transsexualism, gender dysphoria, sexual reassignment or sex change; 12. Procedures that relate to obesity, obesity therapy and/or special diets (including medically supervised fasting and liquid nutrition) related to weight reduction whether necessitated by surgery or a specifically identified medical condition; 13. 14. Services provided by an interpreter; Services provided by a relative of the enrollee or a member of his or her household; 15. Services and supplies that are provided under any governmental plan or law under which the individual is or could be covered (e.g., Victims of Crime, Texas Rehabilitation Commission, Veteran’s Benefits, Medicare, Medicaid, TRICARE, CHAMPUS, etc.); 16. Co-insurance fees and deductibles. MAP is not a secondary payer for any other insurance or governmental health care program, nor does MAP coordinate benefits with any other payer; 17. Services not medically necessary, which are not incident to and necessary for the treatment of an injury or illness; 18. Acute hospital services and supplies provided as an inpatient to the extent that it is established upon review of the claim submitted that the enrollee’s condition did not require a hospital level of care and could have been provided safely at a lesser level of care; 19. Services resulting from or in connection with the commission of any illegal act, occupation or event (including the commission of a crime or violation of conditions of probation) if the covered individual is incarcerated; 20. Services resulting from or in connection with any acts of war, declared or undeclared, or any type of military conflict, charges incurred due to diseases contracted or injuries sustained in any country while such country is at war or while en route to or from any such country at war, charges resulting from illness/injuries incurred while engaged in military services; 21. Inpatient and Intensive outpatient rehabilitation; 22. Charges for custodial or sanitaria care, rest cures, or for respite care; 23. Care and treatment of mental and/or nervous disorders, psychiatric treatment or individual, family, or group counseling services unless as a co-morbidity or secondary diagnosis during a medical inpatient stay or in a primary care setting. 24. Treatment programs for substance abuse and/or detoxification. 25. Non-emergency air transport; 26. Private room except when appropriate documentation of medical necessity is provided; 27. Chiropractic services/treatment; 28. Rolfing; 29. Acupuncture, acupressure, or biofeedback; 30. Services rendered by a massage therapist; 31. Hypnosis; 32. Eye refractions, eye glasses, eye exercises, contact lenses, or other corrective devices, including materials and supplies, or for the fitting or examinations for prescribing, fitting or changing of these items; 33. Whole blood or packed red cells that are available at no cost to the client; 34. Autologous blood donations; 35. Blood clotting factors; 36. Luxury/entertainment items (e.g., TV, video, beauty aids, etc.); 37. Charges/fees for completing or filing required forms/pre-authorizations; 38. Charges which accumulate during any period of time in which the client removes rental equipment from the delivery site and fails to immediately notify the Medical Assistance Program of the new location; 39. Autopsies; 40. Cellular Therapy; 41. Chemolase injections (Chemodiactin, Chymopapain); 42. Chemonucleolysis intervertebral disc; 43. Dermabrasion; 44. Dialysis (in-patient or out-patient) or supplies related to dialysis, except for acute conditions not related to chronic renal failure while in the inpatient setting; 45. Educational counseling; 46. Ergonovine provocation test; 47. Fabric wrapping of abdominal aneurysms; 48. 49. Hair analysis; Histamine therapy - intravenous; 50. Professional component of Hospice Services 51. Hyperactivity testing; 52. Hyperthermia; 53. Immunotherapy for malignant disease; 54. Immunizations required for travel outside the United States; 55. Implantations (e.g., silicone, saline, penile, etc.); 56. Joint sclerotherapy; 57. Laetrile therapy; 58. Organ transplants, medications and/or treatments associated with the transplant; 59. Orthodontic treatment, root canal, crown, and bridge procedures; 60. Specialized pain management programs and/or treatment designed to provide chronic pain care unless provided through contracted MAP providers 61. Prosthetic eye or facial quarter; 62. Radial and hexagonal keratotomy or refractive surgeries; keratoprosthesis/refractive keratoplasty; 63. Routine circumcision for clients one year of age or older; 64. 65. Sterilization reversal; Tattooing and/or tattoo removal; 66. 67. Thermogram; TORCH screen; 68. Adaptive equipment for daily living such as eating utensils, reachers, handheld shower extensions, etc.; 69. Admission kits; 70. Air cleaners/purifiers; 71. Any equipment, supplements, or supplies not ordered by a physician or provider and/or not considered appropriate and necessary to treat a documented medical condition/disease process; 72. Augmentive communication devices, e.g., TTY device, artificial voice box, and machinery of this nature; 73. Bed cradles; 74. Bladder stimulators (pacemakers); 75. 76. Car seats; Cervical pillows; 77. Electric wheelchairs or scooters (outpatient); 78. Enuresis monitors; 79. Equipment or services not primarily and customarily used to serve a medical purpose (e.g., an air conditioner might be used to lower room temperature to reduce fluid loss in a cardiac patient or a whirlpool bath might be used in the treatment of osteoarthritis, however because the primary and customary use of these items is a non-medical one, they cannot be considered as medical equipment); 80. Evaluations for learning disabilities; 81. Feeding supplements (e.g., Ensure, Osmolyte) and supplies for long-term use; 82. Hearing aids; 83. Home and vehicle modifications, including ramps, tub rails/bars; 84. Humidifiers, except when used with respiratory equipment (e.g., oxygen concentrators, CPAP/BIPAP, nebulizers, or for clients with a tracheostomy ; 85. Over bed tables; 86. Implantable medication pumps and related supplies, with the exception of insulin pumps and related supplies; 87. Prosthetic breasts and mastectomy bras; 88. Thermometers; 89. Vocational, educational, exercise, and recreational equipment; 90. Waist/gait belts; 91. Whirlpool baths and saunas; 92. Treatment or correction of temporomandibular joint (TMJ) dysfunction; 93. Refills or prescriptions in excess of the number specified by the Doctor, or refills dispensed one year or more after the date of the Doctor’s original order. 6. HEALTH SERVICES Health Services Case Management Credentialing Compliments and Complaints CCC Clinical Protocols Health Services Case Management The purpose of the case management program is to maintain MAP patients in a quality oriented and medically appropriate environment, promoting optimal outcomes through early intervention cost effectiveness, while utilizing community and other available resources. The case management program promotes accessibility, availability, and effectiveness of care. It also strives to improve quality of life outcomes and monitor cost of care. Case Management Activities: 1. Assist in locating and linking to alternative sources of care and funding. 2. Negotiate fair and accurate reimbursement. 3. Assist primary care physician to provide quality care by offering coordination of services needed for the patient. 4. Eliminate barriers to care and services by providing innovative solutions that will meet the patient’s need in a cost effective manner. 5. Involve the patient and the family throughout the case management process. 6. Serve as an advocate to coordinate and optimally utilize health care and community related services for the patient. 7. Assist in the transition of care with the different delivery points through the continuum of healthcare services. COMPLEX CASE MANAGEMENT REFERRAL FORM Please see below for submittal instructions REFERRAL SOURCE Referral Date: ________________Referral Name: ________________________________________ Referral sources: □ Provider □ Member/Relative □ UM □ Community Agency □ Other (Please check one) Phone no. of referral source: ___________________ Fax no. of referral source: _________________ MAP MEMBER INFORMATION Member name: ________________________________ DOB: _________________ □ Male □ Female MAP ID #:__________ Home Address: ___________________________ Language: ______________ Member home no.:_____________ cell: _____________ work: ____________ other: ____________ REASON FOR REFERRAL Reason for Referral/need for case management: __________________________________________________________________________________ __________________________________________________________________________________ __________________________________________________________________________________ __________________________________________________________________________________ Other diagnoses affecting Member: Diagnosis #1:________________ Diagnosis #2:______________ Diagnosis #3:___________________ Are other providers involved in care: □ No □Yes If yes, who? ________________________ _______________________ _____________________ Priority status of referral: □ Urgent: needs to be contacted within 2 working days □ Standard: needs to be contacted within 7 working days Please Submit Referral Form to the CCC Medical Management Department via: Phone: 512-978-8300 or fax 512-901-9787 Credentialing The Provider will participate in the formal process through which the Community Care Collaborative or its designee collects, verifies, and evaluates the professional credentials and qualifications of licensed individual providers against the criteria, standards, and requirements established by the District for providing health care services to Eligible Patients. Provider Credentialing for MAP is handled by Seton Health Plan. Compliments and Complaints The Community Care Collaborative endeavors to provide the best medical care to the persons it serves. The CCC invites enrollees to let us know when they receive exceptional services and when they feel the services were not successful in meeting their specific needs. The CCC encourages enrollees to discuss any concerns or questions about their treatment or medical care with her or his primary care provider. If the enrollee is unable to resolve issues with the primary care office, please give the enrollee our telephone number (512) 978-8150. 7. CCC- CLINICAL PROTOCOLS Community Care Collaborative Clinical Protocols The following Community Care Collaborative clinical protocols can be accessed via the CCC website: Adult Health- Clinical Protocols Type 2 Diabetes Mellitus Protocol Depression & Generalized Anxiety Disorder Protocol Hypertension Protocol Heart Failure Protocol Tobacco Protocol Hepatitis C Protocol Normal Interval OB Care Protocol Prevention of Type 2 Diabetes in Adults Protocol Chest Pain Protocol Website: http://www.ccc-ids.org/clinicalprotocols/ Password: ccc 8. CONTRACTED PROVIDERS CONTRACTED PROVIDERS Primary Care Dental Services Diabetic Retinal Screening Durable Medical Equipment Home Health Services Home Infusion Therapy Orthotics and Prosthetics Radiation Oncology Urgent Care PRIMARY CARE: CommUnity Care http://communitycaretx.org/locations/ A.K. Black ARCH Blackstock Family Health Center David Powell Del Valle East Austin Manor North Central Health Center Oak Hill 928 Blackson Avenue Austin, TX 78752 Telephone: 512-978-9740 Fax: 512-978-9741 500 East Seventh Street Austin, TX 78701 Telephone: 512-978-9920 Fax: 5112-978-8129 1313 Red River Suite 100 Austin, TX 78702 Telephone: 512-324-8600 4614 North IH-35 Austin, TX 78751 Telephone: 512-978-9100 Fax: 512-901-9751 3518 FM 973 Austin, TX 78617 Telephone: 512-978-9760 Fax: 512-978-9767 211 Comal Street Austin, TX 78702 Telephone: 512-978-9200 Fax: 512-978-9238 600 West Carrie Manor Manor, Texas 78653 Telephone: 512-978-9780 Fax: 512-978-9781 1210 West Braker Ln. Austin, TX 78758 Telephone: 512 978-9300 Fax: 512-279-2556 8656 Highway 71 West Suite C Austin, TX 78735 Telephone: 512-978-9820 Fax: 512-978-9830 Continued: CommUnity Care 15822 Foothill Farms Loop Pflugerville, TX 78660 Pflugerville Telephone: 512-978-9840 Fax: 512-978-9860 1000 E. 41st St. Suite 960 Austin, Hancock TX 78751 Telephone: 512-978-9940 Fax: 512-901-9702 2802 Webberville Road Austin, TX 78702 Rosewood Zaragosa Telephone: 512-978-9400 Fax: 512-901-9726 825 East Rundberg Lane, B-1 Austin, TX 78753 Rundberg Telephone: 512-978-9600 Fax: 512-978-9601 Sandra Joy Anderson Health & Wellness 1705 E. 11th Street Austin, TX 78702 Center Telephone: 512-978-8400 Fax: 512-901-9785 2529 South First Street Austin, TX 78704 South Austin Telephone: 512-978-9500 Fax: 512-978-9558 2901 Montopolis Drive Austin, TX 78741 Southeast Health and Wellness Center Telephone: 512-978-9901 and Internal Medicine Clinic Fax: 512-901-9765 6801 South IH-35 Suite 1-E Austin, TX 78745 William Cannon Telephone: 512-978-9960 Fax: 512-978-9961 PRIMARY CARE: Lone Star Circle of Care Ben White Health Center 1221 W. Ben White Blvd, Suite B-200 Austin, TX 78704 Phone: 877-800-5722 Fax: 512-448-1311 Lake Aire Medical Center Pediatrics, Family, Behavioral Health 2423 Williams Dr Georgetown, TX 78628 Phone: 877-800-5722 Fax: 512-864-7238 Family Care Center at Northwest Pediatrics, Family, OB/GYN, BH 11111 Research Blvd. Austin, TX 78759 Phone: 877-800-5722 Fax: 512-605-6400 Round Rock Health Clinic- Pediatrics and BH 2120 North Mays, Suite 430 Round Rock, TX 78664 Phone: 877-800-5722 Fax: 512-255-5268 TAMU Pediatrics, Family, Behavioral Health 3950 N. AW Grimes, Suite n201 Round Rock, TX 78664 Phone: 877-800-5722 Fax: 512-218-0515 Dell Children’s Circle of Care Pediatrics at Whitestone Fax: 1730 E. Whitestone Blvd. Cedar Park, TX 78613 Phone: 877-800-5722 Fax: 512-259-1994 Dell Children’s Circle of Care Pediatrics at Hutto 123 Ed Schmidt Blvd., Suite 140 Hutto, TX 78634 Phone: 877-800-5722 Fax: 512-846-2072 Health Center at Taylor 305 Mallard Lane Taylor, TX 76574 Phone: 877-800-5722 Fax: 512-352-6112 Georgetown Women’s Center OB/GYN 1900 Scenic Dr., Suite 3326 Georgetown, TX 78626 Phone: 877-800-5722 Fax: 512-869-1788 Round Rock OB/Gyn 2300 Round Rock Ave, Suite 208 Round Rock, TX 78681 Phone: 877-800-5722 Fax: 512-255-5307 PRIMARY CARE- OTHER People’s Community Clinic El Buen Samaritano 2909 North IH-35 Austin, TX 78722 Telephone: 512-478-4939 Fax: 512-708-1835 7000 Woodhue Dr. Austin, TX 78745 Telephone: 512-439-0700 DENTAL SERVICES: CommUnity Care http://communitycaretx.org/locations/ RBJ Dental Clinic North Central Dental Clinic South Austin Dental Clinic Southeast Health and Wellness Center Ben White Dental 15 Waller Street Austin, TX 78702 Telephone: 512-978-9895 Fax: 512-978-9900 1210 W. Braker Ln, 2nd floor Austin, TX 78758 Telephone: 512-978-9880 Fax: 512-279-2556 2529 South First St. Austin, TX 78704 Telephone: 512-978-9865 Fax: 512-978-9558 2901 Montopolis Drive Austin, TX 78741 Telephone: 512-978-9901 1221 W. Ben White, Suite 112B Austin, TX 78704 Phone: 512-978-9700 Fax: 512-279-2307 DIABETIC RETINAL SCREENING 801 West 38th Street, Suite 200 Austin, TX 78705 Austin Retina Associates 170 Deepwood Drive, Suite 105 Round Rock, TX 78681 Telephone: 512-451-0103 Fax: 512-451-9276 Brian B. Berger, MD 3705 Medical Parkway, Suite 410 Austin, TX 78705 Telephone: 512-454-4851 Fax: 512-454-5853 Richard B. Briggs, MD 6801 Manchaca Road Austin, TX 78745 Telephone: 512-444-2015 Fax: 512-444-2010 DURABLE MEDICAL EQUIPMENT Animas Diabetes Care Austin Wheelchair Company A&P Quality Care Medical Edgepark Medical Supplies AAA Oxygen & Medical Supply Applied Orthotics The Comfort Store Travis Medical Telephone: 877-937-7867 Fax: 866-212-1852 5555 N Lamar Blvd #D107 Austin, TX 78751 Telephone: 512-452-7988 8220 Cross Park Dr #100 Austin, TX 78754 Telephone: 512-452-5111 1810 Summit Commerce Park Twinsburg, OH 44087 Telephone: 888-394-5375 Fax: 330-425-4355 2801 Oakmont Dr #1400 Round Rock, TX 78665 Telephone: 512-248-2888 7801 N Lamar Blvd F30 Austin, TX 78752 Telephone: 512-380-0259 7301 Burnet Rd #200n Austin, TX 78757 Telephone: 512-323-6181 1104 W. 34th Street Austin, TX 78705 Telephone: 800-458-4590 Fax: 512-454-9521 HOME HEALTH SERVICES Balex Healthcare Services Gilead Health Care Guardian Healthcare 7703 N Lamar Blvd #115 Austin, TX 78752 Telephone: 512-762-6966 8100 Cameron Rd B200 Austin, TX 78754 Telephone: 512-323-5858 8716 N. Mopac Expy, Ste. 320 Austin, TX 78759 Telephone: 512-863-3842 Fax: 512-863-2018 HOME INFUSION THERAPY Infusion Partners dba CarePoint Partners 5446 W US Hwy 290 Svc Rd #203 Austin, TX 78735 Telephone: 512-637-4949 Fax: 855-737-4299 Coram Healthcare 1905-A Kramer Ln, Ste 500 Austin, TX 78758 Telephone: 512-832-1330 Fax: 512-832-1240 ORTHOTIC & PROSTHETICS Applied Orthotics Hanger Orthotics & Prosthetics The Orthotic Specialist 7801 North Lamar Blvd., Suite F-30 Austin, TX 78752 Telephone: 512-380-0259 Fax: 512-380-0281 10910 Domain Dr., Suite 300 Austin, TX 78758 Telephone: 512-377-3800 2102 Blalock Drive, Suite 102 Austin, TX 78758 Telephone: 512-490-1255 Fax: 512-490-1297 RADIATION ONCOLOGY Austin Cancer Center – Central Austin Austin Cancer Center - Northwest Austin Austin Cancer Center – North Austin Austin Cancer Center - Lakeway Austin Cancer Center - Kyle 2600 East MLK Jr. Blvd. Austin, TX 78702 Telephone: 512-505-5500 Fax: 512-334-2883 11111 Research Blvd., LL2 Austin, TX 78759 Telephone: 512-505-5500 Fax: 512-334-2883 12221 North MoPac Expressway Austin, TX 78758 Telephone: 512-505-5500 Fax: 512-334-2883 200 Medical Parkway Lakeway, TX 78738 Telephone: 512-505-5500 Fax: 512-334-2883 1180 Seton Parkway, Ste 150 Kyle, TX 78640 Telephone: 512-505-5500 Fax: 512-334-2883 URGENT CARE NextCare Urgent Care Austin — William Cannon NextCare Urgent Care Austin — Cedar Park NextCare Urgent Care Round Rock NextCare Urgent Care Georgetown 6001 West William Cannon #302 Austin, TX 78749 Telephone: 888-381-4858 351 Cypress Creek Rd #103 Cedar Park, TX 78613 Telephone: 888-381-4858 1240 East Palm Valley Road Round Rock, TX 78664 Telephone: 888-381-4858 900 North Austin Avenue #105 Georgetown, TX 78626 Telephone: 888-381-4858 9. CLAIMS MAP Plan Responsible for: Third Party Administrator: Submit Electronic Claims: Submit Paper Claims: CCC- MAP Payment of primary care services, dental services, custom orthotics, and selected specialty services. Seton Health Plan/MediView Seton Health Plan EDI Vendor ID: TCMAP Travis County MAP PO Box 14447 Austin, TX 78761 Seton- MAP Hospital based and specialty services, diagnostics, home health, and durable medical equipment services Seton Health Plan/MediView EDI Vendor ID: SHMAP Seton MAP PO Box 14447 Austin, TX 78761 Claims processing: Claims are processed as they are received. Claims must be submitted within 95 days from date of service. Payment: Check or Electronic Funds Transfer (EFT) is made by Seton Health Plan To enroll with EFT and ERA with Seton Health Plan use the following link to access the EFT and ERA forms. EFT Form: http://www.setonhealthplan.com/providers/EFT%20Authorization%20Agreement. pdf ERA Form: http://www.setonhealthplan.com/providers/ERA%20Enrollment.pdf Explanation of Benefits (EOB): Seton Health Plan will send a corresponding EOB to the provider. To access EOBs online providers can use the Seton Health Plan Provider Self Service Center. To access the Provider Self Service Center, use the following link for registered users: https://www.mediview.net/cmsweb/webinquiry.asp If you are a first time user, use the following link for forms and instructions to set up access to the Seton Health Plan Provider Self Service Center: http://setonhealthplan.com/providers/physician_selfservice_center/ Appeals: Providers can submit claims reconsideration using the Seton Health Plan Claim Reconsideration Face Sheet. :> See additional document entitled “Seton Health Plan Claim Reconsideration Face Sheet and instructions.” Check Status of Claims: By Phone: Providers can call MediView to check on claims status- 512-421-5664 Online: Seton Health Plan Provider Self Portal Center can also be used to check claim status and status of authorizations. To access the Provider Self Service Center, use the following link for registered users: https://www.mediview.net/cmsweb/webinquiry.asp If you are a first time user, use the following link for forms and instructions to set up access to the Seton Health Plan Provider Self Service Center: http://setonhealthplan.com/providers/physician_selfservice_center/ Subrogation: Subrogation is the right to recover amounts paid by a government-sponsored plan that are the obligation of other payers (such as an insurance company). If you are injured or become ill under circumstances in which a third party may legally be obligated to pay the medical, dental and/or pharmacy expenses, MAP will pay your covered expenses. MAP reserves the right, however, to be reimbursed for all medical expenses from the settlement or judgment paid by a third party. Other providers may also have subrogation rights in any settlement or judgment made by a third party. CLAIM RECONSIDERATION FACE SHEET Date:_______________________ To: Seton Health Plan Benefit Administrators Phone: (512) 421-5664 P.O Box 14447 Austin, TX 78761 Fax: (512) 421-4860 From*: ____________________ Phone*:__________________ Member Name*:______________________________ Member ID*: Fax: __________________ ____________________ Claim Number*:______________________________ Date(s) of Service: _________________ State Reason for Reconsideration (this form is not for Retro Authorization requests)*: Attachments are required for reconsideration review. Check Appropriate Reason: Processed as Inpatient vs. Observation stay History & Physical Copy of physician’s order for observation Past filing deadline SmartHealth Explanation of Benefits Documentation with date of original submission to another carrier (certified mail receipt, other carrier’s EOB, electronic filing report, etc.) Reimbursement Adjustment SmartHealth Explanation of Benefits (EOB) or other payor EOB Explanation: Other: UB92/HCFA Explanation of Benefits History & Physical/Office Notes Discharge Summary ++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ MediView Internal Use Only: Incident #: ____________________________ Provider Education: Yes No Summary: *Required fields. Incomplete requests will result in claim reconsideration to be rejected. Revised 3/1/15 MAP CLAIM RECONSIDERATION FACE SHEET INSTRUCTIONS 1. Each claim reconsideration is to be submitted in writing with the “Claim Reconsideration Face Sheet” and supporting attachments listed under each category “Reason for Reconsideration.” 2. Reconsideration’s and attachments can be mailed or electronically submitted to: □ CCC MAP electronic claims to: Seton Health Plan/MediView EDI Vendor ID: TCMAP CCC MAP paper claims to: Travis County MAP P.O. Box 14447 Austin, TX 78661 □ SHP MAP electronic claims to: Seton Health Plan/MediView EDI Vendor ID: SHMAP SHP MAP paper claims to: Seton MAP P.O. Box 14447 Austin, TX 78661 3. Required fields to be completed: □ Submitting person’s name, phone and fax number □ Claim number □ Reason for reconsideration □ Applicable attachments □ Member name and ID number 4. Incomplete requests will result in claim reconsideration rejection. 5. Resubmissions and Claims Status Checks are not appeals. Call Customer Service at 512-421-5664 for claim status checks 10. SPECIALTY CARE University Medical Center at Brackenridge Specialty Clinics University Medical Center Brackenridge Specialty Clinics Table of Contents Clinic Rotation Schedule 5 Asthma Clinic 7 Breast Surgery Clinic 8 Cardiology Clinic 10 12 Cardiology Clinic Worksheet Dermatology Clinic 13 Endocrinology Clinic _____ 14 16 Endocrinology Clinic Worksheet ENT Clinic ______18 ENT Ov erb o ok Fax Re ques t Eye (Ophthalmology) Clinic Foot Clinic _____20 22 _________________________________________________________________24 Fracture Clinic ______________________________________________________________25 Gastroenterology Clinic ______________________________________________________ 26 Gastr oe nte r ol og y Clinic Worksheet ________________________ 27 Gynecology/Oncology Clinic __________________________________________________33 Hematology Clinic _____________________________________________________________35 Hematology Clinic Worksheet __________________________________________36 Neurology Clinic ___________________________________________________________ 38 Neurology Clinic Worksheet ___________________________________________ 40 EMG Referral Form Oncology Clinic _________________________________________________________ 42 ____________________________________________________________ 44 Orthopedic Clinic ___________________________________________________________ 46 Pulmonary Clinic ____________________________________________________________47 University Medical Center Brackenridge Specialty Clinics Table of Contents (continued) Renal/Hypertension Clinic Renal /H ype rte nsi on Cli nic Work she et Rheumatology Clinic R h e u m a t o l o g y Cli nic Work she et 48 49 50 51 Surgery Clinic 53 Urology Clinic 55 U r o l o g y Cli nic Work she et 57 Referral Form — UMCB Specialty Clinics 58 Seton Imaging and Radiology — Required Labs 59 Diagnostic Order Forms 60 Audiology Testing 62 Cardiology Electroneurodiagnostic Testing 64 Physical Therapy 66 Map of Seton Rehabilitation Facilities 67 Directions to Paul Bass Clinic (English) 68 Directions to Paul Bass Clinic (Spanish) 69 Map of Paul Bass Clinic 70 First-Time Referring Physician Setup Form Physician Exclusions List Search Physician License Practice Status University Medical Center Brackenridge Specialty Clinics University Medical Center Brackenridge Specialty Clinics Clinic Rotation Schedule Friday Thursday Wednesday Tuesday Monday Day Specialty Clinic Anticoag Breast Cardiology Cast/Fractures Medicine Psychiatry Urology Surgical Oncology Anticoag Dermatology Eye Gyn/Onc Hem/Onc Medicine Orthopedics Rheumatology Surgery Anticoag Asthma/Allergy Eye (Ophthalmology) GI Hem/Onc Medicine Renal Surgery Anticoag Endocrinology ENT Hem/Onc Medicine Neurology Palliative Care Surgery Anticoag Derm Suture Removal Eye-Visual Fields Hem/Onc Medicine Neurology Neuro Epilepsy Neuro Trauma Podiatry Pulmonary Rheumatology UTHSCSA Frequency 1st, 3rd each week 2nd, 3rd, 4th each week each week each week each week each week each week each week each week each week each week each week each week each week each week each week 2nd, 4th each week each week each week each week each week each week each week each week 1st, 2nd, 3rd each week each week each week each week each week each week each week each week each week each week each week 2nd 2nd, 4th 1st, 3rd 1st, 3rd each week 2nd, 4th Location Sub-Specialty 220 Shivers 217 Paul Bass Clinic Sub-Specialty 220 Paul Bass Clinic Paul Bass Clinic Sub-Specialty 220 Shivers 217 Sub-Specialty 220 Paul Bass Clinic Sub-Specialty 220 Shivers 217 Shivers 217 Paul Bass Clinic Sub-Specialty 220 Paul Bass Clinic Sub-Specialty 220 Sub-Specialty 220 Sub-Specialty 220 Sub-Specialty 220 Paul Bass Clinic Shivers 217 Paul Bass Clinic Sub-Specialty 220 Sub-Specialty 220 Sub-Specialty 220 Paul Bass Clinic Paul Bass Clinic Shivers 217 Paul Bass Clinic Sub-Specialty 220 Shivers 217 Sub-Specialty 220 Sub-Specialty 220 Paul Bass Clinic Sub-Specialty 220 Shivers 217 Paul Bass Clinic Sub-Specialty 220 Sub-Specialty 220 Sub-Specialty 220 Sub-Specialty 220 Paul Bass Clinic Paul Bass Clinic Shivers 217 Pg.5 University Medical Center Brackenridge Specialty Clinics PAUL BASS CLINIC MONDAY AM TUESDAY Cardio 2, 3, 4 wk Derm wkly Psychiatry wkly Rheum wkly WEDNESDAY GI wkly THURSDAY FRIDAY Endo wkly Pulm 1, 3 wk ENT 1, 2, 3 wk Rheum wkly Derm. Suture Removal Medicine wkly Medicine wkly Medicine wkly Medicine wkly Medicine wkly PM SHIVERS CENTER MONDAY AM PM TUESDAY WEDNESDAY THURSDAY FRIDAY Surg/Onc wkly Hem/Onc wkly Hem/Onc wkly Hem/Onc wkly Hem/Onc wkly Chemo/Infusion Chemo/Infusion Chemo/Infusion Palliative Med Wkly Chemo/Infusion Chemo/Infusion Breast Surgery wkly Gyn/Onc wkly Hem/Onc wkly Hem/Onc wkly UTHSCSA 2,4 wk Chemo/Infusion Chemo/Infusion Chemo/Infusion Chemo/Infusion Chemo/Infusion SUITE 220 Sub-Specialties MONDAY Cast wkly TUESDAY WEDNESDAY THURSDAY FRIDAY Anti-coag. Wkly Anti-coag. Wkly Anti-coag. Wkly Anti-coag. Wkly Orthopedics wkly Eye wkly Neurology wkly Eye Visual Field wkly Renal 1,2,3,4 wk EMG Neuro Trauma 2,4 wk AM Neuro Epi 2 wk PM Anti-coag. 1, 3 wk Surgery wkly Asthma 2,4 wk Urology wkly Eye wkly Allergy/Pulm 2, 4 wk Surgery wkly Pg.6 Surgery wkly Neurology wkly Podiatry 1, 3 wk University Medical Center at Brackenridge Specialty Clinics Asthma Clinic Appropriate patients for referral: • • • • • • • Patients with refractory asthma having difficulty controlling symptoms despite appropriate treatment Patients needing evaluation of their current asthma management plan Patients with recent ED visit or hospitalization for asthma Patients with chronic urticaria Patients with immunodeficiency Patients with chronic sinusitis Patients needing skin testing for allergen avoidance counseling Documentation required for scheduling an appointment: 1. 2. 3. 4. Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. 5. If reports are available, include with referral. If patient has not had testing, reports are not required for scheduling appointment. Examples of report: chest films, pulmonary function testing, labs, skin testing results. Revised May 2015 Pg.7 University Medical Center at Brackenridge Specialty Clinics Breast Surgery Clinic Scope • • To evaluate and treat newly diagnosed breast cancer patients. To provide consultation and care that is beyond the routine abilities of the primary care physicians. Appropriate patients for referral include: • • • • • • • • • • Positive pathology per biopsy Obvious tumor growth by exam (nipple inversion, dimpling, peau d ‘orange, ulceration) Bloody nipple discharge Fibro adenomas over 2 cm BRCA positive patients Abscess unresolved by full course of antibiotics BIRADS 3, 4, and 5 Mammogram and US (please see additional information under breast mass below) Breast Papilloma’s Paget’s disease Atypical Hyperplasia Please do NOT refer the following patients: • • • • • • • • • • • Fibro adenomas under 2 cm Breast Cyst Breast pain Benign masses diagnosed by pathology Extra breast tissue Extra nipple Nipple discharge with abnormal prolactin levels High risk patients for BRCA testing (please refer to the Myriad website for assistance) Mastitis Breast mass on exam but normal imaging (BRADS 1-2). Recommendation: Repeat imaging as suggested by radiology along with clinical breast exam. Consider ultrasound guided biopsy if clinically indicated. Axillary mass with normal breast imaging Documentation required for scheduling all appointments: • Completed referral form • Mammogram or ultrasound within the past 3 months • History and Physical • Current medications Pg.8 University Medical Center at Brackenridge Specialty Clinics Breast Mass • If Mammogram or ultrasound suggests biopsy, please obtain biopsy and refer with FINAL pathology report. For microcalcifications, order stereotactic biopsy. For breast mass, order ultrasound guided biopsy. To schedule either of these at a Seton facility call Central Scheduling at 512-324-1199. Nipple Discharge • • Serum Prolactin level cytology of nipple discharge BRCA positive patients • • BRCA results Any surgical reports related to BRCA results (mastectomy/oopherectomy) Revised May 2015 Pg.9 University Medical Center at Brackenridge Specialty Clinics Cardiology Clinic Scope: • • Cardiology consultation On-going cardiology care for some chronic cardiac conditions which require adjustment in Therapy. Once stable, ongoing follow up by PCP. Appropriate patients for referral include: • • • • • • • • • CAD (Coronary Artery Disease) previously evaluated with stress test or angiogram Uncontrolled Angina despite appropriate medical treatment Refractory Heart failure CHF (Congestive Heart Failure) previously evaluated with echocardiogram and with symptoms despite standard treatment Documented arrhythmias (excluding PACs and PVCs) Syncope (suspicious of cardiac source) – refer after EKG, Echo and Holter have been performed Documented significant valvular disease Newly diagnosed CHF New onset or unstable AFIB Patients discharged from the hospital requiring Cardiology follow up will be seen no later than 1 week. Please do NOT refer patients with the following: • • • • • • Atypical chest pain without stress test results Dizziness (refer to ENT) Palpitations without documented arrhythmia Pre-operative clearance without a cardiac problem Pediatric patients age < 18 Pacemaker/ICD Management (refer to Cardiac Electrophysiology) Documentation required for scheduling an appointment: 1. 2. 3. 4. Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. 5. EKG within the last 3 months Pg.10 University Medical Center at Brackenridge Specialty Clinics 6. Other studies if appropriate including those on the following worksheet (e.g., stress test, echo, Holter Monitor, etc.) Revised May 2015 Pg.11 University Medical Center at Brackenridge Specialty Clinics Cardiology Clinic Worksheet Chest Pain • • Normal EKG: o Patient able to exercise�Exercise stress test results o Patient unable to exercise�Pharmacologic SPECT results Abnormal EKG: o Patient able to exercise�Exercise SPECT results o Patient unable to exercise�Pharmacologic SPECT results Refractory CHF • • • EKG results Echocardiogram results Chest X-Ray results/film Pulmonary HTN • • EKG results Echocardiogram results Arrhythmia • • 12 lead EKG 24 hour holter monitor digital recording Heart Murmur • Echocardiogram results Revised May 2015 Pg.12 University Medical Center at Brackenridge Specialty Clinics Dermatology Clinic Scope: • To provide general dermatology consultation and diagnostic testing with referral back to the Primary Care Physician for management. Appropriate patients for referral include: • • • • • • • General skin problems - < 4 cm or located on face or scalp Symptomatic skin lesions or moles Lesions or moles suspicious for cancer Dermatoses such as psoriasis, eczema, contact dermatitis, etc Alopecia (hair loss) Onchymycosis Keloids Please do NOT refer the following patients: • • • • • Cosmetic Problems Acne Rosacea Pediatric patients age <18 Eyelid lesions – refer to Eye Clinic Documentation required for scheduling an appointment: • • • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Documentation of prior treatment Final path report if biopsy was done Revised May 2015 Pg.13 University Medical Center at Brackenridge Specialty Clinics Endocrinology Clinic Scope • To provide consultations at a subspecialty level in endocrinology. Appropriate patients for referral include: • • • • • • • • • • • • • • Lipid Abnormalities in a patient with family or personal history of early CVD, inability to achieve LDL-C<100 and/or non-HDL-C<130 in a patient with CVD or a CVD equivalent who cannot tolerate a statin or who is taking a maximum dose of statin and Hypertriglyceridemia, defined as fasting Tg level>500 or non-fasting >800 Thyroid Nodule Thyroid Cancer Hyperthryoidism Difficult to Control Hypothyroidism Osteoporosis and osteopenia Calcium and Parathyroid Disorders Pituitary Masses and Disorders Adrenal Masses and Disorders Amenorrhea & Galactorrhea Hypogonadism; referral for new diagnoses must include two low testosterone levels collected on separate days before 9AM Type 1 Diabetics Type 2 Diabetics requiring ≥ 300 units of insulin daily or U-500 insulin Diabetes being managed with an insulin pump Please do NOT refer the following patients: • • • Pediatric patients < 18 years old Diabetic patients unless already using an Insulin Pump or requiring ≥ 300 units of insulin daily or U-500 insulin Gender Dysphoria / Transsexual Patients Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Pg.14 University Medical Center at Brackenridge Specialty Clinics • • Recent pertinent labs (Appropriate labs per worksheet, drawn within the past month, substantiating the disorder. Please send lab flow sheets if they exist.) Recent pertinent scans or X-rays Revised May 2015 Pg.15 University Medical Center at Brackenridge Specialty Clinics Endocrinology Clinic Worksheet • Difficult to Control Lipid Abnormalities o Fasting Lipid Panel o Fasting Glucose • Thyroid Nodule o Thyroid Ultrasound within past 12 months for nodules ≥ 1cm o TSH o Free T4 • Hyperthyroidism o TSH o Free T 4 o I-123 Iodine uptake and scan • Difficult to Control Hypothyroidism o TSH o Free T4 • Osteoporosis o DXA Scan Results o CMP o TSH o Intact PTH o 25 (OH) Vitamin D o SPEP o UPEP o 24 hour urine for calcium and creatinine • Calcium and Parathyroid Disorders o Intact PTH o Serum Calcium o Serum Albumin o 24 hour urine for calcium and creatinine Revised May 2015 Pg.16 University Medical Center at Brackenridge Specialty Clinics Endocrinology Clinic Worksheet (continued) • Pituitary Masses and Disorders o MRI of the Sella Turcica o Serum Prolactin Level o TSH o Free T 4 o LH o FSH o IGF-1 o 8am Serum Cortisol Level • Adrenal Masses and Disorders o BMP o 8am Plasma Renin Activity o Aldosterone o 24 hour urine for Free Cortisol, Creatinine, Metanephrines and Catecholamines • Amenorrhea & Galactorrhea o Prolactin level o TSH o FSH o LH • Diabetes o Hgb A1C o CMP o Fasting Lipid Panel o Urine spot microalbumin and creatinine • Hypogonadism o 8am Total Testosterone o Prolactin level o TSH o FSH o LH o For patients age < 40: Ferritin, Serum Iron, TIBC Revised May 2015 Pg.17 University Medical Center at Brackenridge Specialty Clinics ENT Clinic (Head and Neck Surgery) • Provide care that is beyond the routine abilities of primary care physicians. Patients referred to the clinic should have problems that may require surgery or advanced ENT physician care. Appropriate patients for referral include: • • • • • • • • • • • • • • • • • • • • • Masses in the head and neck Suspected Cancer Thyroid Masses Parathyroid Masses Bleeding from unknown ENT source Chronic draining ear discharge persistent despite 3 weeks of treatment with appropriate topical and oral antibiotics Hoarseness persistent greater than 6 weeks Chronic Recurrent Tonsillitis with 4 or more episodes in the past year and/or 2-3 episodes annually over multiple years Chronic Recurrent Sinusitis evident on CT scan after 3 weeks of appropriate antibiotic treatment Obstructive Sleep Apnea (must have completed Sleep Study prior to referral)(less than 1 yr.) Vertigo persistent for greater than 6 weeks – need Audio Tinnitus (must have audiogram prior to referral) Tympanic Membrane Perforation (must have audiogram prior to referral) Conductive Hearing Loss (see Note below) Unilateral Sensorineural Hearing Loss (see Note below) Bilateral Sensorineural Hearing Loss in individuals less than age 65 (see Note below) Ankyloglossia (Tongue tie) Impacted ear was Snoring Tonsilar hypertrophy Deviated septum NOTE: Hearing loss must be documented by a formal audiogram at UMCB prior to ENT referral. Based on UMCB audiogram results, patients may be scheduled in ENT clinic or referred back to the primary care physician. Ears with drainage do not need Audiology. Pg.18 University Medical Center at Brackenridge Specialty Clinics Please do NOT refer the following patients: • • • Colds, minor infections, routine sinus problems TMJ Disorder Patient with obstructive sleep apnea already on machine and doing well. Documentation required for scheduling an appointment: • • • • • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Brief synopsis of prior pertinent treatments Pertinent imaging studies (send with patient if available) Pertinent negatives studies (eg. nl EKG, nl CT of brain) If another specialty has seen patient, send copy of their notes. Revised May 2015 Pg.19 University Medical Center at Brackenridge Specialty Clinics ENT Overbook Fax Request This form must be filled out entirely and faxed to (512) 380-7508. This form applies only to overbook requests from the Clinic for MAP patients. Patient Name: Authorization Number (if required) Reason for Referral: Please see patient: Next Clinic 4-8 weeks 9-12 weeks Please provide a brief medical justification for overbooking the patient: Pg.20 University Medical Center at Brackenridge Specialty Clinics Referring Clinic: Clinic Phone#: Clinic Fax# Referring Physician: Patient Contact Information: Please fax the completed form along with copies of pertinent physician findings, laboratory studies, and radiological studies. You should receive this form back within 1 week with an appointment time and date. It is the primary care clinic’s responsibility to notify the patient with their appointment date and time. If you do not receive the form within 1 week you may need to re-fax. For Office Use Only: Approved Denied Recommendations Revised May 2015 Pg.21 University Medical Center at Brackenridge Specialty Clinics Eye (Ophthalmology) Clinic Scope • To provide medical and surgical evaluation and management of patients with visual or ocular disorders. Appropriate patients for referral: • • • • • • • • • • • • • • • • Blurred vision, unexplained (not related to glasses) Persistent red eyes greater than 1 week ALL red eyes with pain or decreased vision Eye pain Glaucoma or at risk patients (Positive family history, race, high myopes) Cataracts – no overbooks allowed per physician Exophthalmos Advancing Pterygia Strabismus or diplopia (double vision) Lid lesions (cancer or Herpes Zoster) Abnormal lid contour (ectropion, entropion) Screening for patients taking Plaquenil Increased intracranial pressure (Pseudotumor) Structural brain abnormalities suspected of impairing visual pathway (e.g. pituitary tumors, A-V malformations, etc.) Macular degeneration Diabetic patients for retinal screening Please do NOT refer the following patients: • • • • • Sudden change in vision (refer to ED) Flashing lights and floaters (refer to ED) Patients needing glasses or contact lenses (no refraction is done in the eye clinic) Hypertensive patients without ocular symptoms Note: Children failing their vision test at school need to be referred to the Lion's Club (through the school nurse) where free glasses will be provided. Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Pg.22 University Medical Center at Brackenridge Specialty Clinics • Blurry vision, cataracts, glaucoma need optometrist note Revised May 2015 Pg.23 University Medical Center at Brackenridge Specialty Clinics Foot Clinic Scope • Examination and treatment (medical and surgical) of ankle and foot pathology. Appropriate patients for referral: • • • • • • • Foot / ankle deformities* Bunions * Ingrown toe nails Plantar fasciitis (does not need xray) Ganglion cyst Foot / ankle pain (need xray) Ulcerations of the foot in diabetes / neuropathies (no work up needed) Please do NOT refer the following patients: • • • • Referrals for routine foot care including diabetic foot checks Referrals for toenail debridement and/or onychomycosis** Referrals for orthotics (we cannot get these for patients) Pediatric patients age < 18 Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. • *Pre-examination x-rays – usually a standing AP and lateral of the affected foot (feet) is required. X-rays need to be sent to the clinic with the patient **refer to Derm Xrays must be less than 1 year old Revised May 2015 Pg.24 University Medical Center at Brackenridge Specialty Clinics Fracture Clinic Scope: • To evaluate and stabilize acute closed fractures involving upper & lower extremities, and manage splinting, casting and x-rays. All other non-traumatic orthopedic issues should be referred to Ortho Clinic. No emergency care is rendered in Fracture Clinic. Appropriate patients for referral include: • • • • Patients age 15 and above with acute closed fractures or dislocations verified by x-ray Patients with old fractures if experiencing new or worsening pain or deformity, or patients with new complaints about prior fracture surgery Sprains and strains seen in the ED Avulsion fractures, suspected avulsion fractures and stress fractures Please do NOT refer the following: • • • • • Suspected fractures not verified by x-ray Fractures in pediatric patients age 14 and younger (should be referred to DCMC Clinics) Open fractures (send to ED) Chronic orthopedic issues – Arthritis, Rotator Cuff Tear, Carpal Tunnel Syndrome (should be referred to Ortho Clinic) Fractures and injuries involving the hand and wrist including navicular/scaphoid injuries (should be referred to Plastic Surgery/Hand Clinic) Documentation required for scheduling an appointment: • • • • Radiographs (actual x-ray films, not just transcribed report) Pertinent ER reports / clinical reports Pertinent consult reports Pertinent operative reports NOTE: Referral RN to review, then print to Xray Room printer: BH/POB/2/Xray Revised May 2015 Pg.25 University Medical Center at Brackenridge Specialty Clinics Gastroenterology Clinic Scope • To evaluate complaints and/or abnormal objective findings attributed to the GI system including liver & pancreas and to recommend diagnostic testing, therapy and continuing care for these patients. Appropriate patients for referral include: • Please see worksheet The following are NOT appropriate for referral: • • Pediatric patients < 18 years old Incomplete work up (see worksheet below for recommendations) Documentation required for scheduling an appointment: • • • Completed referral form including documentation as indicated by worksheet Most recent lab and imaging results Specific question being asked Revised May 2015 Pg.26 University Medical Center at Brackenridge Specialty Clinics Gastroenterology Clinic Worksheet 1. GI Bleeding (occult or symptomatic) a. CBC b. Iron, Ferritin b. Medication history 2. Iron Deficiency Anemia and no evident source (if no iron deficiency consider hematological evaluation prior to GI referral) a. CBC b. Iron, TIBC or Ferritin c. Stool hemoccult. 3. Abnormal Liver Tests [LFTs First assess alcohol use and review medication causes a. Abnormal LFTs on 2 sets of results at least 6 weeks apart b. Abdominal liver ultrasound c. Ferritin, Iron, TIBC d. Acute Viral hepatitis panel 4. Cirrhosis a. CBC, PT/INR, CMP b. Acute Viral Hepatitis Panel, hepatitis A antibody total, Hepatitis B surface antibody total, and Hepatitis B core antibody total. c. Abdominal/liver ultrasound d. Documentation of ETOH history Pg.27 University Medical Center at Brackenridge Specialty Clinics e. Document Hepatitis A and B vaccination according to serologies. (Do not exclude patient if this is not included but other materials are present.) f. Recommend Flu/Pneumovax. 5. Hepatitis C Antibody Positive [HCV Ab +] Check the following and refer to GI if HCV is present by PCR. a. HCV RNA PCR quantitative & genotype b. CMP, CBC, HIV antibody c. Hepatitis A total antibody d. Hepatitis B surface antigen, surface antibody, core total antibody e. Abdominal/ liver Ultrasound 6. Hepatitis B Surface Antigen Positive [HBSAg +] Check the following and refer if HBV is present by PCR. a. HBV DNA PCR quantitative b. Hepatitis B surface antigen, surface antibody, e antigen and e antibody c. CMP, CBC, HIV antibody d. Hepatitis A total antibody e. Hepatitis C antibody f. Abdominal/liver Ultrasound 7. Inflammatory Bowel Disease a. Previous History b. Most recent endoscopy and colonoscopy reports Pg.28 University Medical Center at Brackenridge Specialty Clinics c. Pathology reports. d. LFTs, CBC, CMP e. Recommend Pneumovax vaccination f. Document Hepatitis A and B vaccination according to serologies. (Do not exclude patient if this is not included but other materials are present.) g. Recommend flu shot (Must check the type of IBD therapy that the patient is getting before flu shot). 8. Family History of Colon Polyps or Cancer [any age] Refer to GI Clinic if 1st degree family history- Age and what relative, 10 years of diagnosis of relative 9. Chronic Diarrhea (> 3 weeks duration) (refer to GI Clinic for any 1 or more of the following): I. Diagnostic uncertainty despite history, physical examination, and laboratory testing including: a. CBC, CMP and sedimentation rate b. Stool C&S, O&P X3 c. C. difficile toxin d. Stool WBCs e. HIV f. Thyroid studies g. Fecal occult blood X 3 If appropriate clinical history: Celiac panel, Qualitative Fecal fat. Giardia antigen, cyclospora, microspora, cryptosporidium. II. History or findings suggestive of malabsorption, or colonic or terminal ileal disease Pg.29 University Medical Center at Brackenridge Specialty Clinics III. Previous surgery involving extensive resection of ileum, right colon, bypass procedures, or cholecystectomy 10. Abdominal Pain (refer to GI Clinic for any 1 or more of the following): I. Diagnostic or therapeutic uncertainty after evaluation, including ALL of the following: a. Laboratory testing (CBC, CMP, serum amylase, serum lipase, urinalysis, urine pregnancy test) b. Noninvasive imaging studies (plain x-rays, ultrasonography, and/or computed tomography) II. Abdominal pain in special populations, including 1 or more of the following: a. Patients > 50 years old b. HIV-positive patients c. Immunosuppressed patients 11. Dysphagia Get ESOPHAGRAM on all patients 12. Dyspepsia (refer to GI Clinic for any 1 or more of the following): a. Persistent symptoms despite negative H. pylori stool antigen or Urea Breath test testing and 4 week PPI trial b. Persistent symptoms despite positive Helicobacter pylori stool antigen or Urea Breath test testing and eradication therapy. The Urea Breath test is a good option instead of the stool antigen with the following precautions: Patient must fast at least one hour prior to testing Pg.30 University Medical Center at Brackenridge Specialty Clinics The patient should not take: Antimicrobials within 4 weeks prior to testing. Proton pump inhibitors or bismuth preparations within 2 weeks prior to testing. H2 antaganist within 3 days prior to testing. Phenylketonuria patients should not have Urea breath test. Wait a minimum of 4 weeks following treatment prior to Urea Breath testing-because of false negative results. c. Patients with 1 or more of the following: Involuntary weight loss Gastrointestinal bleeding Dysphagia Odynophagia Unexplained iron-deficiency anemia Persistent vomiting Palpable mass or lymphadenopathy Jaundice Family history of upper gastrointestinal cancer Patients 50 years of age or older 13. Gastroesophageal Reflux Disease (GERD) (refer to GI Clinic for any 1 or more of the following): a. Symptoms of heartburn or regurgitation that have not responded to 8 week PPI trial b. Symptoms of laryngeal origin (eg, dyspnea, cough, hoarseness) that have not responded to 8 week PPI trial c. Suspected complicated GERD, as indicated by 1 or more of the following: Pg.31 University Medical Center at Brackenridge Specialty Clinics Dysphagia Odynophagia Bleeding Weight loss Early satiety Choking Anorexia Frequent vomiting d. Symptoms of GERD that have lasted longer than 5 years 14. Chronic Constipation a. Documentation of fiber, laxatives, stool softeners tried b. Acute bowel habit change c. List of medications d. TSH e. Serum Calcium f. CBC 15. Suspected Gastroparesis FOUR HOUR Gastric Emptying Study Revised May 2015 Pg.32 University Medical Center at Brackenridge Specialty Clinics Gynecology/Oncology Clinic Scope • • To evaluate newly diagnosed and recurrent or previously treated gynecologic type cancers. To evaluate pelvic masses with suspicion for gynecological malignancies. Appropriate patients for referral include: • • • • • • Any invasive gynecological cancer, newly diagnosed or recurrent Pelvic masses suspicious for invasive gynecological cancer Patients receiving treatment for their gynecological cancer Patients needing surveillance for their gynecological cancer BRCA positive patients VIN II and III Do NOT refer the following patients (Unless there has been a doctor to doctor consult and is approved by the Gyn/Onc clinic physician) • • • Any pre-invasive cancers o CIN I, II, III o VIN I o HGSIL or LGSIL on pap smear o Carcinoma in situ Fibroids Simple ovarian cyst Documentation required for scheduling an appointment • Documentation required for scheduling all appointments: o Completed referral form o History and physical with documented gynecology exam o Current medication list and co-morbidities o Patient demographics o If already diagnosed, pathology confirming cancer diagnosis o If previously treated for diagnosis, send all oncology notes and all treatment records (chemotherapy records, surgical records, radiation records) Pg.33 University Medical Center at Brackenridge Specialty Clinics • Additional information needed for Ovarian Cancer: o Any pertinent abdominal or pelvic imaging o CA125 o Supporting documentation for recurrence if suspected o If metastatic disease present, send supporting documentation for metastatic locations. • Additional information needed for Endometrial, Cervical, and Uterine Cancers: o Any pertinent abdominal or pelvic imaging o If metastatic disease present, send supporting documentation for metastatic locations. o Supporting documentation for recurrence if suspected • Additional information needed for pelvic masses suspicious for invasive cancer o Cat Scan or Ultrasound confirming mass • BRCA positive patients o BRCA results o Any abdominal or pelvic imaging done o CA 125 o Any surgical reports related to BRCA results (mastectomy/oophorectomy) PLEASE SEND LAST PAP SMEAR IF AVAILABLE FOR ALL REFERRALS DO NOT ASK FOR PAST MEDICAL HISTORY Revised May 2015 Pg.34 University Medical Center at Brackenridge Specialty Clinics Hematology Scope • • To provide specialty expertise in the evaluation and management of blood disorders beyond the scope of primary care physicians. To prioritize limited availability to patients with malignancies or complex hematologic disorders Appropriate patients for referral include: • • • • • • Persistent, severe anemia after complete evaluation and treatment Severe and/or clinically significant o thrombocytopenia o thrombocytosis o leukopenia o leukocytosis Monoclonal gammopathy Sickle Cell disease Hypercoagulable state Bleeding disorder Documentation required for scheduling an appointment: • • • • • • Completed referral form Patient demographics Current medication list and co-morbidities or problem list Two most recent provider notes Recent pertinent labs (See worksheet by diagnosis, drawn within the past 6 months, substantiating the disorder. Please send actual lab results not hand written flow sheets.) If previously treated by a Hematologist, send all hematology notes and previous treatment records. Additional information needed from previous 6 months (IF APPLICABLE) • • • • • Notes from all consultants (inpatient and outpatient) Discharge summaries from relevant hospitalizations All operative reports Diagnostic procedure reports (endoscopy, bronchoscopy, biopsies) All radiology reports Revised May 2015 Pg.35 University Medical Center at Brackenridge Specialty Clinics Hematology Referral Worksheet • Persistent, severe anemia after complete evaluation and treatment o Three consecutive CBC’s within the last year at least 1 month apart, most recent within 1 month of referral, with hemoglobin less than 10.0 o TIBC, Ferritin, Serum Iron, B12 level, Folate level, TSH o Iron deficiency is not appropriate for referral unless a complete GI evaluation has been performed (colonoscopy and upper endoscopy) o Anemia of renal insufficiency should be treated by nephrologist and is not appropriate for referral • Thrombocytosis o Three consecutive CBC’s within the last year at least 1 month apart, most recent within 1 month of referral o Persistent platelet count > 600 o Peripheral Smear o Iron deficiency has been ruled out • Thrombocytopenia o Three consecutive CBC’s within the last year at least 1 month apart, most recent within 1 month of referral o Persistent platelet count < 100, or two platelet counts < 50 o 1 CBC in citrated (blue top) tube to evaluate for clumping • Leukopenia o Three consecutive CBC’s within the last year at least 1 month apart, most recent within 1 month of referral o Persistent absolute neutrophil count less than 1500 o Lymphopenia is not appropriate for referral • Leukocytosis o Three consecutive CBC’s within the last year at least 1 month apart, most recent within 1 month of referral o Physician documentation excluding infection o Persistent absolute neutrophil count > 20,000 o Persistent absolute lymphocyte count > 10,000 • Monoclonal gammopathy o Serum protein electrophoresis (SPEP) o Serum immunofixation o Urine protein electrophoresis o CBC, CMP Pg.36 University Medical Center at Brackenridge Specialty Clinics • Sickle Cell disease o Hemoglobin electrophoresis documenting diagnosis • Hypercoagulable state (high risk thrombo-embolic event: DVT, PE, or atypical arterial event) o All radiology reports documenting thrombosis o Coumadin flowsheets if applicable o Specific question from referring physician, written on referral form, which is to be addressed by consultant • Bleeding disorder o Documentation of clinically significant bleeding o All related labs Revised May 2015 Pg.37 University Medical Center at Brackenridge Specialty Clinics Neurology Clinic Scope • • Neurology consultation Follow-up of complex neurological patients Appropriate patients for referral include: • • • • • • • • • Central Nervous System Diseases Parkinson's Disease Multiple Sclerosis Epilepsy not stable on a single medication (do not refer if seizure free ≥ 1 year)— must have current EEG within 6 months of appointment ((((MD to review))) Gait Disturbance Tremors that have not responded to trial of at least one medication Migraines persistent despite at least one prophylactic medication Back Pain—must have radicular signs and symptoms Peripheral Neuropathy (for suspected Carpal Tunnel Syndrome please use EMG referral form) Please do NOT refer the following patients: • • • • • • • • • Disability Evaluations Patients with suspected Carpal Tunnel Syndrome (please use EMG referral form) Back pain with positive MRI without radicular signs/symptoms Chronic Non-specific Pain (Complex Regional Pain Syndrome, Fibromyalgia, etc) Pediatric patients age < 18 Patients needing Pain Management Bell’s Palsy unless recurrent Patients with known Neurosurgery Needs (refer directly to Neurosurgery) Lime Disease Please Note: Appointments for EMGs are scheduled internally only Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Pg.38 University Medical Center at Brackenridge Specialty Clinics • • Previous diagnostic evaluations, including any head imaging Previous subspecialty evaluation Revised May 2015 Note: Neuro Epilepsy schedule comes from Liz Wedberg, NP Pg.39 University Medical Center at Brackenridge Specialty Clinics Neurology Clinic Worksheet Back Pain (acute only with no neurological signs) D D Problem list and problem list MRI Carpal Tunnel Syndrome D EMG Referral Form Seizures (do not refer if seizure free for 1 year) D D D Medication List and Problem list EEG (within the last 6 months) Anticonvulsant levels Parkinson’s Disease D Medication list and problem list Migraines (that have failed at least one prophylactic med) D Problem list and medication list. Multiple Sclerosis D Problem list and medication list. Gait Disturbances D Problem list and medication list Peripheral Neuropathy D D Problem list and medication list Fasting glucose, B12, folate, TSH, ANA, CK, Sjogren, Viral hepatitis panel, HIV if indicated, immunoelectrophoresis with fixation Pg.40 University Medical Center at Brackenridge Specialty Clinics Tremors (that have not responded to at least one drug trial) D Problem list and medication list. Memory loss D D D D Problem list and medication list. MRI brain TSH, B12, RPR EEG Revised May 2015 Pg.41 University Medical Center at Brackenridge Specialty Clinics EMG Referral Form Fax: (512) 380-7508 Patient Name / DOB: Referring Clinic: Referring Provider: Please do NOT refer the following: • • Patients with suspected CTS without trial of appropriate conservative therapy o Rest and wrist splinting for at least 1 month Patients with chronic pain without new focal symptoms/signs: o Fibromyalgia o Complex Regional Pain Syndrome Reason for Referral: □ □ Numbness/Paresthesias/Tingling Pain □ □ Weakness/Fatigue Increased CK, Possible Myopathy Prior treatment: Prior EMG’s Date & Reason: Other pertinent test results: Extremity Affected: □ □ □ □ □ Arm Leg Face/Tongue Diaphragm/Trunk/Abdomen Other: Pg. 42 Side: □ □ □ □ Right Left Right + Left Other: University Medical Center at Brackenridge Specialty Clinics Duration of Symptoms: □ <4 weeks (it takes 3-6 weeks to fully develop EMG abnormalities after nerve injury; schedule EMG on appropriate date, otherwise, repeat EMG may be necessary) □ □ □ □ >4 weeks >3 months >6 months >1 year Other Medical Problems (i.e. – DM, HIV, Alcohol Abuse): Physician Signature: Revised May 2015 Pg. 43 University Medical Center Brackenridge Specialty Clinics Oncology Clinic Scope • To evaluate and treat patients who have been diagnosed with cancer or treated for cancer. Appropriate patients for referral include: • • • • Newly diagnosed cancers Recurrent cancers Patients receiving treatment for cancer Patients needing follow-up for previously treated cancer Do NOT refer the following patients: • Patients suspicious for malignancy but no biopsy (pathology) confirming cancer. Biopsy Exception: Suspected Hepatocellular Carcinoma can be seen without a biopsy if liver imaging is diagnostic of HCC and AFP is elevated • • • • Thyroid cancer that has not spread (non-metastatic) Prostate cancer that has not spread Kidney cancer that has not spread Skin Cancer (except metastatic melanoma) Documentation required for scheduling all appointments: • • • • • • • Current referral form Patient demographics Current medication list and co-morbidities or problem list Two most recent provider notes Original pathology report confirming tissue diagnosis If previously treated for cancer diagnosis, all oncology notes and treatment records (chemotherapy flow sheets, operative notes) If recurrence suspected, send supporting documentation (radiology, biopsies, pathology) Additional information needed related to cancer (IF APPLICABLE) • • • • Notes from all consultants (inpatient and outpatient) All operative reports Diagnostic procedure reports (endoscopy, bronchoscopy) All radiology reports Pg. 44 University Medical Center Brackenridge Specialty Clinics NOTE: If additional documentation or testing is required, a request will be FAXED back to the referring clinic outlining the specific data needed. If the referral is incomplete or seems inappropriate, the MD will be consulted, and his recommendations will be stated on the form. Revised May 2015 Pg. 45 University Medical Center Brackenridge Specialty Clinics Orthopedic Clinic Scope: • To provide consultation and orthopedic care for orthopedic problems which are unable to be managed in outlying primary care clinics. Surgery may be arranged as indicated. Appropriate patients for referral: • • • • • • • • • Musculoskeletal complaints including problems involving joints, tendons and muscles after appropriate screening and adequate conservative care in the primary clinics Chronic arthritis Chronic tendonitis Ganglion cyst Arthralgia Carpal tunnel (need EMG report) Achilles tendon mass Trigger finger (no xray needed) Acute worsening arthritis Please do NOT refer the following: • • • • • • • • Acute closed fractures verified by x-ray (refer to Cast Clinic) Acute infections or injuries (send to ER) Neck pain and injuries (refer to Neurology Clinic) Foot problems (refer to Foot Clinic) Pediatric patients age 17 and under (refer to DCMC Ortho Clinic) Patients needing prostheses Acute or chronic low back pain Back, feet or hand problems Documentation required for scheduling an appointment: • • • • • • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Imaging of involved anatomic structure Lab/Imaging results can be more than 6 months but less than 1 year Specific statement of concern or question to be answered regarding orthopedic complaint Description, including time and duration, of conservative treatment Relevant lab data Revised May 2015 Pg. 46 University Medical Center Brackenridge Specialty Clinics Pulmonary Clinic Scope: • Evaluate patients with pulmonary disease beyond the scope of internal medicine and family practice. Appropriate patients for referral include: • • • • • • • Steroid dependent / difficulty with controlling asthma Lung mass Interstitial lung disease Sleep apnea—must have current sleep studies (within 3 months of appointment) Newly diagnosed COPD Unstable COPD Emphysema Please do NOT refer the following patients: • • • Stable/chronic low-level COPD (chronic obstructive pulmonary disease) Asthma (send to Asthma clinic) Pediatric patients Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. • • • • Current Chest X-ray (within the past 3 months) and old films if available Copy of prior work-up including any pulmonary function tests, CT scans, labs, etc. Results of any skin tests performed elsewhere (with dates & techniques). Current Pulmonary Function Tests (within 3 months of appointment) Revised May 2015 Pg. 47 University Medical Center Brackenridge Specialty Clinics Renal/Hypertension Clinic Scope • Evaluate and treat patients with renal insufficiency, significant proteinuria, past renal transplant, SLE with possible nephropathy, and refractory hypertension. Appropriate patients for referral include: • • • • • Renal Insufficiency (men Cr ≥ 1.4, women Cr ≥ 1.2 or SLE with any increase) Proteinuria ≥ 500mg/day (urine protein/urine creatinine ratio ≥ 0.5) Uncontrolled Hypertension (persistent SBP ≥ 160 despite compliance with 3 or more antihypertensive medications) Renal Transplant SLE with abnormal urinalysis or increased creatinine Please do NOT refer the following patients: • • • • Kidney stones (refer to Urology Clinic.) Hematuria with normal renal function and no proteinuria (refer to Urology Clinic) Proteinuria on dipstick alone (must have qualitative urine protein/urine creatinine ratio ≥ 0.5) Pediatric patients (age<18) Documentation required for scheduling an appointment: • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. • • • • Labs need to be within 1 month at the time of referral Renal ultrasound need to be within last 6 months Retinal exam need to be within last 2 years For Hospital and ER follow up, lab work 48 hours before appointment date Revised May 2015 Pg. 48 University Medical Center Brackenridge Specialty Clinics Renal/Hypertension Clinic Worksheet • Increased Creatinine o CMP o CBC o Urinalysis with micro o Renal Ultrasound (with post-void residual if age ≥ 50 or diabetic) o If diabetic, need Hbg A1C and ophthalmic exam results with referral papers • Proteinuria o o o o • Hypertension o o o o o • CMP Urinalysis with micro Urine protein/urine creatinine ratio If diabetic, need Hbg A1C and ophthalmic exam results sent before renal appointment CMP Complete urinalysis Renal Ultrasound if abnormal creatinine Echocardiogram if available Past medication trials Renal Transplant o Immunosuppressive (cyclosporine, prograf, or cellcept) trough level taken 15 minutes before medication dose o CMP o CBC • SLE o CMP o CBC o Urinalysis with micro o Urine protein/urine creatinine ratio o Renal Ultrasound Revised May 2015 Pg. 49 University Medical Center Brackenridge Specialty Clinics Rheumatology Clinic Scope: • To provide consultations at a subspecialty level in rheumatology. Appropriate patients for referral include: • • • • • • • • • (+)RF, (+)ANA titer =/> 1/160, (+) CCP Rheumatoid Arthritis Systemic Lupus Erythematosis Gout Ankylosing Spondylitis Reiter’s Syndrome Psoriatic Arthritis Scleroderma Muscle Diseases o Polymyositis o Dermatomyositis Please do NOT refer the following patients: • • • • Osteoarthritis Fibromyalgia Chronic Pain Migraines Documentation required for scheduling an appointment: • • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Recent pertinent lab (Complete lab profile, drawn within the past month, substantiating the disorder. Please send lab flow sheets if they exist.) Need CBC, CMP, Urinalysis, ESR, RF, ANA, CCP • Recent pertinent scans or X-rays Revised May 2015 Pg. 50 University Medical Center Brackenridge Specialty Clinics Rheumatology Clinic Worksheet o +ANA (R/O SLE or Lupus-like syndrome) & Connective Tissue Disease o ANA Panel with ANA titer =/> 1/160 o Anticardiolipins, o lupus anticoagulant o ESR o CBC o CPK o Beta 2 Glycoprotein o Hepatitis Panel o +RF o Anti CCP ab o Hepatitis screening panel o Serum immunofixation o Bilateral wrist and hand films o ANA Panel o Anticardiolipins, o lupus anticoagulant o ESR o CBC o CPK o *Negative Quantiferon TB or documented treatment of TB or documented negative PPD o Gout o Joint fluid crystal results o Uric acid level, CBC, CMP o List of Medications o Past Medical history o Ankylosing Spondylitis (spondyloarthropathy) o SI joint films (2 views) o HLAB 27 (Lab) o Hepatitis screening panel o *Negative Quantiferon TB or documented treatment of TB or documented negative PPD o Sclerdoderma o ANA Panel with ANA titer o CPK o Chest Xray o Barium swallow Pg. 51 University Medical Center Brackenridge Specialty Clinics o Hep screening panel o *Negative Quantiferon TB or documented treatment of TB or documented negative PPD o Muscle Diseases o Polynyositis o Dermatomyositis o CPK o ESR o Chest Xray o Barium swallow o *Negative Quantiferon TB or documented treatment of TB or documented negative PPD o Hepatitis screening panel o Psoriatic Arthritis o Anti CCP ab o ANA Panel o UA o CBC o CMP o ESR o Hepatitis panel o *Negative Quantiferon TB or documented treatment of TB or documented negative PPD *Only needed if patient has a history of positive TB test Revised May 2015 Pg. 52 University Medical Center Brackenridge Specialty Clinics Surgery Clinic Scope • • • Seeing referrals from outlying clinics Seeing referrals from other Brackenridge outpatient clinics Follow-up of surgical and trauma patients Appropriate patients for referral include: (any referrals outside this list will need to be Pre-approved by the surgeon) *(If suspicious for malignancy refer to Surgical Oncology)* • • • • • • • • • • • • • • • • • • • • • • • • • • Any hospital follow-up from general / trauma surgical service * Abdominal mass Ventral hernia / Incisional hernia** Umbilical hernia / mass** Inguinal hernia / mass** Groin hernia / mass** Thyroid mass / tumor / nodule / goiter (Team B) Parathyroid hyperplasia / nodule / adenoma (Team B) Lymph node biopsy / lymphadenopathy (((ASK MD IF IMAGING IS REQUIRED))) *Pancreatic cyst / pseudocyst / mass / tumor / nodule Splenomegaly *Liver / hepatic mass / tumor / nodule Gallstones / gallbladder / cholecystitis / biliary colic *Stomach mass / tumor / nodule / ulcer *Colon mass / tumor / nodule Bowel obstruction *Rectal mass / tumor / nodule / pain Anal fissure / abscess Guaiac / hemoccult positive / blood in stool (no colon screenings; limit 2 colon evals per day). Diverticulosis / diverticulitis Appendicitis Hemorrhoids Hidradenitis Melanoma Port-a-cath placement / removal / chemotherapy access Pilonidal cyst / abscess – any size, no xray Pg. 53 University Medical Center Brackenridge Specialty Clinics Please do NOT refer the following patients: • • • • • • • • • • • • • Small lipomas, cysts, or skin lesions less than 4 cm (Refer to Derm) GI bleeding which has not had H/H, stool guaiac Vague abdominal pain Breast Masses/Breast Disease (Refer to Shivers Center Breast Clinic) Testicular Masses Pediatric patients Screening Colonoscopy (((ASK MD))) Patient requesting cosmetic surgery evaluation Cancer (Refer to Shivers Center) Varicose Veins Hyperhydrosis Hydrocele – refer to Urology Cystocele – refer to Urogyn Documentation required for scheduling an appointment: • • • • • • • • Completed Referral form Past Medical History (PMH) Current medication list Most recent progress note describing condition for which patient is being referred. Include H&H and stool Guaiac if referring for GI bleeding Does referring physician wish patient to return after consult or desire surgical team to manage the problem patient is referred for Study results indicating need for surgery Pertinent X-ray films and reports Revised May 2015 Pg. 54 University Medical Center Brackenridge Specialty Clinics Urology Clinic Scope: • Urology care for adults. Appropriate patients for referral: • • • • • • • • Cancers of urinary tract (kidney, bladder, prostate, testicular) Obstructing kidney stones or stones > 1 cm (need non contrast CT prior) Hematuria (CT/IVP and urine cytology prior) document x 2 with micro. UA Urinary retention (after failed alpha blocker and voiding trial) Elevated PSA (confirmed with repeat value) PCKD without renal failure Peyronies Phimosis Please do NOT refer the following patients: • • • • • • • • • • • • • • • • Proteinuria (Refer to Renal Clinic) Skin rashes in genital area Pediatric patients age < 18 Acute UTI's Circumcisions (elective) Vasectomy or reversals Infertility Cystocele in women (Urogyn) PCKD with renal failure (Renal Clinic) Erectile Dysfunction Urinary incontinence for women (Urogyn) Sexual Dysfunction BPH Chronic testicular pain Hydrocele – unless patient is having persistent pain for 2-3 months Urinary incontinence for men Documentation required for scheduling an appointment: • • Completed referral form, problem list, and medication list Urinalysis and any other current, pertinent lab results. (Labs should be less than 3 months) Pg. 55 University Medical Center Brackenridge • Specialty Clinics Pertinent X-ray films (CT or US) and reports (should be less than 3 months) Revised May 2015 Pg. 56 University Medical Center Brackenridge Specialty Clinics Urology Clinic Worksheet • UTI – chronic or reoccurring only: o Send urine culture results – recent to appointment <3 months o IVP • Hematuria and Micro hematuria: o IVP (Priority)(or CT scan abdominal /pelvis with contrast), microscopic urinalysis (at least 2) documenting abnormal # of blood cells and absence of active infection o Urine Cytology • Urinary Frequency: • UA • Urine Culture • PSA required for men • Kidney Stones: o IVP or CT/abd/pelvis • Scrotal/Testicular Mass/Testicular Pain: o Scrotal Ultrasound • Prostate Problem: o PSA o Urine culture Note: If unable to do IVP (eg: allergic to contrast) get a Renal (abdominal) Ultrasound Revised May 2015 Pg. 57 University Medical Center Brackenridge Specialty Clinics FAX Transmittal — Specialty Clinics — MAP Patients Paul Bass Clinic — FAX #324-8074/324-8072 Shivers — Breast/Hem/Onc Clinic — FAX #324-7972/324-7138 Sub-specialty Clinic — FAX #324-7857/324-8203 From Clinic: Fax: Contact Name: Contact Phone: Pages (including fax transmittal): Re: NOTE: Appointment information will be faxed to the PCP clinic within 72 business hours of receiving a completed referral with all pertinent documentation. The PCP clinic is responsible for notifying the patient of the specialty appointment. Comments: The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the entity named above. If the reader of this transmission is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this transmission is strictly prohibited. If you received this transmission in error, please immediately notify us by telephone to arrange for return of the original documents. Pg. 58 University Medical Center Brackenridge Specialty Clinics Seton Imaging and Radiology — Required Labs Labs required prior to scheduled test: 1. ULTRASOUND a. Labs: PT, PTT CBC w/platelets, total INR i. US Guided Breast localization ii. US Breast tissue specimen iii. US Biospy Abdomen iv. US Guided Biopsy Breast v. US Biopsy Lung/mediastinum vi. US guided amniocentesis vii. US guided Biopsy viii. US Guided Biopsy Liver ix. US Guided Biopsy Renal x. US Guided Cyst Aspiration xi. US Guided paracentesis xii. US guided Percutaneous drainage xiii. US guided RAD SEEDS xiv. US guide THER FLD xv. US guided thoracentesis xvi. US mammography core biopsy left xvii. US mammography core biopsy right xviii. US Mammo cyst additional left/right xix. US Mammo cyst aspiration xx. US mammo needle placement left/right xxi. US Sed IV/IM/NHL xxii. US sed ORL/REC/NA 2. FLUOROSCOPY a. LABS: PT/PTT CBC w/platelets and total INR i. Lumbar puncture ii. C2 puncture w/injection (BUN, Creat.) iii. C2 puncture iv. Flouro needle biopsy (ALL FLUORO EXAMS WITH IV CONTRAST REQUIRES BUN AND CREATININE) Pg. 59 University Medical Center Brackenridge Specialty Clinics Seton Imaging and Radiology — Required Labs ( c o n ti n ue d) 3. CAT SCAN a. Labs: PT/PTT, CBC w/platelets and total INR, BUN and CREAT i. CT Biopsy- Abdomen ii. CT Biopsy Bone iii. CT biopsy Lung Left iv. CT Biopsy Lung Right v. CT Biopsy Liver vi. CT Biopsy Pancreas vii. CT Biopsy Pleura left viii. CT Biopsy Pleura right ix. CT Biopsy Renal left x. CT Biopsy Renal right xi. CT Cervical Puncture xii. CT C1/C2 Puncture xiii. CT Drainage Lung left xiv. CT Drainage Lunt right xv. CT Drainage liver xvi. CT drainage pancreas xvii. CT drainage peritoneal xviii. CT drainage retroperitoneal abscess xix. CT drainage renal left xx. CT drainage renal right xxi. CT drainage Subdiaphragm/subphrenic xxii. CT Guided Cyst aspiration xxiii. CT guided lumb kypho xxiv. CT guided lumb vert xxv. CT guide needle biopsy xxvi. CT guide percutaneous drainage xxvii. CT guide RFA xxviii. CT guide RTF placement xxix. CT injection Lumbar or Thoracic Spine (BUN and CREATININE REQUIRED FOR ALL CT EXAMS WITH IV CONTRAST) 4. MRI a. Labs: PT/PTT CBC w/platelets Total INR i. MR guided needle placement (All MRI EXAMS WITH IV CONTRAST REQUIRE BUN AND CREATININE) 5. NUCLEAR MEDICINE a. Labs: PT, PTT, CBC w/platelets INR i. NM lymphoscintgraph — breast(labs needed for surgery Pg. 60 University Medical Center Brackenridge Diagnostic Order Forms Specialty Clinics See attached order forms for the following: □ Audiology Testing o Phone 324-9999 x 77826 o Fax 380-7508 □ Cardiology Electroneurodiagnostic Testing o Phone 324-1375 o Fax 380-4263 □ Physical Therapy (OP Wound Care; OP OT Low Vision; OP MBS) o Phone 324-7600 o Fax 324-7566 □ Pulmonary Function Test □ Pulmonary Function Lab o Phone 324-1375 o Fax 380-4263 Pg. 61 University Medical Center Brackenridge Specialty Clinics Adult Audiology Request Form Phone: 512-324-9999 x77826 Fax: 512-380-7508 Please COMPLETE this updated Physician Order form for ADULT audiology referrals > Please include a demographics sheet, & please encourage your patients to show up for their appointments Requesting: D Basic Audio D Other THIS VISIT FROM: D REQUIRES AUTHORIZATION PHONE: Authorization #: FAX: D DOES NOT REQUIRE AUTHORIZATION ***Referrals without a fax number will be rejected*** (Must be) Full Name of Referring Physician: M.D. or D.O. Name of Patient’s PCP: Diagnosis/Reason for Referral (Check ALL that apply): D Decreased hearing D Otitis/inflammation of ear D Speech delay D Unilateral/asymmetric loss D TM perforation Pg. 62 D Tinnitus University Medical Center Brackenridge Specialty Clinics D Sudden hearing loss D Discharge from ear D Vertigo/dizziness D Ear Pain D Adverse affects of medication D Other Patient name:_ Date of birth / / Contact Numbers:_ Insurance Company: _Group or ID#: x _Date: Physician Signature and Date Required Pg. 63 University Medical Center Brackenridge Specialty Clinics Pg. 64 University Medical Center Brackenridge Specialty Clinics Pg. 65 University Medical Center Brackenridge Specialty Clinics Pg. 66 University Medical Center Brackenridge Specialty Clinics Pg. 67 University Medical Center Brackenridge Specialty Clinics Directions to Paul Bass Clinic: Directions from the Clinical Education Center (CEC) parking garage: (ONLY pink map card holders can receive a parking validation) □ The parking garage is located on the access road of 1-35 South, on the corner of 15th street □ Park in the parking garage and enter through the main entrance of the Clinical Education Center (CEC) □ Walk toward the right, passing the first set of elevators, and then follow the signs of the Paul Bass Clinic until the second set of elevators. □ Take the elevators down to Lower Level (LL). □ Make a right when you get out of the elevators and follow the signs to the Paul Bass Clinic. Directions from the Brackenridge Hospital parking garage: (ONLY pink map card holders can receive a parking validation) □ □ □ □ □ □ The parking garage is located on the corner of 15th Street and Red River. Take the parking garage elevator to Level 4. Follow the hallway to the entrance of Brackenridge Hospital. Pass the first set of elevators, and then follow the long hallway until you reach the second set of elevators. Take the elevators down of Lower Level (LL). Make a right when you get out of the elevators and follow the signs to the Paul Bass Clinic. Directions from the Capital Metro bus stop: 10 & 20 □ Enter the hospital through the main entrance located on the 1st floor. □ Pass the first set of elevators, pass the cafeteria, and then follow the long hallway until you get to the second set of elevators. □ Take the elevators down to the Lower Level (LL). □ Turn to the right when you get off the elevator and follow the signs to the Paul Bass Clinic. Directions from the Capital Metro bus stop: 37 □ Get off the bus on the corner of Red River and 15th Street. □ Enter the hospital through the main entrance located on the 1st floor. □ Pass the first set of elevators, pass the cafeteria, and then follow the long hallway until you get to the second set of elevators. □ Take the elevators down to the Lower Level (LL). □ Turn to the right when you get off the elevator and follow the signs to the Paul Bass Clinic. Pg. 68 University Medical Center Brackenridge Specialty Clinics Instrucciones si entre en el estacionamiento de CEC: (SOLAMENTE los recipientes de la tarjeta de MAP rosada pueden recibir la validación del estacionamiento) □ El estacionamiento está localizado en la carretera de acceso de 1-35 Sur, en la esquina de Calle 15. □ Estaciónese en el estacionamiento y entre en la entrada mayor del Centro de Educación Clinica (CEC). □ Camine hacia la derecha, pase los primeros elevadores, luego siga los signos de la Clinica de Paul Bass hasta los segundos elevadores. □ Tome los elevadores abajo al Piso LL. □ Dase una vuelta a la derecha cuando salga del elevador y siga los signos hacia la Clinica de Paul Bass. Instrucciones si entre en el estacionamiento del Hospital de Brackenridge: (SOLAMENTE los recipientes de la tarjeta de MAP rosada pueden recibir la validación del estacionamiento) □ □ □ □ □ □ El estacionamiento está localizado en la esquina de Calle 15 y Red River. Tome el elevador del estacionamiento al Nivel 4. Siga el vestibulo hacia la entrada del hospital de Brackenridge. Pase los primeros elevadores y siga el largo vestibulo hasta los segundos elevadores. Tome los elevadores abajo al Piso LL. Dase una vuelta a la derecha cuando salga del elevador y siga los signos hacia la Clinica de Paul Bass. Instrucciones desde la parada de Autobñs: 10 y 20 □ □ □ □ Entre en el hospital por la entrada mayor localizada en el primer piso. Pase los primeros elevadores, pase la cafeteria, luego siga el largo vestibulo hasta los segundos elevadores. Tome los elevadores abajo al Piso LL. Dase una vuelta a la derecha cuando salga del elevador y siga los signos hacia la Clinica de Paul Bass. Instrucciones desde la parada de Autobñs: 37 □ Salga del autobüs en la esquina de Red River y Calle 15. □ Entre en el hospital por la entrada mayor localizada en el primer piso. □ Pase los primeros elevadores, pase la cafeteria, luego siga el largo vestibulo hasta los segundos elevadores. □ Tome los elevadores abajo al Piso LL. □ Dase una vuelta a la derecha cuando salga del elevador y siga los signos hacia la Clinica de Paul Bass. Pg. 69 Pg. 70 University Medical Center Brackenridge Specialty Clinics University Medical Center Brackenridge Specialty Clinics REFERRAL FORM This form is intended to assure prompt communication back to requesting providers. Please Fax referral form and supporting documents to (512)380-7508. *Check Specialty Preference (Check one): Asthma Cardiology Cast Dermatology Endocrinology Nephrology Neurology Ophthalmology Orthopedic Podiatry Gastroenterology Pulmonology Rheumatology Surgery ENT Urology First Available No Preference *Patient Name: *Telephone: *Primary Language: *Alternative Number: Address: *Insurance Information (Plan Name): City: *DOB: State: *Policy number: Authorization number (if applicable): Exp Date: Pg. 71 Zip: *Exp Date *Referring Clinic: *Telephone: *Date: *Referring Physician: *Fax: *Submitted by: Reason for the Referral (please include appropriate diagnosis and attach pertinent clinical/progress notes or provide clinical narrative, including duration of problem, types of treatment, pertinent physical findings, pertinent testing results, diagnostic work-ups, including lab and imaging supporting documents): Overbook Request Information (Please specify below in detail reason for overbook): (For CommUnityCare Use) Appointment date: Time: * In order to process request all required fields must be completed NOTICE OF CONFIDENTIALITY – This document is intended solely for the use of the individual identity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or individual responsible for delivering the message to the intended recipient, you are hereby advised that any dissemination, distribution or copying of this information is strictly prohibited If you have received this communication in error please advise us immediately by telephone and destroy these papers Pg. 72 Pg. 73 Pg. 74 Pg. 75 Pg. 76 11. PHARMACY SERVICES PHARMACY SERVICES Pharmacy Co-payments MAP Network Pharmacies MAP Formulary Non-Formulary Medication Request Patient Assistance Programs (PAP) Medication Interim Fill MAP Pharmacy Hotline PHARMACY SERVICES Pharmacy Co-payments GROUP CBRACKFQ CBRACKFQ PLAN CBRACKFQ CPENDSSI Formulary Drug $7 co-pay for 1-30 day supply or $14 co-pay for 31-90* day supply or $0 co-pay if noted on MAP card * 90-day supply on selected drugs only Non-Formulary Drug $7 co-pay for 1-30 day supply or $14 co-pay for 31-90* day supply or $0 co-pay if noted on MAP card * 90-day supply on selected drugs only $7 co-pay for 1-30 day supply or $20 co-pay for 31-90* day supply or $0 co-pay if noted on MAP card $7 co-pay for 1-30 day supply or $20 co-pay for 31-90* day supply or $0 co-pay if noted on MAP card * 90-day supply on selected drugs only * 90-day supply on selected drugs only MAP Network Pharmacies A list of in-network pharmacies can be found on MAP website: http://www.medicalaccessprogram.net/get-care/sites-pharmacy/ :> See document entitled “MAP Network Pharmacies.” MAP Formulary :> See document entitled “MAP Formulary.” Non-Formulary Medication Request Submit a Medication Override Request Form if the patient cannot tolerate generic or formulary medication and requires a medication that is non- formulary. :> See document entitled “Medication Override Request Form.” Patient Assistance Programs (PAP) Medications If a patient is eligible for Patient Assistance Program (PAP) medications, Provider should: a. submit PAP paperwork on behalf of the patient and b. submit a Medication Override Request Form for consideration of an interim fill. :> See document entitled “Medication Override Request Form.” MAP Pharmacy Hotline: Telephone: (512) 978-8139 Fax: (512) 901-9763 Call the Pharmacy Hotline if you have questions or need copies of MAP pharmacy documents. Pharmacy Locations MAP clients assigned to CommUnityCare can use one of the listed pharmacies: H-E-B (512-478-8086) 2701 E. Seventh St., 78702 H-E-B (512-926-0586) 7112 Ed Bluestein Blvd., 78723 H-E-B (512-442-1578) 2400 S. Congress Ave., 78704 H-E-B (512-448-3353) 2508 E. Riverside Dr., 78741 H-E-B (512-441-3692) 6607 S. IH35, 78744 H-E-B (512-282-0990) 2110 New Slaughter Ln., 78748 H-E-B (512-301-9772) 5800 W. Slaughter Ln., 78749 H-E-B (512-837-9580) 9414 N. Lamar Blvd., 78753 H-E-B (512-459-8308) 1000 E. 41 St., 78751 H-E-B (512-339-6644) 12407 N. Mopac, 78758 H-E-B (512-251-5286) 1434 Wells Branch Pkwy., 78660 H-E-B (512-336-7706) 7301 N FM 620, 78726 H-E-B (512-474-2662) 1801 E 51st St, 78723 Rite-Away Pharmacy (512-827-2600) 730 West Stassney Lane, Suite 160, 78745 Lamar Plaza (512-442-6777) 1132 S. Lamar Blvd., 78704 38th St. Pharmacy (512-458-3784) 711 W. 38th St. #C3, 78705 Southeast Health & Wellness Center (512-978-9901) 2901 Montopolis Dr., 78741 Medical Access Program (MAP) Formulary- 2016 AHFS Classification 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 100000 ANTINEOPLASTIC AGENTS 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120400 PARASYMPATHOMIMETIC (CHOLINERGIC AGENTS) 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 120808 ANTIMUSCARINICS/ANTISPASMODICS 121208 BETA-ADRENERGIC AGONISTS 121208 BETA-ADRENERGIC AGONISTS 121208 BETA-ADRENERGIC AGONISTS 121208 BETA-ADRENERGIC AGONISTS 121208 BETA-ADRENERGIC AGONISTS 121208 BETA-ADRENERGIC AGONISTS 121212 ALPHA- AND BETA-ADRENERGIC AGONISTS 121212 ALPHA- AND BETA-ADRENERGIC AGONISTS 121604 ALPHA-ADRENERGIC BLOCKING AGENT(SYMPATH) 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122004 CENTRALLY ACTING SKELETAL MUSCLE RELAXNT 122012 GABA-DERIVATIVE SKELETAL MUSCLE RELAXANT 122012 GABA-DERIVATIVE SKELETAL MUSCLE RELAXANT Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name HYDROXYUR CAP 500MG PAR 100@ LETROZOL TAB 2.5MG UD+ AHP 30 MEGESTR AC OS 40MG/ML SKY 20@ MEGESTR TAB 40MG ROX 100 MERCAPTOPUR TAB 50MG ROX 25@ METHOTREXATE 2.5MG TAB AVK 100 TAMOXIFEN CITR TB 10MG MYL 60@ TAMOXIFEN CITR TB 20MG MYL 30@ BETHANECOL TB 10MG UD AHP 100 BETHANECOL TB 25MG UD AHP 100 DONEPEZIL 10MG TAB GOLD 30 DONEPEZIL 5MG TAB GOLD 30 GALANTAM TAB 4MG UD UDL 30@ GALANTAM TAB 8MG UD UDL 30@ PILOCAR TAB 5MG ACTA 100@ PILOCARP HCL TAB 7.5MG MARL100 CHLORDIAZ+CLIN+BR5/2.5MGOCE1C@ DICYCLOM CAP 10MG LANN 100@ DICYCLOM O/S 10MG/5ML Q/P 16Z@ DICYCLOM TAB 20MG WAT 100@ HYOSCYAM ER TB .375MG BCPI100@ HYOS SUL O/D TB.125MG BCPI100 HYOS SUL SUBL TB.125MG BCPI100 HYOS SUL ORAL TB.125MG BCPI100 IPRATRO INH SOL 0.02%UDNEPH25@ RR IPRATRO BR/ALBU 3MLUDNEPH30 PROVENTIL HFA INH 6.7GM 200DSE ALBUTEROL INH 0.5% HI-T 20ML@ ALBUTEROL SYRP 2MG TEV 16OZ@ ALBUTEROL SUL TAB 2MG MUT 100@ ALBUTEROL SUL TAB 4MG MUT 100@ ALBUTEROL INH 0.083%MYL 3ML30@ EPIPEN JR .15MG .3ML 1:2M 2PK EPIPEN 0.3MG 0.3ML 1:1M 2PK TAMSUL HYD CAP 0.4MG AURO100@ CARISOPRODOL 350MG TAB VEN100@ CHLORZOX TAB 500MG WAT 100@ CYCLOBENZA HCI TAB10MG MARL100 CYCLOBENZ TAB 5MG UD+ AHP 30 METAXALONE TAB 800MG UD AHP30 METHOCARB TAB 500MG UD AVK50 METHOCARB TAB 750MG UD AVK50 TIZANIDINE CAP 2MG MYL 150 TIZANIDINE CAP 4MG MYL 150 TIZANIDINE TAB 2MG UD+ AHP 30 TIZANIDINE TAB4MG UD MMP10X10@ BACLOFEN TAB 10MG AVK 90 BACLOFEN TAB 20MG UD AHP 100 GenericName HYDROXYUREA LETROZOLE MEGESTROL ACETATE MEGESTROL ACETATE MERCAPTOPURINE METHOTREXATE SODIUM TAMOXIFEN CITRATE TAMOXIFEN CITRATE BETHANECHOL CHLORIDE BETHANECHOL CHLORIDE DONEPEZIL HCL DONEPEZIL HCL GALANTAMINE HBR GALANTAMINE HBR PILOCARPINE HCL PILOCARPINE HCL CHLORDIAZEPOXIDE/CLIDINIUM BR DICYCLOMINE HCL DICYCLOMINE HCL DICYCLOMINE HCL HYOSCYAMINE SULFATE HYOSCYAMINE SULFATE HYOSCYAMINE SULFATE HYOSCYAMINE SULFATE IPRATROPIUM BROMIDE IPRATROPIUM/ALBUTEROL SULFATE ALBUTEROL SULFATE ALBUTEROL SULFATE ALBUTEROL SULFATE ALBUTEROL SULFATE ALBUTEROL SULFATE ALBUTEROL SULFATE EPINEPHRINE EPINEPHRINE TAMSULOSIN HCL CARISOPRODOL CHLORZOXAZONE CYCLOBENZAPRINE HCL CYCLOBENZAPRINE HCL METAXALONE METHOCARBAMOL METHOCARBAMOL TIZANIDINE HCL TIZANIDINE HCL TIZANIDINE HCL TIZANIDINE HCL BACLOFEN BACLOFEN Generic Dose Form CAPSULE TABLET ORAL SUSP TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE SOLUTION TABLET TAB ER 12H TAB RAPDIS TAB SUBL TABLET SOLUTION AMPUL-NEB HFA AER AD SOLUTION SYRUP TABLET TABLET VIAL-NEB AUTO INJCT AUTO INJCT CAP ER 24H TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE TABLET TABLET TABLET TABLET Dose Strength Description Name 500 MG 2.5 MG 400MG/10ML 40 MG 50 MG 2.5 MG 10 MG 20 MG 10 MG 25 MG 10 MG 5 MG 4 MG 8 MG 5 MG 7.5 MG 5 MG-2.5MG 10 MG 10 MG/5 ML 20 MG 0.375 MG 0.125 MG 0.125 MG 0.125 MG 0.2 MG/ML 0.5-3MG/3 90 MCG 5 MG/ML 2 MG/5 ML 2 MG 4 MG 2.5 MG/3ML 0.15MG/0.3 0.3MG/0.3 0.4 MG 350 MG 500 MG 10 MG 5 MG 800 MG 500 MG 750 MG 2 MG 4 MG 2 MG 4 MG 10 MG 20 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 129200 AUTONOMIC DRUGS, MISCELLANEOUS 129200 AUTONOMIC DRUGS, MISCELLANEOUS 129200 AUTONOMIC DRUGS, MISCELLANEOUS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201204 ANTICOAGULANTS 201218 PLATELET-AGGREGATION INHIBITORS 201218 PLATELET-AGGREGATION INHIBITORS 201218 PLATELET-AGGREGATION INHIBITORS 202400 HEMORRHEOLOGIC AGENTS 202816 HEMOSTATICS 240404 ANTIARRHYTHMIC AGENTS 240404 ANTIARRHYTHMIC AGENTS 240404 ANTIARRHYTHMIC AGENTS 240408 CARDIOTONIC AGENTS 240408 CARDIOTONIC AGENTS 240604 BILE ACID SEQUESTRANTS 240604 BILE ACID SEQUESTRANTS 240604 BILE ACID SEQUESTRANTS 240604 BILE ACID SEQUESTRANTS 240606 FIBRIC ACID DERIVATIVES 240606 FIBRIC ACID DERIVATIVES 240606 FIBRIC ACID DERIVATIVES 240606 FIBRIC ACID DERIVATIVES 240606 FIBRIC ACID DERIVATIVES 240606 FIBRIC ACID DERIVATIVES 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS 240608 HMG-COA REDUCTASE INHIBITORS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name NICOTINE PATCH S-2 14MG NOV 7 NICOTINE PATCH S-1 21MG NOV 14 NICOTINE PATCH S-3 7MG NOV 7 HEPAR CPJ 5MU 1ML SLMPK HW 50 HEPAR SOD MDV 50MU 10ML SKY25@ JANTOVEN TAB 1MG 100 JANTOVEN TAB 10MG 100 JANTOVEN TAB 2MG 100 JANTOVEN TAB 2.5MG 100 JANTOVEN TAB 3MG 100 JANTOVEN TAB 4MG 100 JANTOVEN TAB 5MG 100 COUMADIN TAB 6MG 100 COUMADIN TAB 7.5MG 100 CILOSTAZ TAB 100MG SAN 60@ CILOSTAZ TAB 50MG UD+ AHP 30 CLOPIDOGREL TAB 75MG VEN30@ PENTOXIFYL ER TB 400MG AVK 100 AMINOCAP AC SOL 25% VERS 8OZ RR AMIODARONE TB 200MG UDL 25@ FLECAIN ACET TB100MG UDAVK5X10 FLECAIN ACET TB50MG UD AVK5X10 DIGOX TAB 125MCG PAR 100@ DIGOX TAB 250MCG PAR 100@ CHOLESTYR PW 4GM/5GM U/S 60@ CHOLESTYR PW 4GM/5GM U/S378GM@ PREVALITE PWD 4GM PKT U/S 42@ PREVALITE PWD CAN42DSU/S231GM@ FENOFIBRATE TAB 160MG AVK 30 FENOFIBR TB 54MG UD+ AHP 30 FENOFIBR CP 134MG UD AHP 20 FENOFIBR CAP 200MG UD AHP 30@ FENOFIBRATE CAP 67MG MYLN 90@ GEMFIBR TAB 600MG UD AVK 50 ATORVASTATIN 10MG UD GOLD 100 ATORVASTATIN 20MG UD GOLD 100 ATORVASTATIN 40MG UD GOLD 100 ATORVASTATIN 80MG UD GOLD 30 LOVASTAT TAB 10MG UD AVK 5X10 LOVASTAT TAB 20MG UD AVK 5X10 LOVASTAT TAB 40MG UD AVK 5X10 PRAVAST SOD TAB 10MG GLEN 90@ PRAVAST NA TAB 20MG APX 90@ PRAVAST TAB 40MG SAN 90@ PRAVAST NA TB 80MG UD AHP 30 SIMVASTATIN TB 10MG UD AVK5X10 SIMVASTATIN TB 20MG UD AVK5X10 SIMVASTATIN TB 40MG UD AVK5X10 GenericName NICOTINE NICOTINE NICOTINE HEPARIN SODIUM PORCINE HEPARIN SODIUM PORCINE WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM WARFARIN SODIUM CILOSTAZOL CILOSTAZOL CLOPIDOGREL BISULFATE PENTOXIFYLLINE AMINOCAPROIC ACID AMIODARONE HCL FLECAINIDE ACETATE FLECAINIDE ACETATE DIGOXIN DIGOXIN CHOLESTYRAMINE (WITH SUGAR) CHOLESTYRAMINE (WITH SUGAR) CHOLESTYRAMINE/ASPARTAME CHOLESTYRAMINE/ASPARTAME FENOFIBRATE FENOFIBRATE FENOFIBRATE MICRONIZED FENOFIBRATE MICRONIZED FENOFIBRATE MICRONIZED GEMFIBROZIL ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM LOVASTATIN LOVASTATIN LOVASTATIN PRAVASTATIN SODIUM PRAVASTATIN SODIUM PRAVASTATIN SODIUM PRAVASTATIN SODIUM SIMVASTATIN SIMVASTATIN SIMVASTATIN Generic Dose Form PATCH TD24 PATCH TD24 PATCH TD24 CARTRIDGE VIAL TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET ER SOLUTION TABLET TABLET TABLET TABLET TABLET POWD PACK POWDER POWD PACK POWDER TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET Dose Strength Description Name 14MG/24HR 21 MG/24HR 7MG/24HR 5000/ML(1) 5000/ML 1 MG 10 MG 2 MG 2.5 MG 3 MG 4 MG 5 MG 6 MG 7.5 MG 100 MG 50 MG 75 MG 400 MG 250 MG/ML 200 MG 100 MG 50 MG 125 MCG 250 MCG 4G 4G 4G 4G 160 MG 54 MG 134MG 200 MG 67 MG 600 MG 10 MG 20 MG 40 MG 80 MG 10 MG 20 MG 40 MG 10 MG 20 MG 40 MG 80 MG 10 MG 20 MG 40 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 240608 HMG-COA REDUCTASE INHIBITORS 240692 ANTILIPEMIC AGENTS, MISCELLANEOUS 240692 ANTILIPEMIC AGENTS, MISCELLANEOUS 240692 ANTILIPEMIC AGENTS, MISCELLANEOUS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240816 CENTRAL ALPHA-AGONISTS 240820 DIRECT VASODILATORS 240820 DIRECT VASODILATORS 240820 DIRECT VASODILATORS 240820 DIRECT VASODILATORS 240820 DIRECT VASODILATORS 240820 DIRECT VASODILATORS 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 241208 NITRATES AND NITRITES 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242000 ALPHA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name SIMVASTATIN TB 5MG UD AVK5X10 NIASPAN ER TAB 1000MG 90 NIASPAN ER TAB 500MG 90 NIASPAN ER TAB 750MG 90 CLONIDINE 0.1MG/D PATCH ACT 4@ CLONIDINE 0.2MG/D PATCH ACT 4@ CLONIDINE 0.3MG/D PATCH ACT 4@ CLONIDINE TAB 0.1MG Q/P 90@ CLONIDINE TAB 0.2MG Q/P 100@ CLONIDINE HCI TAB .3MG UNI500@ METHYLD TAB 250MG TEV 100@ METHYLDOPA TAB 500MG ACC 100@ HYDRALZNE HCITB UD10MGMMP10X10 HYDRALAZ HCL TAB 100MG STR100@ HYDRALAZ HCL TAB 25MG STR100@ HYDRALAZ HCL TAB 50MG STR100@ MINOXIDIL TAB 10MG MUT 100@ MINOXIDIL TAB 2.5MG AVK 90 ISOSOR DIN TAB 10MG UD AHP100@ ISOSOR DIN TAB 20MG UD AHP100@ ISOSOR OR TB 30MG PAR 100@ ISOSOR DIN TAB 5MG PAR 100 ISOSOR MON ER TB 120MG UDAVK50 ISOSOR MON ER TB 30MG UDMMP100 ISOSOR MON ER TB 60MG UDMMP100 ISOSOR MON TB 10MG KREM 100@ ISOSOR MON TB 20MG ACTA 100@ NITRO TD PATCH-A 0.1MG MYL 30@ NITROGLYC TRNS DRM.2MG HERC30@ NITROGLYC TRNS DRM.4MG HERC30@ NITROSTAT SUBL TAB 0.3MG 100 NITROSTAT SUBL TAB 0.4MG 4X25 NITROSTAT SUBL TAB 0.6MG 100 CARDURA XL TAB 4MG 30 CARDURA XL TAB 8MG 30 DOXAZOSIN TAB 1MG UD+ AHP 30 DOXAZOSIN TAB 2MG UD+ AHP 30 DOXAZOSIN TAB 4MG UD+ AHP 30 DOXAZOSIN TAB 8MG GRE 100 PRAZOSIN CAP 1MG TEV 100@ PRAZOSIN CAP 2MG TEV 100@ PRAZOSIN CAP 5MG TEV 100@ TERAZOSIN HCL CAP 1MG MYLN 1C@ TERAZOSIN HCL CP 10MG MYLN 1C@ TERAZOSIN HCL CAP 2MG MYLN 1C@ TERAZOSIN HCL CAP 5MG MYLN 1C@ ATENOL TAB 100MG AVK 45 ATENOL TAB 25MG AVK 45 GenericName SIMVASTATIN NIACIN NIACIN NIACIN CLONIDINE CLONIDINE CLONIDINE CLONIDINE HCL CLONIDINE HCL CLONIDINE HCL METHYLDOPA METHYLDOPA HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL HYDRALAZINE HCL MINOXIDIL MINOXIDIL ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE NITROGLYCERIN NITROGLYCERIN NITROGLYCERIN NITROGLYCERIN NITROGLYCERIN NITROGLYCERIN DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE DOXAZOSIN MESYLATE PRAZOSIN HCL PRAZOSIN HCL PRAZOSIN HCL TERAZOSIN HCL TERAZOSIN HCL TERAZOSIN HCL TERAZOSIN HCL ATENOLOL ATENOLOL Generic Dose Form TABLET TAB ER 24H TAB ER 24H TAB ER 24H PATCH TDWK PATCH TDWK PATCH TDWK TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TAB ER 24H TAB ER 24H TAB ER 24H TABLET TABLET PATCH TD24 PATCH TD24 PATCH TD24 TAB SUBL TAB SUBL TAB SUBL TAB ER 24 TAB ER 24 TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE TABLET TABLET Dose Strength Description Name 5 MG 1000 MG 500 MG 750 MG 0.1MG/24HR 0.2MG/24HR 0.3MG/24HR 0.1 MG 0.2 MG 0.3 MG 250 MG 500 MG 10 MG 100 MG 25 MG 50 MG 10 MG 2.5 MG 10 MG 20 MG 30 MG 5 MG 120 MG 30 MG 60 MG 10 MG 20 MG 0.1MG/HR 0.2MG/HR 0.4MG/HR 0.3 MG 0.4 MG 0.6 MG 4 MG 8 MG 1 MG 2 MG 4 MG 8 MG 1 MG 2 MG 5 MG 1 MG 10 MG 2 MG 5 MG 100 MG 25 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242400 BETA-ADRENERGIC BLOCKING AGENTS 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242808 DIHYDROPYRIDINES 242892 CALCIUM-CHANNEL BLOCKING AGENTS, 242892 CALCIUM-CHANNEL BLOCKING AGENTS, 242892 CALCIUM-CHANNEL BLOCKING AGENTS, 242892 CALCIUM-CHANNEL BLOCKING AGENTS, 242892 CALCIUM-CHANNEL BLOCKING AGENTS, 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. MISC. MISC. MISC. MISC. MISC. Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name ATENOL TAB 50MG AVK 45 ATENOL+CHL TAB 1C/25 WAT 100@ ATENOL+CHL TAB 50/25 WAT 100@ BISOPR+HCTZ 10/6.25MG UNIC 30@ BISOPR+HCTZ 2.5/6.25MG UNIC30@ BISOPR+HCTZ 5/6.25MG UNIC 30@ CARVEDILOL TB 12.5MGUD AHP100@ CARVEDILOL TB 25MG AVK 90 CARVEDILOL TB3.125MG UDAHP1C@ CARVEDILOL TB 6.25MGUD AHP100@ LABETALO HCI TB 100MG COUN100@ LABETALO HCI TB 200MG COUN100@ LABETALO HCI TB 300MG COUN100@ METOPROL TRT TB100MG UDMMP100@ METOPRO TRT TB 25MG UD MMP100@ METOPROL TRT TB50MG UD MMP100@ NADOLOL TB 20MG UD AHP 30 NADOLOL TB 40MG UD AHP 30 NADOLOL TAB 80MG GRE 100 PROPRAN ER CAP 120MG BRECK 500 PROPRAN ER CAP 160MG BRECK 500 PROPRAN ER CAP 60MG BRECK 500 PROPRAN ER CAP 80MG BRECK 500 PROPRANOLOL TAB 10MG 100 NSTR PROPRANOLOL TAB 20MG NSTR 100 PROPRANOLOL TAB 40MG 100 NSTR PROPRANOLOL TAB 60MG 100 NSTR PROPRANOLOL TAB 80MG 100 NSTR SOTALOL AF TAB 120MG MYLN 100 SOTALOL AF TAB 160MG MYLN 100 SOTALO HCL TB 80MG UD AHP 100@ AMLODIPINE BES 10MG UD AVK50@ AMLODIPINE BES 2.5MG UD AVK 50 AMLODIPINE BES 5MG UD AVK 50@ AMLODIPINE BENZ 10/20 UD+AHP20 AMLO BESY+BNZ 10/40MG DR/R 1C@ AMLODIPINE CP 2.5/10MG WAT 100 AMLODIPINE CP 5/10MG WAT 100 AMLODIPINE CP 5/20MG WAT 100 AMLO BESY+BENZ 5/40MG DR/R 1C@ NIFEDIPINE CAP 10MG AVK UD50 NIFEDIPINE CAP 20MG AVK UD50 DILTIAZEM ER CP 120MG MYLN 1C@ DILTIAZEM SR CP 60MG UD UDL1C@ DILTIAZEM ER CP 90MG MYLN 100@ CARTIA XT CAP 120MG WAT 90@ CARTIA XT CAP 180MG WAT 90@ CARTIA XT CAP 240MG WAT 90@ GenericName ATENOLOL ATENOLOL/CHLORTHALIDONE ATENOLOL/CHLORTHALIDONE BISOPROLOL FUMARATE/HCTZ BISOPROLOL FUMARATE/HCTZ BISOPROLOL FUMARATE/HCTZ CARVEDILOL CARVEDILOL CARVEDILOL CARVEDILOL LABETALOL HCL LABETALOL HCL LABETALOL HCL METOPROLOL TARTRATE METOPROLOL TARTRATE METOPROLOL TARTRATE NADOLOL NADOLOL NADOLOL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL SOTALOL HCL SOTALOL HCL SOTALOL HCL AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL AMLODIPINE BESYLATE/BENAZEPRIL NIFEDIPINE NIFEDIPINE DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL Generic Dose Form TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAP SA 24H CAP SA 24H CAP SA 24H CAP SA 24H TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAP ER 12H CAP ER 12H CAP ER 12H CAP ER 24H CAP ER 24H CAP ER 24H Dose Strength Description Name 50 MG 100MG-25MG 50 MG-25MG 10-6.25MG 2.5-6.25MG 5-6.25MG 12.5 MG 25 MG 3.125 MG 6.25 MG 100 MG 200 MG 300 MG 100 MG 25 MG 50 MG 20 MG 40 MG 80 MG 120 MG 160 MG 60 MG 80 MG 10 MG 20 MG 40 MG 60 MG 80 MG 120 MG 160 MG 80 MG 10 MG 2.5 MG 5 MG 10 MG-20MG 10 MG-40MG 2.5MG-10MG 5 MG-10 MG 5 MG-20 MG 5 MG-40 MG 10 MG 20 MG 120 MG 60 MG 90 MG 120 MG 180 MG 240 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 242892 CALCIUM-CHANNEL BLOCKING AGENTS, MISC. 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name CARTIA XT CAP 300MG WAT 90@ DILTIAZEM CD CAP 360MG OCEA 90 DILTIAZEM XR CP 120MG APX 100@ DILTIAZEM ER CP 180MG APX 100@ DILTIAZEM XR CP 240MG APX 100@ TAZTIA XT CAP 120MG WAT 30@ TAZTIA XT CAP 180MG WAT 30@ TAZTIA XT CAP 240MG WAT 30@ TAZTIA XT CAP 300MG WAT 30@ TAZTIA XT CAP 360MG WAT 30@ DILTIAZ HCL ER CP 420MG VAL 90 DILTIAZEM TAB 120MG TEV 100@ DILTIAZEM TAB 30MG TEV 100@ DILTIAZEM TAB 60MG TEV 100@ DILTIAZEM TAB 90MG TEV 100@ VERAPAM SR CAP 120MG WAT 100@ VERAPAM ER CAP 180MG MYLN 100@ VERAPAM SR CAP 240MG WAT 100@ VERAPAM SR CAP 360MG WAT 100@ VERAPAM TAB 120MG WHT WAT 100@ VERAPAMIL TAB 40MG WAT 100@ VERAPAM TAB 80MG UD UDL 100 VERAPAM ER TAB 120MG IVA 100@ VERAPAM ER TAB 180MG IVA 100@ VERAPAM ER TB 240MG UD AHP100 BENAZEP TAB 10MG UD AVK 50 BENAZEP TAB 20MG UD AVK 50 BENAZEP TAB 40MG UD+ AHP 30 BENAZEP TAB 5MG UD AVK 50 BENAZEP HCTZ 10/12.5MG SAN100@ BENZEP HYD TB 20/12.5MG RIS100 BENAZ HCTZ FCT 20/25MG APOT100 CAPTOPR TAB 100MG MYL 100@ CAPTOPR TAB 12.5MG MYL 100@ CAPTOPR TAB 25MG MYL 100@ CAPTOPR TAB 50MG MYL 100@ CAPTOPR HCTZ TAB 25/15 MYL 1C@ CAPTOPR HCTZ TAB 25/25 MYL 1C@ ENALAPR MAL TAB 10MG VAL 30 ENALAPR MAL TAB 2.5MG VAL 30 ENALAPR MAL TAB 20MG VAL 30 ENALAPR MAL TAB 5MG VAL 30 ENALAPR TAB 10MG/25MG VAL 100 ENALAPR HCTZ TB 12.5MG APX 100 FOSINOP TAB 10MG SAN 90@ FOSINOP TAB 20MG SAN 90@ FOSINOP TAB 40MG SAN 90@ FOSINOP SO/HCTZ 10/12.5 CIT 30 GenericName DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL DILTIAZEM HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL VERAPAMIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL HCL BENAZEPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL/HYDROCHLOROTHIAZIDE CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL CAPTOPRIL/HYDROCHLOROTHIAZIDE CAPTOPRIL/HYDROCHLOROTHIAZIDE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL MALEATE ENALAPRIL/HYDROCHLOROTHIAZIDE ENALAPRIL/HYDROCHLOROTHIAZIDE FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL SODIUM FOSINOPRIL/HYDROCHLOROTHIAZIDE Generic Dose Form CAP ER 24H CAP ER 24H CAP ER DEG CAP ER DEG CAP ER DEG CAPSULE ER CAPSULE ER CAPSULE ER CAPSULE ER CAPSULE ER CAPSULE ER TABLET TABLET TABLET TABLET CAP24H PEL CAP24H PEL CAP24H PEL CAP24H PEL TABLET TABLET TABLET TABLET ER TABLET ER TABLET ER TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET Dose Strength Description Name 300 MG 360 MG 120 MG 180 MG 240 MG 120 MG 180 MG 240 MG 300 MG 360 MG 420MG 120 MG 30 MG 60 MG 90 MG 120 MG 180 MG 240 MG 360 MG 120 MG 40 MG 80 MG 120 MG 180 MG 240 MG 10 MG 20 MG 40 MG 5 MG 10-12.5MG 20-12.5 MG 20-25MG 100 MG 12.5 MG 25 MG 50 MG 25 MG-15MG 25 MG-25MG 10 MG 2.5 MG 20 MG 5 MG 10 MG-25MG 5MG-12.5MG 10 MG 20 MG 40 MG 10-12.5MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243204 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243208 ANGIOTENSIN II RECEPTOR ANTAGONISTS 243220 MINERALOCORTICOID (ALDOSTERONE) ANTAGNTS 243220 MINERALOCORTICOID (ALDOSTERONE) ANTAGNTS 243220 MINERALOCORTICOID (ALDOSTERONE) ANTAGNTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name LISINOPRIL TB 10MG EXEL 45 LISINOPR TAB 2.5MG UD+ AHP 30 LISINOPRIL TB 20MG EXEL 45 LISINOPRIL TB 30MG EXEL 100 LISINOPRIL TB 40MG EXEL 45 LISINOPRIL TB 5MG EXEL 45 LISINOPR+HCTZ10/12.5MGUD+AHP30 LISINOPR+HCTZ20/12.5MGUD+AHP30 LISINOPR+HCTZ 20/25MGUD+AHP30 QUINAPRIL TAB 10MG GRE 90@ QUINAPRIL TAB 20MG GRE 90@ QUINAPRIL TAB 40MG LUPI 90@ QUINAPRIL TAB 5MG GRE 90@ QUINAPR TAB 20/12.5MG APX 90 QUINAPRIL TAB 20/25MG APX 90 RAMIPRIL CAP 10MG ACC 100@ RAMIPRIL CAP 2.5MG ACCO 100@ RAMIPRIL CAP 5MG ACCO 100@ IRBESART TAB 150MG UD AHP30 IRBESARTAN TAB 300MG SOLC 30@ IRBESARTAN TAB 75MG LUP 30 IRBES/HCTZ TB150/12.5MGSOLC30@ IRBESART-HCTZ300/12.5MGSOLC30@ LOSARTAN POT TAB 100MG VIRT30@ LOSARTAN POT TB 25MG UD AVK 50 LOSARTAN POT TAB 50MG VIRT 30@ LOSARTAN HCTZ 100/12.5 AVK 30 LOSARTAN HCTZ 100/25 AVK 30 LOSARTAN HCTZ 50/12.5 AVK 30 SPIRONOL TAB 100MG CAD 100 SPIRONOL TAB 25MG AMN 100@ SPIRONOL TAB 50MG CAD 100 BUTAL+AS+CA 50/325/40 WAT 100@ VOLTAREN GEL 1% 100GM DICLOFEN SOD 100MG ER SAN 100 DICLOFEN SOD DR 25MG PACK 100@ DICLOFEN DR TAB 50MG ACTA 60@ DICLOFEN TAB 75MG ACTA 60@ ETODOLAC CAP 200MG ANI 100@ ETODOLAC CAP 300MG ANI 100@ ETODOL ER TAB 500MG ZYD 60@ ETODOLAC TB 400MG UD AHP 30 ETODOLAC TAB 500MG SAN 100@ IBUPROFEN TAB 400MG GOLD 20 IBUPROFEN TAB 600MG AVK 90 IBUPROFEN TAB 800MG GOLD 30 INDOMETHACIN CP 25MG AVK 50 INDOMETHACIN CP 50MG AVK 50 GenericName LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL LISINOPRIL/HYDROCHLOROTHIAZIDE LISINOPRIL/HYDROCHLOROTHIAZIDE LISINOPRIL/HYDROCHLOROTHIAZIDE QUINAPRIL HCL QUINAPRIL HCL QUINAPRIL HCL QUINAPRIL HCL QUINAPRIL/HYDROCHLOROTHIAZIDE QUINAPRIL/HYDROCHLOROTHIAZIDE RAMIPRIL RAMIPRIL RAMIPRIL IRBESARTAN IRBESARTAN IRBESARTAN IRBESARTAN/HYDROCHLOROTHIAZIDE IRBESARTAN/HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN POTASSIUM LOSARTAN/HYDROCHLOROTHIAZIDE LOSARTAN/HYDROCHLOROTHIAZIDE LOSARTAN/HYDROCHLOROTHIAZIDE SPIRONOLACTONE SPIRONOLACTONE SPIRONOLACTONE BUTALBITAL/ASPIRIN/CAFFEINE DICLOFENAC SODIUM DICLOFENAC SODIUM DICLOFENAC SODIUM DICLOFENAC SODIUM DICLOFENAC SODIUM ETODOLAC ETODOLAC ETODOLAC ETODOLAC ETODOLAC IBUPROFEN IBUPROFEN IBUPROFEN INDOMETHACIN INDOMETHACIN Generic Dose Form TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE GEL (GRAM) TAB ER 24H TABLET DR TABLET DR TABLET DR CAPSULE CAPSULE TAB ER 24H TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE Dose Strength Description Name 10 MG 2.5 MG 20 MG 30 MG 40 MG 5 MG 10-12.5MG 20-12.5 MG 20-25MG 10 MG 20 MG 40 MG 5 MG 20-12.5 MG 20-25MG 10 MG 2.5 MG 5 MG 150 MG 300 MG 75 MG 150-12.5MG 300-12.5MG 100 MG 25 MG 50 MG 100-12.5MG 100MG-25MG 50-12.5 MG 100 MG 25 MG 50 MG 50-325-40 1% 100 MG 25 MG 50 MG 75 MG 200 MG 300 MG 500 MG 400 MG 500 MG 400 MG 600 MG 800 MG 25 MG 50 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280804 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280808 OPIATE AGONISTS 280892 ANALGESICS AND ANTIPYRETICS, MISC. 280892 ANALGESICS AND ANTIPYRETICS, MISC. 280892 ANALGESICS AND ANTIPYRETICS, MISC. Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name INDOMETHACIN CAP 75MG UD AVK50 KETOPROFEN CAP 50MG MYLN 100 KETOPROFEN CAP 75MG AVK 90 MELOXICAM TAB 15MG CIP 100 MELOXICAM TAB 7.5MG CIP 100 NABUMET TAB 500MG UD AHP 100@ NABUMET TAB 750MG AVK 100 NAPROXEN TAB 250MG UD AVK 50 NAPROXEN TAB 375MG UD AVK 50 NAPROXEN TAB 500MG UD AVK 50 NAPROXEN SOD TB 275MG UD AVK50 NAPROXEN SOD TB 550MG GLEN100@ SALSALATE TAB UD 750MG AVK 50 ACETAM+COD TB #2 AURO 100@ ACETAM+COD TB 3C/30 AURO 1000 APAP+COD TAB 60MG Q/P 100@ FIORICET+COD CAP 30MG 100 HYDROC B+AC TB 10/750 MALL100 HYDROC B+AC 10/325 UD AVK 50@ HYDROC B+AC TB10/500MG MAL100 HYDROCOD+AP TB 2.5/5C WAT 100 HYDROC B+AC 5/325 UD AVK 50@ HYDROC B+AP 7.5/325 UD AHP 80 HYDROC B+AC TB 7.5/5C MALL 1C HYDROCOD+IBU 7.5/200 AHP UD80 HYDROMORPH TAB 2MG MALL 100@ HYDROMORPH TAB 4MG ROX 100@ HYDROMORPH TAB 8MG UD+ AHP 30 METHADONE TB 10MG UD AHP 100@ METHADONE TAB 5MG ROX 100@ MORPHI SULF ER CAP3OMG ACT60@ MORPH SULF O/S10MG/5ML ROX15ML MORPHINE SUOS100MG/5MLPADD30ML MORPHINE IR TAB 15MG ROX 100@ MORPHINE IR TAB 30MG ROX 100@ MORPHINE SU ER 15MG UD AHP 100 MORPHINE SU ER 30MG UD AHP 100 MORPHINE ER TB 60MG RHODE 100@ OXYCODONE HCL CP 5MG GAVI 100 OXYCOD HCL TAB 5MG RHOD 100@ ENDOCET TB 10/325MG ENDO 100@ ROXICET TAB 5/325MG ROX 100 ENDOCET TB 7.5/325MG ENDO 100@ TRAMADOL TAB 50MG SKY UD 100@ TRAMADOL + ACET 37.5/325 AVK50 BUTALB+AC+CA50/300/40MGAVK100 ESGIC CAP 100 BUTALB+AC+CA 50/325/40MG UD50@ GenericName INDOMETHACIN KETOPROFEN KETOPROFEN MELOXICAM MELOXICAM NABUMETONE NABUMETONE NAPROXEN NAPROXEN NAPROXEN NAPROXEN SODIUM NAPROXEN SODIUM SALSALATE ACETAMINOPHEN WITH CODEINE ACETAMINOPHEN WITH CODEINE ACETAMINOPHEN WITH CODEINE BUTALBIT/ACETAMIN/CAFF/CODEINE HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/ACETAMINOPHEN HYDROCODONE/IBUPROFEN HYDROMORPHONE HCL HYDROMORPHONE HCL HYDROMORPHONE HCL METHADONE HCL METHADONE HCL MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE MORPHINE SULFATE OXYCODONE HCL OXYCODONE HCL OXYCODONE HCL/ACETAMINOPHEN OXYCODONE HCL/ACETAMINOPHEN OXYCODONE HCL/ACETAMINOPHEN TRAMADOL HCL TRAMADOL HCL/ACETAMINOPHEN BUTALB/ACETAMINOPHEN/CAFFEINE BUTALB/ACETAMINOPHEN/CAFFEINE BUTALB/ACETAMINOPHEN/CAFFEINE Generic Dose Form CAPSULE ER CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAP ER PEL SOLUTION SOLUTION TABLET TABLET TABLET ER TABLET ER TABLET ER CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE TABLET Dose Strength Description Name 75 MG 50 MG 75 MG 15 MG 7.5 MG 500 MG 750 MG 250 MG 375 MG 500 MG 275 MG 550 MG 750 MG 300MG-15MG 300MG-30MG 300MG-60MG 50-325-30 10-750MG 10MG-325MG 10MG-500MG 2.5-500 MG 5 MG-325MG 7.5-325MG 7.5-500MG 7.5-200 MG 2 MG 4 MG 8 MG 10 MG 5 MG 30 MG 10 MG/5 ML 100 MG/5ML 15 MG 30 MG 15 MG 30 MG 60 MG 5 MG 5 MG 10MG-325MG 5 MG-325MG 7.5-325MG 50 MG 37.5-325MG 50-300-40 50-325-40 50-325-40 Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 280892 ANALGESICS AND ANTIPYRETICS, MISC. 281000 OPIATE ANTAGONISTS 281204 BARBITURATES (ANTICONVULSANTS) 281204 BARBITURATES (ANTICONVULSANTS) 281208 BENZODIAZEPINES (ANTICONVULSANTS) 281208 BENZODIAZEPINES (ANTICONVULSANTS) 281208 BENZODIAZEPINES (ANTICONVULSANTS) 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281212 HYDANTOINS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS 281292 ANTICONVULSANTS, MISCELLANEOUS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name ISO+DIC+APAP65/100/325MG AVK90 NALTREXONE TAB 50MG UD P/D 30 PRIMIDONE TAB 250MG UD AVK 50@ PRIMIDONE TAB 50MG UD AVK 50@ CLONAZEP TAB 0.5MG Q/P 15@ CLONAZEP TAB 1MG Q/P 15@ CLONAZEP TAB 2MG Q/P 30@ PEGANONE TAB 250MG 100 CEREBYX 100MG/2ML PF PFIZ 25 PHENYT OS 100MG/4ML UD VIS 50 DILANTIN-125 SUSP 8OZ DILANTIN INFATAB 50MG 100 DILANTIN CAP 100MG 100 PHENYTEK CAP 200MG 30 DILANTIN CAP 30MG 100 PHENYTEK CAP 300MG 30 CARBAMAZ ER CAP 100MG APX 120 CARBAMAZ ER CAP 200MG APX 120 CARBAMAZ CH TB 100MG TAR 100@ TEGRETOL-XR ER TB 100MG 100 CARBAMAZ ER TB 200MG UD AHP 30 CARBAMAZ ER TB 400MG UD AHP 30 EPITOL TAB 200MG TEV 100 DIVALP ER TB 250MG UD MMP8X10@ DIVALP ER TB 500MG UD MMP8X10@ DIVALP DR TAB 125MG U/S 100@ DIVALP SOD DR TB 250MG UDAHP60 DIVALP SOD DR TB500MG UDAHP20@ GABAPENT CAP 100MG UD SKY 100@ GABAPENT CAP 300MG ACTA 100@ GABAPENT CAP 400MG UD AVK 5X10 GABAPENTIN TB 600MG UD AVK5X10 GABAPENTIN TB 800MG UD AVK3X10 LEVETIRAC OS100MG/ML LUPI473ML LEVETIRACET OS 100MG/5ML PAI40 LEVETIRAC TB 1000MG UD AHP100 LEVETIRAC TB 250MG UD MMP10X10 LEVETIRAC TB 500MG UD AHP 100 LEVETIRAC TB 750MG UD AHP 100@ OXCARBAZEP OS 300/5MLAVK 250ML OXCARBAZ TAB 150MG CAD 100 OXCARBAZ TAB 300MG CAD 100 OXCARBAZ TAB 600MG CAD 100 VALPROIC ACID CP 250MG U/S 100 VALPROIC OS 250MG/5ML HI-T 40 VALPROIC OS 500MG/10ML HI-T100 VALPROIC SYRP 250MG/5ML P/D 50 ZONISAMIDE CAP 100MG UD AHP50@ GenericName ISOMETHEPT/DICHLPHN/ACETAMINOP NALTREXONE HCL PRIMIDONE PRIMIDONE CLONAZEPAM CLONAZEPAM CLONAZEPAM ETHOTOIN FOSPHENYTOIN SODIUM PHENYTOIN PHENYTOIN PHENYTOIN PHENYTOIN SODIUM EXTENDED PHENYTOIN SODIUM EXTENDED PHENYTOIN SODIUM EXTENDED PHENYTOIN SODIUM EXTENDED CARBAMAZEPINE CARBAMAZEPINE CARBAMAZEPINE CARBAMAZEPINE CARBAMAZEPINE CARBAMAZEPINE CARBAMAZEPINE DIVALPROEX SODIUM DIVALPROEX SODIUM DIVALPROEX SODIUM DIVALPROEX SODIUM DIVALPROEX SODIUM GABAPENTIN GABAPENTIN GABAPENTIN GABAPENTIN GABAPENTIN LEVETIRACETAM LEVETIRACETAM LEVETIRACETAM LEVETIRACETAM LEVETIRACETAM LEVETIRACETAM OXCARBAZEPINE OXCARBAZEPINE OXCARBAZEPINE OXCARBAZEPINE VALPROIC ACID VALPROIC ACID (AS SODIUM SALT) VALPROIC ACID (AS SODIUM SALT) VALPROIC ACID (AS SODIUM SALT) ZONISAMIDE Generic Dose Form CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET VIAL ORAL SUSP ORAL SUSP TAB CHEW CAPSULE CAPSULE CAPSULE CAPSULE CPMP 12HR CPMP 12HR TAB CHEW TAB ER 12H TAB ER 12H TAB ER 12H TABLET TAB ER 24H TAB ER 24H TABLET DR TABLET DR TABLET DR CAPSULE CAPSULE CAPSULE TABLET TABLET SOLUTION SOLUTION TABLET TABLET TABLET TABLET ORAL SUSP TABLET TABLET TABLET CAPSULE SOLUTION SOLUTION SYRINGE CAPSULE Dose Strength Description Name 65-100-325 50 MG 250 MG 50 MG 0.5 MG 1 MG 2 MG 250 MG 100MG PE/2 100 MG/4ML 125 MG/5ML 50 MG 100 MG 200 MG 30 MG 300 MG 100 MG 200 MG 100 MG 100 MG 200 MG 400 MG 200 MG 250 MG 500 MG 125 MG 250 MG 500 MG 100 MG 300 MG 400 MG 600 MG 800 MG 100 MG/ML 500 MG/5ML 1000 MG 250 MG 500 MG 750 MG 300 MG/5ML 150 MG 300 MG 600 MG 250 MG 250 MG/5ML 500MG/10ML 250 MG/5ML 100 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 281292 ANTICONVULSANTS, MISCELLANEOUS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name ZONISAMIDE CAP 50MG GLEN 100@ AMITRIP TAB 10MG 100 NSTR@ AMITRIP HCL TAB 100MG ACC 100 AMITRIP TAB 150MG 100 NSTR@ AMITRIP TAB 25MG 1000 NSTR@ AMITRIP TAB 50MG 1000 NSTR@ AMITRIP HCL TAB 75MG ACC 100 BUPROPIO ER TAB 150MG ACTA 30@ BUPROPRI HCI ER TB300MG ZYD30@ BUPROPIO HCL TAB 1CMG MYLN100@ BUPROPIO HCL TAB 75MG MYLN100@ BUPROP HCI ER TB100MG UDAHP100 BUPROPION HCL ER TB 150MG 60 BUPROPION HCL TB 200MG 60 NSTR CITALOPRAM TAB 10MG UD AHP100 CITALOPRAM TAB 20MG UD AHP100@ CITALOPRAM TAB 40MG DR/R 30 DOXEPIN CAP 10MG MYLN 100@ DOXEPIN CAP 100MG MYLN 100@ DOXEPIN CAP 150MG PAR 50@ DOXEPIN CAP 25MG MYLN 100@ DOXEPIN CAP 50MG MYLN 100@ DOXEPIN CAP 75MG MYLN 100@ ESCITAL OX OS 5MG TARO 5ML@ ESCITALOP TB 10MG UDMMP 10X10@ ESCITALOP TB20MG UD MMP 10X10@ ESCITALOP TAB 5MG CAMB 90 FLUOXET CAP 10MG UD AVK 5X10 FLUOXET CAP 20MG UD AVK 5X10 FLUOXET CAP 40MG UD AVK 50 FLUOXET TAB 10MG MYLN 30@ FLUOXET TAB 20MG MYLN 30@ FLUVOXAMIN TAB 100MG APX 100@ FLUVOXAMIN TAB 50MG UD+ AHP 30 IMIPRAM TAB 10MG MUT 100@ IMIPRAM TAB 25MG MUT 100@ IMIPRAM TAB 50MG MUT 100@ MIRTAZAP TAB 15MG AURO 30 MIRTAZAP TAB 30MG AURO 30 MIRTAZAP TAB 45MG AURO 30@ NORTRIP HYD CAP 10MG TARO500@ NORTRIPTYL HYD CP 25MG TAR 90@ NORTRIP HYD CAP 50MG TARO 500@ NORTRIPTYL HYD CP 75MG TAR 90@ PAROXETIN ER TB 12.5MG MYL 30@ PAROXETIN ER TAB 25MG MYLN 30@ PAROXETIN TB 37.5MG CR APX 30 PAROXETIN TAB 10MG AURO 30 GenericName ZONISAMIDE AMITRIPTYLINE HCL AMITRIPTYLINE HCL AMITRIPTYLINE HCL AMITRIPTYLINE HCL AMITRIPTYLINE HCL AMITRIPTYLINE HCL BUPROPION HCL BUPROPION HCL BUPROPION HCL BUPROPION HCL BUPROPION HCL BUPROPION HCL BUPROPION HCL CITALOPRAM HYDROBROMIDE CITALOPRAM HYDROBROMIDE CITALOPRAM HYDROBROMIDE DOXEPIN HCL DOXEPIN HCL DOXEPIN HCL DOXEPIN HCL DOXEPIN HCL DOXEPIN HCL ESCITALOPRAM OXALATE ESCITALOPRAM OXALATE ESCITALOPRAM OXALATE ESCITALOPRAM OXALATE FLUOXETINE HCL FLUOXETINE HCL FLUOXETINE HCL FLUOXETINE HCL FLUOXETINE HCL FLUVOXAMINE MALEATE FLUVOXAMINE MALEATE IMIPRAMINE HCL IMIPRAMINE HCL IMIPRAMINE HCL MIRTAZAPINE MIRTAZAPINE MIRTAZAPINE NORTRIPTYLINE HCL NORTRIPTYLINE HCL NORTRIPTYLINE HCL NORTRIPTYLINE HCL PAROXETINE HCL PAROXETINE HCL PAROXETINE HCL PAROXETINE HCL Generic Dose Form CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TAB ER 24H TAB ER 24H TABLET TABLET TABLET ER TABLET ER TABLET ER TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE SOLUTION TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE CAPSULE TAB ER 24H TAB ER 24H TAB ER 24H TABLET Dose Strength Description Name 50 MG 10 MG 100 MG 150 MG 25 MG 50 MG 75 MG 150 MG 300 MG 100 MG 75 MG 100 MG 150 MG 200 MG 10 MG 20 MG 40 MG 10 MG 100 MG 150 MG 25 MG 50 MG 75 MG 5 MG/5 ML 10 MG 20 MG 5 MG 10 MG 20 MG 40 MG 10 MG 20 MG 100 MG 50 MG 10 MG 25 MG 50 MG 15 MG 30 MG 45 MG 10 MG 25 MG 50 MG 75 MG 12.5 MG 25 MG 37.5 MG 10 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281604 ANTIDEPRESSANTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name PAROXETIN TAB 20MG AURO 90 PAROXETIN TAB 30MG AURO 30 PAROXETIN TAB 40MG AURO 30 SERTRALIN TAB 100MG CAMB 30@ SERTRALIN TAB 100MG GRE 5000@= SERTRALIN TAB 25MG UD UDL 100@ SERTRALIN TAB 50MG UD UDL100@ SERTRALIN TAB 50MG GRE 5000@ TRAZOD TAB 100MG UD AHP 100 TRAZOD TAB 150MG AVK 500 TRAZOD TAB 300MG AVK 100 TRAZOD TAB 50MG UD AHP 100 VENLAF ER CAP 150MG UD SKY100@ VENLAF ER CP 37.5MG UD AHP100@ VENLAF ER CP UD 75MG MMP10X10 VENLAF ER TAB 150MG CARA 30 VENLAF ER TAB 225MG UPS 90@ VENLAF ER TAB 37.5MG CARA 30 VENLAF ER TAB 75MG CARA 30 VENLAFAXINE HCL TB100MG HERI90 VENLAFAXINE HCL TB 25MG HERI90 VENLAFAX HCL TB 37.5MG HERI90 VENLAFAXINE HCL TB 50MG HERI90 VENLAFAXINE HCL TB 75MG HERI90 CHLORPROM TAB 10MG SAN 100 CHLORPROM TAB 100MG SAN 100 CHLORPROM TAB 200MG SAN 100@ CHLORPROM TAB 25MG U/S 100@ CHLORPROM TAB 50MG U/S 100@ FLUPHENAZ TB 1MG LANN 100@ FLUPHENAZ TB 10MG LANN 100@ FLUPHENAZ TB 2.5MG LANN 100@ FLUPHENAZ TB 5MG UD+ AHP 30 HALOP TAB 0.5MG SAN 100@ HALOP TAB 1MG SAN 100@ HALOP TAB 10MG UD MMP 100@ HALOPERIDOL TAB 2MG SAN 100@ HALOP TAB 20MG UD AHP 30 HALOPERIDOL TAB 5MG ZYD 100 LOXAPINE CAP 10MG MARL 100 LOXAPINE CAP 25MG UD AHP 30@ LOXAPINE CAP 50MG UD AHP 30@ PERPHEN TAB 16MG UD+ AHP 30 PERPHEN TAB 2MG UD AHP 30 PERPHEN TAB 4MG Q/P 100@ PERPHEN TAB 8MG Q/P 100@ QUETIAPIN FUM TB 200MG AVK 90 QUETIAPIN FUM TB 25MG TEV 100@ GenericName PAROXETINE HCL PAROXETINE HCL PAROXETINE HCL SERTRALINE HCL SERTRALINE HCL SERTRALINE HCL SERTRALINE HCL SERTRALINE HCL TRAZODONE HCL TRAZODONE HCL TRAZODONE HCL TRAZODONE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL VENLAFAXINE HCL CHLORPROMAZINE HCL CHLORPROMAZINE HCL CHLORPROMAZINE HCL CHLORPROMAZINE HCL CHLORPROMAZINE HCL FLUPHENAZINE HCL FLUPHENAZINE HCL FLUPHENAZINE HCL FLUPHENAZINE HCL HALOPERIDOL HALOPERIDOL HALOPERIDOL HALOPERIDOL HALOPERIDOL HALOPERIDOL LOXAPINE SUCCINATE LOXAPINE SUCCINATE LOXAPINE SUCCINATE PERPHENAZINE PERPHENAZINE PERPHENAZINE PERPHENAZINE QUETIAPINE FUMARATE QUETIAPINE FUMARATE Generic Dose Form TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAP ER 24H CAP ER 24H CAP ER 24H TAB ER 24 TAB ER 24 TAB ER 24 TAB ER 24 TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET Dose Strength Description Name 20 MG 30 MG 40 MG 100 MG 100MG 25 MG 50 MG 50MG 100 MG 150 MG 300 MG 50 MG 150 MG 37.5 MG 75 MG 150 MG 225 MG 37.5 MG 75 MG 100 MG 25 MG 37.5 MG 50 MG 75 MG 10 MG 100 MG 200 MG 25 MG 50 MG 1 MG 10 MG 2.5 MG 5 MG 0.5 MG 1 MG 10 MG 2 MG 20 MG 5 MG 10 MG 25 MG 50 MG 16 MG 2 MG 4 MG 8 MG 200 MG 25 MG Comments 1 0 Medical Access Program (MAP) Formulary- 2016 AHFS Classification 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 281608 ANTIPSYCHOTIC AGENTS 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282004 AMPHETAMINES 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282032 RESPIRATORY AND CNS STIMULANTS 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282404 BARBITURATES (ANXIOLYTIC, SEDATIVE/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name QUETIAPINE TAB 300MG AVK 60 QUETIAPIN FUM TB 400MG AVK 90 QUETIAPIN FUM TB 50MG AVK 1000 RISPERID OS 1MG/ML BRECK 1OZ@ RISPERIDONE TB .25MG AJAN 60@ RISPERID TAB 0.5MG UD AVK 50 RISPERID TAB 1MG UD AVK 50 RISPERID TAB 2MG UD AVK 50 RISPERID TAB 3MG UD AVK 50 RISPERID TAB 4MG UD AVK 50 THIOTHIX CAP 10MG MYL 100@ THIOTHIX CAP 2MG MYL 100@ THIOTHIX CAP 5MG MYL 100@ DEXTROAMPH SUL TB 5MGAURO 100@ AMPHET SLT ER CP 10MG UDAHP30 MIX AMPHET SLT ERCP15MGTEV1C@ AMPHET SLT ER CP 20MG UDAHP30 MIX AMPHET SLT ERCP25MGTEV100@ AMPHET SLT ER CP 30MG UDAHP20 MIX AMPHET SLT ERCP5MGTEV 100@ AMPHETA SALT TB 10MG CARA 100@ AMPHET SALTS TB12.5MG CORE100@ AMPHETAM SALT TB 15MG MAL 100@ AMPHETAM SALT TB 20MG MAL 100@ AMPHETAM SALT TB 30MG MAL 100@ AMPHETAM SALT TB 5MG AURO 100@ AMPHETAM SALTS TB7.5MGCORE100@ METHYLPH CD ER CP 10MG TEV100@ METHYLPH CD ER CP 20MG TEV100@ METADATE CD CAP 30MG 100 METHYLPH CD ER CP 40MG TEV100@ METADATE CD CAP 50MG 100 METHYLPH CD ER CP 60MG TEV100@ METHYLPHEN ER CP 20MG ACTA100@ METHYLPHEN TAB 10MG UD+ AHP30 METHYLPHEN TAB 20MG UD+ AHP 30 METHYLPHEN TB 5MG UD+AHP30 METHYLPHEN HCI TAB 10MG KVK60 METHYLPHEN HCI TAB 20MG KVK60 PHENOB 20MG/5ML SOL PACK473ML@ PHENOB TAB 100MG WEST 500@ PHENOB TAB 15MG WEST 500@ PHENOB TAB 30MG WEST 500@ PHENOB TAB 32.4MG UD+ AHP 30 PHENOB TAB 60MG WEST 500@ PHENOB TAB 1GR Q/P 100@ ALPRAZO TAB 0.25MG UD SKY 100@ ALPRAZO TAB 0.5MG UD SKY 100@ GenericName QUETIAPINE FUMARATE QUETIAPINE FUMARATE QUETIAPINE FUMARATE RISPERIDONE RISPERIDONE RISPERIDONE RISPERIDONE RISPERIDONE RISPERIDONE RISPERIDONE THIOTHIXENE THIOTHIXENE THIOTHIXENE DEXTROAMPHETAMINE SULFATE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE DEXTROAMPHETAMINE/AMPHETAMINE METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL METHYLPHENIDATE HCL PHENOBARBITAL PHENOBARBITAL PHENOBARBITAL PHENOBARBITAL PHENOBARBITAL PHENOBARBITAL PHENOBARBITAL ALPRAZOLAM ALPRAZOLAM Generic Dose Form TABLET TABLET TABLET SOLUTION TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET CAP ER 24H CAP ER 24H CAP ER 24H CAP ER 24H CAP ER 24H CAP ER 24H TABLET TABLET TABLET TABLET TABLET TABLET TABLET CPBP 30-70 CPBP 30-70 CPBP 30-70 CPBP 30-70 CPBP 30-70 CPBP 30-70 CPBP 50-50 TABLET TABLET TABLET TABLET ER TABLET ER ELIXIR TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET Dose Strength Description Name 300 MG 400 MG 50 MG 1 MG/ML 0.25 MG 0.5 MG 1 MG 2 MG 3 MG 4 MG 10 MG 2 MG 5 MG 5 MG 10 MG 15 MG 20 MG 25 MG 30 MG 5 MG 10 MG 12.5 MG 15 MG 20 MG 30 MG 5 MG 7.5 MG 10 MG 20 MG 30 MG 40 MG 50 MG 60 MG 20 MG 10 MG 20 MG 5 MG 10 MG 20 MG 20 MG/5 ML 100 MG 15 MG 30 MG 32.4 MG 60 MG 64.8 MG 0.25 MG 0.5 MG Comments Limit 2 capsule per day Limit 2 capsule per day Limit 2 capsule per day Limit 2 capsule per day Limit 2 capsule per day Limit 2 capsule per day Limit 2 capsule per day Medical Access Program (MAP) Formulary- 2016 AHFS Classification 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282408 BENZODIAZEPINES (ANXIOLYTIC,SEDATIV/HYP) 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282492 ANXIOLYTICS, SEDATIVES & HYPNOTICS,MISC. 282800 ANTIMANIC AGENTS 282800 ANTIMANIC AGENTS 282800 ANTIMANIC AGENTS 282800 ANTIMANIC AGENTS 282800 ANTIMANIC AGENTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS 283228 SELECTIVE SEROTONIN AGONISTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name ALPRAZOL TAB 1MG UD SKY 100@ ALPRAZOL TAB 2MG MYL 100@ CHLORDIAZ CAP 10MG BARR 100@ CHLORDIAZ CAP 25MG BARR 100@ CLORAZEP TAB 15MG TAR 100@ CLORAZEP DIP TB 3.75MGUD+AHP30 CLORAZEP TAB 7.5MG TAR 100@ DIAZEPAM TAB 10MG Q/P 30@ DIAZEPAM TAB 2MG Q/P 30@ DIAZEPAM TAB 5MG Q/P 30 FLURAZEP CP 15MG MYL 100@ FLURAZEP CP 30MG MYLN 100@ LORAZEP TAB 0.5MG Q/P 100@ LORAZEP TAB 1MG Q/P 100@ LORAZEP TAB 2MG Q/P 100@ OXAZEPAM CAP 10MG SAN 100@ OXAZEPAM CAP 15MG SAN 100@ OXAZEPAM CAP 30MG SAN 100@ TEMAZEPAM CAP 15MG Q/P 100 TEMAZEPAM CAP 30MG Q/P 100 TEMAZEP CP 7.5MG UD MMP 3X10@ BUSPIR HCL TAB 10MG ZYD 500@ BUSPIR HCL TAB 15MG ZYD 500@ BUSPIR HCL TB 30MG AVK 500 BUSPIR HCL TAB 5MG ZYD 100@ BUSPIR HCL TB 7.5MG AVK 90 HYDROXY HYD SYRP SILA 16OZ@ HYDROXYZ TAB 10MG GLEN 100@ HYDROXYZ TAB 25MG GLEN 100@ HYDROXYZ TAB 50MG GLEN 100@ HYDROXYZ PAM CP 100MG BARR100@ HYDROXYZ PAM CAP25MG UDAHP100@ HYDROXYZ PAM CAP 50MG RIS 500 ZOLPIDEM TAB 10MG UD ROX 100 ZOLPIDEM TART TAB 5MG AHP 100 LITHIUM CARB CP 150MG GLEN100@ LITHIUM CARB CP 300MG CAMB 100 LITHIUM CAR TAB 300MG CARA100@ LITHIUM CARB ER TB300MG UD100@ LITHIUM TAB 450MG UD AHP 100@ SUMATRIP NASAL 20MG UD SAN 6@ SUMATRIP NASAL 5MG UD SAN 6@ SUMATRIP INJ REFIL 6MG SAN 2@ SUMATRIP PFS 6MG/0.5ML DR/R 2@ SUMATRIPTAN TB100MGUD9NSTAR@ SUMATRIP TAB 25MG UD 9 NSTAR@ SUMATRIP TAB 50MG BP 9 NSTAR@ SUMATRIP INJ 6MG/0.5ML WEST 5@ GenericName ALPRAZOLAM ALPRAZOLAM CHLORDIAZEPOXIDE HCL CHLORDIAZEPOXIDE HCL CLORAZEPATE DIPOTASSIUM CLORAZEPATE DIPOTASSIUM CLORAZEPATE DIPOTASSIUM DIAZEPAM DIAZEPAM DIAZEPAM FLURAZEPAM HCL FLURAZEPAM HCL LORAZEPAM LORAZEPAM LORAZEPAM OXAZEPAM OXAZEPAM OXAZEPAM TEMAZEPAM TEMAZEPAM TEMAZEPAM BUSPIRONE HCL BUSPIRONE HCL BUSPIRONE HCL BUSPIRONE HCL BUSPIRONE HCL HYDROXYZINE HCL HYDROXYZINE HCL HYDROXYZINE HCL HYDROXYZINE HCL HYDROXYZINE PAMOATE HYDROXYZINE PAMOATE HYDROXYZINE PAMOATE ZOLPIDEM TARTRATE ZOLPIDEM TARTRATE LITHIUM CARBONATE LITHIUM CARBONATE LITHIUM CARBONATE LITHIUM CARBONATE LITHIUM CARBONATE SUMATRIPTAN SUMATRIPTAN SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE SUMATRIPTAN SUCCINATE Generic Dose Form TABLET TABLET CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE CAPSULE TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET SOLUTION TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET CAPSULE CAPSULE TABLET TABLET ER TABLET ER SPRAY SPRAY CARTRIDGE PEN INJCTR TABLET TABLET TABLET VIAL Dose Strength Description Comments Name 1 MG 2 MG 10 MG 25 MG 15 MG 3.75 MG 7.5 MG 10 MG 2 MG 5 MG 15 MG 30 MG 0.5 MG 1 MG 2 MG 10 MG 15 MG 30 MG 15 MG 30 MG 7.5 MG 10 MG 15 MG 30 MG 5 MG 7.5 MG 10 MG/5 ML 10 MG 25 MG 50 MG 100 MG 25 MG 50 MG 10 MG 5 MG 150 MG 300 MG 300 MG 300 MG 450 MG 20 MG 5 MG 6 MG/0.5ML 6 MG/0.5ML 100 MG Limit 9 tablets/month 25 MG Limit 9 tablets/month 50 MG Limit 9 tablets/month 6 MG/0.5ML Medical Access Program (MAP) Formulary- 2016 AHFS Classification 283604 ADAMANTANES (CNS) 283604 ADAMANTANES (CNS) 283608 ANTICHOLINERGIC AGENTS (CNS) 283608 ANTICHOLINERGIC AGENTS (CNS) 283608 ANTICHOLINERGIC AGENTS (CNS) 283608 ANTICHOLINERGIC AGENTS (CNS) 283608 ANTICHOLINERGIC AGENTS (CNS) 283612 CATECHOL-O-METHYLTRANSFERASE(COMT)INHIB. 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283616 DOPAMINE PRECURSORS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 283620 DOPAMINE RECEPTOR AGONISTS 362600 DIABETES MELLITUS 368812 KETONES 400800 ALKALINIZING AGENTS 401000 AMMONIA DETOXICANTS 401000 AMMONIA DETOXICANTS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401200 REPLACEMENT PREPARATIONS 401818 POTASSIUM-REMOVING AGENTS 401818 POTASSIUM-REMOVING AGENTS 401819 PHOSPHATE-REMOVING AGENTS 401819 PHOSPHATE-REMOVING AGENTS 401819 PHOSPHATE-REMOVING AGENTS 402808 LOOP DIURETICS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name AMANTAD CAP 100MG UD AVK 50 AMANTAD TAB 100MG U/S 100@ BENZTROP MES TB 0.5MG AVK UD50 BENZTROP MES TB 1MG AVK UD 50 BENZTROP MES TB 2MG AVK UD 50 TRIHEXPH TAB 2MG WAT 100@ TRIHEXYPH TAB 5MG UD AHP 30@ ENTCAPONE TB 200MG UD MYLN 30@ CARBID+LEV ODT 10/100 CARA100 CARBID+LEV ODT 25/100 CARA100@ CARBID+LEV OTD 25/250 MYL 100@ CARBID+LEV TB 10/100 ACTA 100@ CARB/LEVO TB 25/100MG GOLD 100 CARBID+LEV TB 25/250 ACTA 100@ CARBID+LEV CR 25/1C UD MMP100 CARBID+LEV ER 50/200 MYLN 1C@ BROMOCRIP TAB 2.5MG MYLN 30 CABERGOLIN TAB 0.5MG TEV 8@ PRAMIP DIHYD TB .125MGUD+AHP30 PRAMIPEXOLE .25MG TAB VEN90@ PRAMIPEXOLE .5MG TAB VEN90@ PRAMIPEXOLE 1MG TAB VEN90@ PRAMIPEXOLE 1.5MG TAB VEN90@ ROPINIROL TB 0.25MG UD AHP100@ ROPINIROL TB 0.5MG UD AHP 30@ ROPINIROL TB 1MG UD AHP 100@ ROPINIROLE TB 2MG UD AHP 30@ ROPINIROLE TB 3MG HERI 100@ ROPINIROLE TB 4MG HERI 100@ SM TRUETEST STRIP E3054-25 25 KETOCARE TEST STRIPS 50 POTASS CIT ER TB10MEQ UD+AHP20 CONSTULOSE SOL10G/15MLACTA8OZ@ LACTULOSE OS 20GM/30MLUDVIS50@ POT CHL ER CAP 10MEQ AMN100@ KLOR-CON PWD PKT 20MEQ UD 30 KLOR-CON E/R TAB M10 90 KLOR-CON E/R TAB M20 90 KLOR-CON E/R TAB 10MEQ 100 POT CHLRO TAB 20EMEQ ZYD500@ SOD CHL SOL 3% SUV 4ML 60 SOD CHL SOL 7% SUV 4ML 60 SPS SUS 30GM 120ML+EZ-EM+TBKIT SOD POLY SULF 15G/60ML ROX500 CALCIUM ACET CP 667MG EXEL 200 RENVELA TAB 800MG 270 RENAGEL TAB 800MG 180 FUROSEM TAB 20MG MMP 100 GenericName AMANTADINE HCL AMANTADINE HCL BENZTROPINE MESYLATE BENZTROPINE MESYLATE BENZTROPINE MESYLATE TRIHEXYPHENIDYL HCL TRIHEXYPHENIDYL HCL ENTACAPONE CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA BROMOCRIPTINE MESYLATE CABERGOLINE PRAMIPEXOLE DI-HCL PRAMIPEXOLE DI-HCL PRAMIPEXOLE DI-HCL PRAMIPEXOLE DI-HCL PRAMIPEXOLE DI-HCL ROPINIROLE HCL ROPINIROLE HCL ROPINIROLE HCL ROPINIROLE HCL ROPINIROLE HCL ROPINIROLE HCL BLOOD SUGAR DIAGNOSTIC URINE ACETONE TEST STRIPS POTASSIUM CITRATE LACTULOSE LACTULOSE POTASSIUM CHLORIDE POTASSIUM CHLORIDE POTASSIUM CHLORIDE POTASSIUM CHLORIDE POTASSIUM CHLORIDE POTASSIUM CHLORIDE SODIUM CHLORIDE FOR INHALATION SODIUM CHLORIDE FOR INHALATION SODIUM POLYSTYRENE SULFONATE SODIUM POLYSTYRENE SULFONATE CALCIUM ACETATE SEVELAMER CARBONATE SEVELAMER HCL FUROSEMIDE Generic Dose Form CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TAB RAPDIS TAB RAPDIS TAB RAPDIS TABLET TABLET TABLET TABLET ER TABLET ER TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET STRIP STRIP TABLET ER SOLUTION SOLUTION CAPSULE ER PACKET TAB ER PRT TAB ER PRT TABLET ER TABLET ER VIAL-NEB VIAL-NEB ENEMA ORAL SUSP CAPSULE TABLET TABLET TABLET Dose Strength Description Name 100 MG 100 MG 0.5 MG 1 MG 2 MG 2 MG 5 MG 200 MG 10MG-100MG 25MG-100MG 25MG-250MG 10MG-100MG 25MG-100MG 25MG-250MG 25MG-100MG 50MG-200MG 2.5 MG 0.5 MG 0.125 MG 0.25 MG 0.5 MG 1 MG 1.5 MG 0.25 MG 0.5 MG 1 MG 2 MG 3 MG 4 MG 10 MEQ 10 G/15 ML 20 G/30 ML 10 MEQ 20 MEQ 10 MEQ 20 MEQ 10 MEQ 20 MEQ 3% 7% 30G/120ML 15 G/60 ML 667 MG 800 MG 800 MG 20 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 402808 LOOP DIURETICS 402808 LOOP DIURETICS 402816 POTASSIUM-SPARING DIURETICS 402816 POTASSIUM-SPARING DIURETICS 402816 POTASSIUM-SPARING DIURETICS 402816 POTASSIUM-SPARING DIURETICS 402816 POTASSIUM-SPARING DIURETICS 402820 THIAZIDE DIURETICS 402820 THIAZIDE DIURETICS 402820 THIAZIDE DIURETICS 402820 THIAZIDE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 402824 THIAZIDE-LIKE DIURETICS 404000 URICOSURIC AGENTS 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40412 PHENOTHIAZINE DERIVATIVES 40420 PROPYLAMINE DERIVATIVES 40492 FIRST GEN. ANTIHIST. DERIVATIVES, MISC. 40492 FIRST GEN. ANTIHIST. DERIVATIVES, MISC. 40800 SECOND GENERATION ANTIHISTAMINES 40800 SECOND GENERATION ANTIHISTAMINES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 480800 ANTITUSSIVES 481008 CORTICOSTEROIDS (RESPIRATORY TRACT) 481008 CORTICOSTEROIDS (RESPIRATORY TRACT) 481024 LEUKOTRIENE MODIFIERS 481024 LEUKOTRIENE MODIFIERS 481024 LEUKOTRIENE MODIFIERS 481032 MAST-CELL STABLILIZERS 520200 ANTIALLERGIC AGENTS 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name FUROSEM TAB 40MG Q/P 100@ FUROSEM TAB 80MG Q/P 90@ AMILOR+HCTZ TB 5/50 BARR 100@ HYDROCHLOROTH TB 25MG MARL 100 TRIAM+HCTZ CP 50/25 RD SAN100@ TRIAMTER+HCTZ 37.5/25 UD+AHP30 TRIAM+HCTZ TB 75/50 WAT 100@ HYDROCHLOROTH CP 12.5MG CIT500 HYDROCHL TAB 12.5MG ACTA 100@ HYDROCHL TAB 25MG HERI 1000@ HYDROCHL TAB 50MG IVA 100@ CHLORTH TAB 25MG MYL 100@ CHLORTH TAB 50MG MYL 100@ INDAPAM TAB 1.25MG MYLN 100@ METOLAZON TAB 10MG UPS 100@ METOLAZON TAB 2.5MG UPS 100@ METOLAZON TAB 5MG MYLN 100@ PROBEN TAB 500MG MARL 100 PROMETH+PHENYL6.25/5MG AKOR16Z PROMETH HCI SUPP12.5MG REN12@ PROMETH HCI SUPP 25MG REN12@ PROMETH HCI SUPP 50MG REN12@ PROMETH SYRP6.25/5MLCARA120ML@ PROMETH HCL TAB 12.5MG KVK100@ PROMETH TAB 25MG UD MMP 10X10 PROMETH TAB 50MG ZYD 100 SUDOGEST TAB CLD&ALLER MMP 24@ CYPROHEPT SYRP 2MG ACTA 16OZ@ CYPROHEPT HCI TAB 4MG CORE100 LEVOCET DIH OS 2.5/5 TARO 4OZ@ LEVOCET DIHYD TAB 5MG UD+AHP30 BENZONATATE SG CP 100MG LIB100 BENZONATATE SG CP 200MG LIB100 BROMFED DM COUGH SYRP 118ML GUAIFEN+COD SYRP AF/SFP/A 4OZ@ HYDROMET SYRP ACTA 16OZ@ GUAIFEN DAC O/S PACK 16OZ@ PROMETH DM SYRP Q/P 4OZ@ QVAR MDI W/CNTR 40MCG 120-DOSE QVAR MDI W/CNTR 80MCG 120-DOSE MONTELUK CHWTB 4MG AURO 30@ MONTELUK SOD TB5MG CHW WEST30 MONTELUKAST 10MG TAB CAM 30 CROMOL SOD OPH 4% VAL 10ML PATANOL OPTH SOL 0.1% 5ML BACITRACIN OPT/OINT PERR 3/1GM CIPROFLOX O/S 0.3% FAL 2.5ML@ CILOXAN OPTH OINT 0.3% 3.5GM GenericName FUROSEMIDE FUROSEMIDE AMILORIDE/HYDROCHLOROTHIAZIDE TRIAMTERENE/HYDROCHLOROTHIAZID TRIAMTERENE/HYDROCHLOROTHIAZID TRIAMTERENE/HYDROCHLOROTHIAZID TRIAMTERENE/HYDROCHLOROTHIAZID HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE CHLORTHALIDONE CHLORTHALIDONE INDAPAMIDE METOLAZONE METOLAZONE METOLAZONE PROBENECID PHENYLEPHRINE HCL/PROMETH HCL PROMETHAZINE HCL PROMETHAZINE HCL PROMETHAZINE HCL PROMETHAZINE HCL PROMETHAZINE HCL PROMETHAZINE HCL PROMETHAZINE HCL PSEUDOEPHED/CHLORPHENIRAMINE CYPROHEPTADINE HCL CYPROHEPTADINE HCL LEVOCETIRIZINE DIHYDROCHLORIDE LEVOCETIRIZINE DIHYDROCHLORIDE BENZONATATE BENZONATATE D-METHORPHAN HB/P-EPD HCL/BPM GUAIFENESIN/CODEINE PHOSPHATE HYDROCODONE BIT/HOMATROP ME-BR P-EPHED HCL/CODEINE/GUAIFEN PROMETHAZINE/DEXTROMETHORPHAN BECLOMETHASONE DIPROPIONATE BECLOMETHASONE DIPROPIONATE MONTELUKAST SODIUM MONTELUKAST SODIUM MONTELUKAST SODIUM CROMOLYN SODIUM OLOPATADINE HCL BACITRACIN CIPROFLOXACIN HCL CIPROFLOXACIN HCL Generic Dose Form TABLET TABLET TABLET CAPSULE CAPSULE TABLET TABLET CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET SYRUP SUPP.RECT SUPP.RECT SUPP.RECT SYRUP TABLET TABLET TABLET TABLET SYRUP TABLET SOLUTION TABLET CAPSULE CAPSULE SYRUP LIQUID SYRUP SYRUP SYRUP AER W/ADAP AER W/ADAP TAB CHEW TAB CHEW TABLET DROPS DROPS OINT. (G) DROPS OINT. (G) Dose Strength Description Name 40 MG 80 MG 5 MG-50 MG 37.5-25 MG 50 MG-25MG 37.5-25 MG 75 MG-50MG 12.5 MG 12.5 MG 25 MG 50 MG 25 MG 50 MG 1.25 MG 10 MG 2.5 MG 5 MG 500 MG 5-6.25MG/5 12.5 MG 25 MG 50 MG 6.25MG/5ML 12.5 MG 25 MG 50 MG 60 MG-4 MG 2 MG/5 ML 4 MG 2.5 MG/5ML 5 MG 100 MG 200 MG 10-30-2/5 100-10MG/5 5-1.5 MG/5 30-10-100 6.25-15/5 40 MCG 80 MCG 4 MG 5 MG 10 MG 4% 0.10% 500 UNIT/G 0.30% 0.30% Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520404 ANTIBACTERIALS (EENT) 520492 EENT ANTI-INFECTIVES, MISCELLANEOUS 520492 EENT ANTI-INFECTIVES, MISCELLANEOUS 520808 CORTICOSTEROIDS (EENT) 520808 CORTICOSTEROIDS (EENT) 520808 CORTICOSTEROIDS (EENT) 520808 CORTICOSTEROIDS (EENT) 520808 CORTICOSTEROIDS (EENT) 520808 CORTICOSTEROIDS (EENT) 520820 EENT NONSTEROIDAL ANTI-INFLAM. AGENTS 520820 EENT NONSTEROIDAL ANTI-INFLAM. AGENTS 520820 EENT NONSTEROIDAL ANTI-INFLAM. AGENTS 520820 EENT NONSTEROIDAL ANTI-INFLAM. AGENTS 521600 LOCAL ANESTHETICS (EENT) 521600 LOCAL ANESTHETICS (EENT) 522400 MYDRIATICS 522400 MYDRIATICS 524004 ALPHA-ADRENERGIC AGONISTS (EENT) 524004 ALPHA-ADRENERGIC AGONISTS (EENT) 524008 BETA-ADRENERGIC BLOCKING AGENTS (EENT) 524008 BETA-ADRENERGIC BLOCKING AGENTS (EENT) 524008 BETA-ADRENERGIC BLOCKING AGENTS (EENT) 524008 BETA-ADRENERGIC BLOCKING AGENTS (EENT) 524012 CARBONIC ANHYDRASE INHIBITORS (EENT) 524012 CARBONIC ANHYDRASE INHIBITORS (EENT) 524012 CARBONIC ANHYDRASE INHIBITORS (EENT) 524012 CARBONIC ANHYDRASE INHIBITORS (EENT) 524012 CARBONIC ANHYDRASE INHIBITORS (EENT) 524020 MIOTICS 524020 MIOTICS 524028 PROSTAGLANDIN ANALOGS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name CIPRODEX OTIC SUSP 7.5ML CIPRO HC OTIC SUSP 10ML DOXYCYC HYC TAB 20MG 60 ILOTYCIN OPT/OINT 1GM GENTAMI SUL OPH SOL .3%PERR5ML GARAMYCIN OPT/OINT PF 3.5GM VIGAMOX OPTH SOL 3ML NEOMY+POL B/DX O/SUS B&L 5ML@ NEOMY+POL B SUL OPH PERR 3.5GM NEO-POLY OINT FERA 3.5GM NEOMY+POLY B+HYD O/S FAL 10ML@ NEOMY+POL B+HYD O/S FAL 7.5ML@ NEOMY+POL+HY OTI SOL FAL 10ML@ NEOMY+POL B SUL OPH B&L 10ML@ OFLOXACIN OPH 0.3% B&L 5ML@ BLEPH-10 OPHTH SOL 10% 5ML TOBRAMY O/S 0.3% FAL 5ML@ TOBRAMYC+DEXAM OS FAL 2.5ML@ ACETIC ACID OTIC SOL MOR 15ML@ HYDROCORT 1% AC+OS 2% TAR10ML@ FLUNISOLI NSL SOL.025%RISI25ML FLUTICAS NAS SP 50MCG APX16GM@ LOTEMAX OPH SUSP 0.5% B&L 5ML PREDNISOL AC OPH 1% FAL 15ML@ PREDNISOL SOD OP/SOL1%B&L10ML@ TRIAM ACE NAS SPR WINT 16.5G DICLOFEN SOD OPH 0.1%FAL2.5ML@ FLURBIPR SOD OS.03% B&L 2.5ML@ KETOR O/S 0.4% APX 5ML KETOR O/S 0.5% APX 5ML PHARMAPURE OT/CRE SOL PUR 14ML ANTIPYR BENZ OS 5.5/1.4% VIRT CYCLOGYL 1% DT 2ML CYCLOGYL 2% DT 2ML BRIMONID OPH SOL 0.15%FAL 5ML@ BRIMONID OPH SOL 0.2% B&L10ML@ LEVOBUN HCL OPH 0.5% ACTA 5ML TIMOLOL MAL OPH .25% RIS 5ML TIMOLOL MAL OPH .50% RIS 5ML TIMOLOL OPH GL/F 0.5% FAL 5ML@ ACETAZOL ER CP UD 500MG AHP30@ ACETAZOL TAB 250MG TAR 100@ AZOPT 10ML DORZOLAMIDE 2% O/S ACTA 10ML DORZOL/TIMOL 2/.5% O/S ACT10ML PILOCAR OPHT SOL 1% FAL 15ML@ PILOCAR OPHT SOL 2% FAL 15ML@ LUMIGAN OPH SOL 0.01% 2.5ML GenericName CIPROFLOXACIN HCL/DEXAMETH CIPROFLOXACIN/HYDROCORTISONE DOXYCYCLINE HYCLATE ERYTHROMYCIN BASE GENTAMICIN SULFATE GENTAMICIN SULFATE MOXIFLOXACIN HCL NEO/POLYMYX B SULF/DEXAMETH NEO/POLYMYX B SULF/DEXAMETH NEOMYCIN SU/BACITRA/POLYMYXIN NEOMYCIN/POLYMYXIN B SULF/HC NEOMYCIN/POLYMYXIN B SULF/HC NEOMYCIN/POLYMYXIN B SULF/HC NEOMYCIN/POLYMYXN B/GRAMICIDIN OFLOXACIN SULFACETAMIDE SODIUM TOBRAMYCIN TOBRAMYCIN/DEXAMETHASONE ACETIC ACID ACETIC ACID/HYDROCORTISONE FLUNISOLIDE FLUTICASONE PROPIONATE LOTEPREDNOL ETABONATE PREDNISOLONE ACETATE PREDNISOLONE SOD PHOSPHATE TRIAMCINOLONE ACETONIDE DICLOFENAC SODIUM FLURBIPROFEN SODIUM KETOROLAC TROMETHAMINE KETOROLAC TROMETHAMINE ANTIPYRINE/BENZOCAINE ANTIPYRINE/BENZOCAINE CYCLOPENTOLATE HCL CYCLOPENTOLATE HCL BRIMONIDINE TARTRATE BRIMONIDINE TARTRATE LEVOBUNOLOL HCL TIMOLOL MALEATE TIMOLOL MALEATE TIMOLOL MALEATE ACETAZOLAMIDE ACETAZOLAMIDE BRINZOLAMIDE DORZOLAMIDE HCL DORZOLAMIDE HCL/TIMOLOL MALEAT PILOCARPINE HCL PILOCARPINE HCL BIMATOPROST Generic Dose Form DROPS SUSP DROPS SUSP TABLET OINT. (G) DROPS OINT. (G) DROPS DROPS SUSP OINT. (G) OINT. (G) DROPS SUSP DROPS SUSP SOLUTION DROPS DROPS DROPS DROPS DROPS SUSP SOLUTION DROPS SPRAY SPRAY SUSP DROPS SUSP DROPS SUSP DROPS SPRAY DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS DROPS SOL-GEL CAPSULE ER TABLET DROPS SUSP DROPS DROPS DROPS DROPS DROPS Dose Strength Description Name 0.3 %-0.1% 0.2 %-1 % 20 MG 5 MG/G 0.30% 0.30% 0.50% 0.10% 3.5-10K-.1 3.5MG-400 3.5-10K-1 3.5-10K-10 3.5-10K-1 1.75MG-10K 0.30% 10% 0.30% 0.3 %-0.1% 2% 2 %-1 % 25 MCG 50 MCG 0.50% 1% 1% 55 MCG 0.10% 0.03% 0.40% 0.50% 5.4 %-1.4% 5.5 %-1.4% 1% 2% 0.15% 0.20% 0.50% 0.25% 0.50% 0.50% 500 MG 250 MG 1% 2% 22.3-6.8/1 1% 2% 0.01% Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 524028 PROSTAGLANDIN ANALOGS 524028 PROSTAGLANDIN ANALOGS 560800 ANTIDIARRHEA AGENTS 560800 ANTIDIARRHEA AGENTS 561200 CATHARTICS AND LAXATIVES 561200 CATHARTICS AND LAXATIVES 561200 CATHARTICS AND LAXATIVES 561400 CHOLELITHOLYTIC AGENTS 561400 CHOLELITHOLYTIC AGENTS 561400 CHOLELITHOLYTIC AGENTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 561600 DIGESTANTS 562208 ANTIHISTAMINES (GI DRUGS) 562208 ANTIHISTAMINES (GI DRUGS) 562220 5-HT3 RECEPTOR ANTAGONISTS 562220 5-HT3 RECEPTOR ANTAGONISTS 562220 5-HT3 RECEPTOR ANTAGONISTS 562220 5-HT3 RECEPTOR ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562812 HISTAMINE H2-ANTAGONISTS 562828 PROSTAGLANDINS 562828 PROSTAGLANDINS 562832 PROTECTANTS 562832 PROTECTANTS 562836 PROTON-PUMP INHIBITORS 562836 PROTON-PUMP INHIBITORS 563200 PROKINETIC AGENTS 563200 PROKINETIC AGENTS 563200 PROKINETIC AGENTS 563200 PROKINETIC AGENTS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name LATANOP OS 0.005% A/R 2.5ML TRAVOPROST SOL .004% PAR2.5ML@ DIPHENOX+ATR SOL 2MG ROX 60ML@ DIPHENOX+ATR TB 2.5MG GRE 100@ GOLYTELY SOL PINEAPLE 4000ML PEG-3350+ELECT O/S KREM 4LT@ TRILYTE O/S W/FLV PK WALL 4L@ URSODIOL CAP 300MG MMP 100 URSODIOL TAB 250MG GPC 100 URSODIOL TAB 500MG PRAS 100 PANCREAZE CAP 10500U 100 CREON 12000 CAP 100 PANCREAZE CAP 16800U 100 CREON 24000 CAP 100 CREON 36000 CAP 100 CREON 3000 CAP 70 PANCREAZE CAP 4200U 100 CREON 6000 CAP 100 PROCHLORP TAB 10MG UD+ AHP 30 PROCHLORP TAB 5MG MYLN 100@ ONDANS OD TAB 4MG MYLN 30@ ONDANS OD TAB 8MG MYLN 10@ ONDANS TAB 4MG UD SAN 3@ ONDANSET TAB 8MG UD SAN 3 FAMOTID O/S 40MG/5ML PAD 50ML HEARTBURN RELF TAB MAX MMP 50 FAMOTID TAB 40MG UD AVK 5X10 RANITID CAP 150MG DR/R 60@ RANITID CAP 300MG SAN 30@ RANITID O/S 15MG/ML CARA 16OZ RANITID TAB 150MG MMP 24 RANITIDINE TAB 300MG AVK UD50 MISOPROST TAB 100MCG IVA 60 MISOPROSTOL TAB 200MCG TEV 60 CARAFATE SUSP 1GM 14OZ SUCRALFATE TAB 1GM UD UDL 100 PANTOPRAZ TAB 20MG PRA 90@ PANTOPRA SOD DR 40MG UDAHP 80@ METOCLOPR SYRP UD 10ML P/A100 METOCLOPR OS 5/5ML AF ANI16OZ@ METOCLOPR TAB 10MG AVK 90 METOCLOPR TAB 5MG AVK 90 DEXAMETH O/S 1MG ROX 30ML@ DEXAMETH TAB 0.5MG PAR 100@ DEXAMETH TAB 0.75MG ROX 100@ DEXAMETH TAB 1MG ROX 100@ DEXAMETH TAB 2MG ROX 100@ DEXAMETH TAB 4MG ROX 100@ GenericName LATANOPROST TRAVOPROST (BENZALKONIUM) DIPHENOXYLATE HCL/ATROPINE DIPHENOXYLATE HCL/ATROPINE PEG 3350/NA SULF BICARB CL/KCL PEG 3350/NA SULF BICARB CL/KCL SODIUM CHLORIDE/NAHCO3/KCL/PEG URSODIOL URSODIOL URSODIOL LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE LIPASE/PROTEASE/AMYLASE PROCHLORPERAZINE MALEATE PROCHLORPERAZINE MALEATE ONDANSETRON ONDANSETRON ONDANSETRON HCL ONDANSETRON HCL FAMOTIDINE FAMOTIDINE FAMOTIDINE RANITIDINE HCL RANITIDINE HCL RANITIDINE HCL RANITIDINE HCL RANITIDINE HCL MISOPROSTOL MISOPROSTOL SUCRALFATE SUCRALFATE PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM METOCLOPRAMIDE HCL METOCLOPRAMIDE HCL METOCLOPRAMIDE HCL METOCLOPRAMIDE HCL DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE DEXAMETHASONE Generic Dose Form DROPS DROPS LIQUID TABLET SOLN RECON SOLN RECON SOLN RECON CAPSULE TABLET TABLET CAPSULE DR CAPSULE DR CAPSULE DR CAPSULE DR CAPSULE DR CAPSULE DR CAPSULE DR CAPSULE DR TABLET TABLET TAB RAPDIS TAB RAPDIS TABLET TABLET ORAL SUSP TABLET TABLET CAPSULE CAPSULE SYRUP TABLET TABLET TABLET TABLET ORAL SUSP TABLET TABLET DR TABLET DR SOLUTION SOLUTION TABLET TABLET DROPS TABLET TABLET TABLET TABLET TABLET Dose Strength Description Name 0.01% 0.00% 2.5-.025/5 2.5-.025MG 236-22.74G 240-22.72G 420G 300 MG 250 MG 500 MG 10.5K-25K 12K-38K-60 16.8-40-70 24-76-120K 36-114-180 3-9.5-15K 4.2K-10K 6K-19K-30K 10 MG 5 MG 4 MG 8 MG 4 MG 8 MG 40MG/5ML 20 MG 40 MG 150 MG 300 MG 15 MG/ML 150 MG 300 MG 100 MCG 200 MCG 1 G/10 ML 1G 20 MG 40 MG 10 MG/10ML 5 MG/5 ML 10 MG 5 MG 1 MG/ML 0.5 MG 0.75 MG 1 MG 2 MG 4 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680400 ADRENALS 680800 ANDROGENS 680800 ANDROGENS 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681200 CONTRACEPTIVES 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681604 ESTROGENS 681612 ESTROGEN AGONIST-ANTAGONISTS 682004 BIGUANIDES 682004 BIGUANIDES Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name FLUDROC TAB 0.1MG UD AVK 50@ HYDROCORT TAB 10MG Q/P 100@ HYDROCORT TAB 20MG Q/P 100@ HYDROCORT TAB 5MG UD+ AHP 30 METHYLPRED TAB 4MG BRECK 21@ METHYLPRED TB 4MG UD AHP100@ PREDNISOL SYRP 15/5 Q/P 240ML PREDNISOL SOD O/S MOR 8OZ@ PREDNISON TAB 10MG Q/P 21@ PREDNISON TB 5MG UNIPK Q/P 21@ PREDNISON TAB 1MG Q/P 100@ PREDNISON TAB 10MG WAT 100 PREDNISON TAB 2.5MG Q/P 100@ PREDNISON TAB 20MG SKY UD 100 PREDNISON TAB 5MG CAD 100@ PREDNISON TAB 50MG ROX 100@ ANDROGEL 1% 2.5GM UD 30 ANDROGEL 1% 5GM UD 30 DROSPIR/ETH TB 3/.03MG LUPI 84 MYZILRA TAB Q/P 3X28@ DELYLA .1MG/.02MG TAB RAN 28@ KURVELO TAB .15MG/.3MG LUPI 3 JENCYCLA TAB 0.35MG LUPI 3 LARIN 1.5MG/0.03MG 3X21 NSTR@ GILDESS TAB 1/0.02MG Q/P 3X21@ JUNEL FE 1.5MG/30MCG BARR6X28@ WERA TAB 0.5/0.035MG 3X28NSTR@ NORTREL TAB 1/35 BARR 3X21@ CYCLAFEM 7/7/70.5/0.035QP3X28@ NORGEST/EE 0.25/0.035GLEN3X28@ TRI-EST 35+180/215/250 3X28SAN ELINEST TB 0.3/0.03MG6X28NSTR@ ESTRADIOL TAB 0.5MG UD AVK 50 ESTRADIOL TAB 1MG UD AVK 50 ESTRADIOL TAB 2MG UD AVK 50 PREMPRO TAB 0.3/1.5MG 28 PREMPRO TAB 0.45/1.5MG 28 PREMPRO TAB 0.625/2.5MG 28 PREMPRO TAB 0.625/5MG 28 PREMARIN VAG CRM 0.625MG 30GM PREMARIN TAB 0.3MG 100 PREMARIN TAB 0.45MG 100 PREMARIN TAB 0.625MG 100 PREMARIN TAB 0.9MG 100 PREMARIN TAB 1.25MG 100 EVISTA TAB 60MG 30 METFORM ER TB 500MG GOLD 60 METFORM HCL ERTB750MG AVK UD30 GenericName FLUDROCORTISONE ACETATE HYDROCORTISONE HYDROCORTISONE HYDROCORTISONE METHYLPREDNISOLONE METHYLPREDNISOLONE PREDNISOLONE PREDNISOLONE SOD PHOSPHATE PREDNISONE PREDNISONE PREDNISONE PREDNISONE PREDNISONE PREDNISONE PREDNISONE PREDNISONE TESTOSTERONE TESTOSTERONE ETHINYL ESTRADIOL/DROSPIRENONE LEVONORGESTREL-ETHIN ESTRADIOL LEVONORGESTREL-ETHIN ESTRADIOL LEVONORGESTREL-ETHIN ESTRADIOL NORETHINDRONE NORETHINDRONE AC-ETH ESTRADIOL NORETHINDRONE AC-ETH ESTRADIOL NORETHINDRONE-E.ESTRADIOL-IRON NORETHINDRONE-ETHINYL ESTRAD NORETHINDRONE-ETHINYL ESTRAD NORETHINDRONE-ETHINYL ESTRAD NORGESTIMATE-ETHINYL ESTRADIOL NORGESTIMATE-ETHINYL ESTRADIOL NORGESTREL-ETHINYL ESTRADIOL ESTRADIOL ESTRADIOL ESTRADIOL ESTROGEN CON/M-PROGEST ACET ESTROGEN CON/M-PROGEST ACET ESTROGEN CON/M-PROGEST ACET ESTROGEN CON/M-PROGEST ACET ESTROGENS CONJUGATED ESTROGENS CONJUGATED ESTROGENS CONJUGATED ESTROGENS CONJUGATED ESTROGENS CONJUGATED ESTROGENS CONJUGATED RALOXIFENE HCL METFORMIN HCL METFORMIN HCL Generic Dose Form TABLET TABLET TABLET TABLET TAB DS PK TABLET SOLUTION SOLUTION TAB DS PK TAB DS PK TABLET TABLET TABLET TABLET TABLET TABLET GEL PACKET GEL PACKET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CREAM/APPL TABLET TABLET TABLET TABLET TABLET TABLET TAB ER 24H TAB ER 24H Dose Strength Description Name 0.1 MG 10 MG 20 MG 5 MG 4 MG 4 MG 15 MG/5 ML 15 MG/5 ML 10 MG 5 MG 1 MG 10 MG 2.5 MG 20 MG 5 MG 50 MG 25MG(1%) 50 MG (1%) 0.03MG-3MG 6/5/2010 0.1-0.02 0.15-0.03 0.35 MG 1.5-0.03MG 1MG-20MCG 1.5-30(21) 0.5-0.035 1 MG-35MCG 7 DAYS X 3 0.25-0.035 7DAYSX3 28 0.3-0.03MG 0.5 MG 1 MG 2 MG 0.3-1.5MG 0.45-1.5MG 0.625-2.5 0.625-5 MG 0.625 MG/G 0.3 MG 0.45MG 0.625 MG 0.9 MG 1.25 MG 60 MG 500 MG 750 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 682004 BIGUANIDES 682004 BIGUANIDES 682004 BIGUANIDES 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682008 INSULINS 682016 MEGLITINIDES 682016 MEGLITINIDES 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682020 SULFONYLUREAS 682028 THIAZOLIDINEDIONES 682028 THIAZOLIDINEDIONES 682028 THIAZOLIDINEDIONES 682212 GLYCOGENOLYTIC AGENTS 682212 GLYCOGENOLYTIC AGENTS 682400 PARATHYROID 682800 PITUITARY 682800 PITUITARY 682800 PITUITARY 682800 PITUITARY 683200 PROGESTINS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name METFORM TB 1000MG BB AMN100@ METFORM TAB 500MG MMP 60 METFORM IR TB 850MGUD GOLD 60 NOVOLOG PENFILL 100U 3ML 5 NOVOLOG F/PEN PREF SYR 3ML 5 NOVOLOG VIAL 100U 10ML NOVOLOG 70/30 FLEX PEN 3ML 5 NOVOLOG 70/30 VL 10ML HUMALOG CART 3-ML 5 HUMALOG KWIK PEN 3ML 5 HUMALOG VIAL 100U 3ML HUMULIN 70/30 PEN 5 HUMULIN 70/30 MDV 10ML HUMULIN N PEN 5 HUMULIN N NPH INSUL U100 10ML HUMALOG KWIK PEN 75/25 5 HUMALOG VIAL 75/25 10ML HUMULIN R REG INSUL U100 10ML NATEGLIN TAB 120MG UD AHP 30 NATEGLIN TAB 60MG UD AHP 30 GLIMEPIR TAB 1MG UD+ AHP 30 GLIMEPIRIDE TAB 2MG VIRT 100 GLIMEPIRIDE TAB 4MG VIRT 100 GLIPIZIDE XL TB 10MG GRE 100 GLIPIZIDE ER TB 2.5MG WAT 30@ GLIPIZIDE XL TB 5MG GRE 100 GLIPIZIDE TAB 10MG MYLN 100@ GLIPIZIDE TAB 5MG MYL 100@ GLIPIZIDE MET 2.5/250 TEV100@ GLIPIZIDE MET 2.5/500 TEV100@ GLIPIZIDE MET 5/500MG TEV100@ GLYBURIDE D TAB 1.25MG TEV 50@ GLYBURIDE TAB 2.5MG AVK 500 GLYBURIDE TAB 5MG UD AHP100 GLYBURIDE MET 1.25/250 ACT100@ GLYBURIDE ME TB 2.5/5C ACT100@ GLYBURIDE MET 5/500MG UD+AHP30 PIOGLITAZONE TAB 15MG MACL 30@ PIOGLITAZONE TB 30MG TEVA 30@ PIOGLITAZONE TAB 45MG MACL 30@ GLUCAGON EMERG KIT 1MG+SYR 1ML GLUCAGEN HYPOKIT NOVO 7065-15 CALCITON SALMNAS200IUPAR3.7ML@ DDAVP NASAL SPR BOTTLE 5ML DESMOPR ACE RHNL TB FER 2.5ML DESMOPR NASAL SOL.01% B&L 5ML@ DESMOPR TAB 0.2MG 100 MEDROXYPR TAB 10MG BARR 100@ GenericName METFORMIN HCL METFORMIN HCL METFORMIN HCL INSULIN ASPART INSULIN ASPART INSULIN ASPART INSULIN ASPART PROTAM & ASPART INSULIN ASPART PROTAM & ASPART INSULIN LISPRO INSULIN LISPRO INSULIN LISPRO INSULIN NPH HUM/REG INSULIN HM INSULIN NPH HUM/REG INSULIN HM INSULIN NPH HUMAN ISOPHANE INSULIN NPH HUMAN ISOPHANE INSULIN NPL/INSULIN LISPRO INSULIN NPL/INSULIN LISPRO INSULIN REGULAR HUMAN NATEGLINIDE NATEGLINIDE GLIMEPIRIDE GLIMEPIRIDE GLIMEPIRIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE GLIPIZIDE/METFORMIN HCL GLIPIZIDE/METFORMIN HCL GLIPIZIDE/METFORMIN HCL GLYBURIDE GLYBURIDE GLYBURIDE GLYBURIDE/METFORMIN HCL GLYBURIDE/METFORMIN HCL GLYBURIDE/METFORMIN HCL PIOGLITAZONE HCL PIOGLITAZONE HCL PIOGLITAZONE HCL GLUCAGON HUMAN RECOMBINANT GLUCAGON HUMAN RECOMBINANT CALCITONIN SALMON SYNTHETIC DESMOPRESSIN (NONREFRIGERATED) DESMOPRESSIN ACETATE DESMOPRESSIN ACETATE DESMOPRESSIN ACETATE MEDROXYPROGESTERONE ACETATE Generic Dose Form TABLET TABLET TABLET CARTRIDGE INSULN PEN VIAL INSULN PEN VIAL CARTRIDGE INSULN PEN VIAL INSULN PEN VIAL INSULN PEN VIAL INSULN PEN VIAL VIAL TABLET TABLET TABLET TABLET TABLET TAB ER 24 TAB ER 24 TAB ER 24 TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET KIT VIAL SPRAY/PUMP SPRAY/PUMP SOLUTION SPRAY/PUMP TABLET TABLET Dose Strength Description Name 1000 MG 500 MG 850 MG 100/ML 100/ML 100/ML 70-30/ML 70-30/ML 100/ML 100/ML 100/ML 70-30/ML 70-30/ML 100/ML (3) 100/ML 75-25/ML 75-25/ML 100/ML 120 MG 60 MG 1 MG 2 MG 4 MG 10 MG 2.5 MG 5 MG 10 MG 5 MG 2.5-250 MG 2.5-500 MG 5 MG-500MG 1.25 MG 2.5 MG 5 MG 1.25-250MG 2.5-500 MG 5 MG-500MG 15 MG 30 MG 45 MG 1 MG 1 MG 200/SPRAY 10/SPRAY 0.1 MG/ML 10/SPRAY 0.2 MG 10 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 683200 PROGESTINS 683200 PROGESTINS 683200 PROGESTINS 683200 PROGESTINS 683604 THYROID AGENTS 683604 THYROID AGENTS 683604 THYROID AGENTS 683608 ANTITHYROID AGENTS 683608 ANTITHYROID AGENTS 80800 ANTHELMINTICS 80800 ANTHELMINTICS 81202 AMINOGLYCOSIDES 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81206 CEPHALOSPORINS 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81212 MACROLIDES 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name MEDROXYPR TAB 2.5MG BARR 100@ MEDROXYPR TAB 5MG BARR 100@ NORETHINDR TAB 5MG UD AVK 50 ENDOMETRIN VAG INSERT TAB 21 LIOTHYRON SOD TB 25MCG SIG100@ LIOTHYRON TAB 5MCG MYL 100 LIOTHYRON TAB 50MCG MYL 100@ METHIMAZ TAB 10MG HERI 100 METHIMAZ TAB 5MG HERI 100 ALBENZA TAB 200MG 2 STROMECTOL TAB 3MG 20 NEOMY SUL TB 500MG BRECK 100@ CEFDINIR CAP 300MG DAVA 60@ CEFDIN OS 125MG/5ML DAVA 60ML CEFDIN OS 250MG/5ML DAVA 100ML CEFUROX AXET TB 250MG AURO 20@ CEFUROX AXET TB 500MG AURO 20@ CEPHALEX CAP 250MG UD AVK 5X10 CEPHALEX CAP 500MG UD AVK 5X10 CEPHALEX O/S 250/5MLLUPI100ML@ CEPHALEX TAB 250MG TEV 100@ CEPHALEX TAB 500MG TEV 100@ AZITHROMY OS 100MG/5MLTEV15ML AZITHROMY OS 200MG/5ML TEV15ML AZITHROMY TAB 250MG UD AVK 50 AZITHROMY TB 500MG BP TEV 1X3@ AZITHROMY TAB 600MG UD AHP20@ CLARITHR OS 125MG/5ML SAN50ML@ CLARITHR TB 250MG CIT 60 CLARITHR TAB 500MG UD AHP 30 ERYTHROMYCIN DR CAP 250MG 100 ERYTHROMY BASE TAB 250MG 100 ERYTHROMY BASE TAB 500MG 100 ERY-TAB 250MG DR 100 ERY-TAB 333MG DR 100 ERY-TAB 500MG E/C 100 ERYTHROMY ETH TAB 400MG 100 ERYTHR STEAR TAB 250MG 100 AMOXICIL CAP 250MG TEV 100@ AMOXICIL CAP 500MG TEV 50@ AMOXICIL SUS 125MG TEV 100ML@ AMOXICIL O/S 200/5ML TEV 50ML@ AMOXICIL O/S 250/5ML Q/P 80ML AMOXICIL O/S 400/5ML TEV 50ML@ AMOXICIL CHW TB 250MG TEV 1C@ AMOXICIL TAB 500MG CIT 100 AMOXICIL TAB 875MG CIT 100@ AUGMENTIN 125 O/S 75ML GenericName MEDROXYPROGESTERONE ACETATE MEDROXYPROGESTERONE ACETATE NORETHINDRONE ACETATE PROGESTERONE MICRONIZED LIOTHYRONINE SODIUM LIOTHYRONINE SODIUM LIOTHYRONINE SODIUM METHIMAZOLE METHIMAZOLE ALBENDAZOLE IVERMECTIN NEOMYCIN SULFATE CEFDINIR CEFDINIR CEFDINIR CEFUROXIME AXETIL CEFUROXIME AXETIL CEPHALEXIN CEPHALEXIN CEPHALEXIN CEPHALEXIN CEPHALEXIN AZITHROMYCIN AZITHROMYCIN AZITHROMYCIN AZITHROMYCIN AZITHROMYCIN CLARITHROMYCIN CLARITHROMYCIN CLARITHROMYCIN ERYTHROMYCIN BASE ERYTHROMYCIN BASE ERYTHROMYCIN BASE ERYTHROMYCIN BASE ERYTHROMYCIN BASE ERYTHROMYCIN BASE ERYTHROMYCIN ETHYLSUCCINATE ERYTHROMYCIN STEARATE AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN AMOXICILLIN/POTASSIUM CLAV Generic Dose Form TABLET TABLET TABLET INSERT TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET CAPSULE SUSP RECON SUSP RECON TABLET TABLET CAPSULE CAPSULE SUSP RECON TABLET TABLET SUSP RECON SUSP RECON TABLET TABLET TABLET SUSP RECON TABLET TABLET CAPSULE DR TABLET TABLET TABLET DR TABLET DR TABLET DR TABLET TABLET CAPSULE CAPSULE SUSP RECON SUSP RECON SUSP RECON SUSP RECON TAB CHEW TABLET TABLET SUSP RECON Dose Strength Description Name 2.5 MG 5 MG 5 MG 100 MG 25 MCG 5 MCG 50 MCG 10 MG 5 MG 200 MG 3 MG 500 MG 300 MG 125 MG/5ML 250 MG/5ML 250 MG 500 MG 250 MG 500 MG 250 MG/5ML 250 MG 500 MG 100 MG/5ML 200 MG/5ML 250 MG 500 MG 600 MG 125 MG/5ML 250 MG 500 MG 250 MG 250 MG 500 MG 250 MG 333 MG 500 MG 400 MG 250 MG 250 MG 500 MG 125 MG/5ML 200 MG/5ML 250 MG/5ML 400 MG/5ML 250 MG 500 MG 875 MG 125-31.25/ Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81216 PENICILLINS 81218 QUINOLONES 81218 QUINOLONES 81218 QUINOLONES 81218 QUINOLONES 81218 QUINOLONES 81218 QUINOLONES 81220 SULFONAMIDES (SYSTEMIC) 81220 SULFONAMIDES (SYSTEMIC) 81220 SULFONAMIDES (SYSTEMIC) 81220 SULFONAMIDES (SYSTEMIC) 81220 SULFONAMIDES (SYSTEMIC) 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81224 TETRACYCLINES 81228 ANTIBACTERIALS, MISCELLANEOUS 81228 ANTIBACTERIALS, MISCELLANEOUS 81404 ALLYLAMINES 81408 AZOLES 81408 AZOLES 81408 AZOLES 81408 AZOLES 81408 AZOLES 81428 POLYENES Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name AMOXICIL CLV 2C/28.5MGSAN50ML@ AMOXICIL CLV 250/62.5 MOR75ML@ AMOXICIL CLV 400/57MG SAN75ML@ AUGMENT ES OS 600MG DR/R 125ML AMOXICI CLV 2CMG/28.5MG TEV20@ AMOXICIL CLV ER1000/62.5SAN28@ AMOXICIL CLV+POT250/12530NSTA@ AMOXICIL CLVPOT500/12520NSTAR@ AMOXICIL CLV+POT875/12520NSTA@ DICLOXAC CAP 250MG SAN 100@ DICLOXAC CAP 500MG SAN 100@ PENICIL-VK O/S 125MG TEV 1CML@ PENICIL-VK O/S 250MG TEV 1CML@ PENICIL-V POT TB 250MG CIT 100 PENICILL V POT TB500MG CIT1000 CIPROFLOX TAB 250MG AVK 100 CIPROFLOX TAB 500MG BLU 20 CIPROFLOX TAB 750MG 50 NSTAR@ LEVOFLOXACIN TAB 250MG UD QP50 LEVOFLOX TAB 500MG QUAL 50 LEVOFLOXACIN TAB 750MG UD QP50 SULFAM+TRI OS CHRY AURO 473ML@ SULFAM+TRI OS 20MLGRP UDHIT40 SULFAM+TRI TB 400/80 UD+AHP 30 SULFAM+TRI TB 800/160 UD AVK30 SULFAS TAB 500MG UD AVK 50@ DOXYCYCLINE CAP 100MG UD AHP30 DOXYCYCLINE CAP 50MG DAVA 50 DOXYCYC HYC TAB 100MG BLU 20 DOXYCYC MONO CP 100MG UD+AHP20 DOXYCYCLINE MONO CP 50MGLUP100 DOXCYCLN CP USP 75MG LUPI 100@ DOXYCYC MONO TB 100MG HERI 50@ MINOCYC HCL CP 100MG AVK UD 30 MINOCYC HCL CP 50MG AVK UD 50 MINOCYCLIN CAP 75MG WAT 100@ MINOCYCLINE HCL TB 100MG AVK60 MINOCYCLINE HCL TB 50MG AVK 90 MINOCYCLIN TAB 75MG PAR 100@ CLINDAMY CAP 150MG UD AVK 5X10 CLINDAMY CAP 300MG UD AVK 5X10 TERBINAF TAB 250MG HARR 30@ FLUCONAZ O/S 40MG/ML ROX 35ML FLUCONAZOLE TB 100MG PACK 30 FLUCONAZ TAB 150MG DR/R 12 FLUCONAZOLE TAB 200MG PACK 30 FLUCONAZ TAB 50MG DR/R 30 NYSTATIN O/S 100MU 5ML SKY 50@ GenericName AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV AMOXICILLIN/POTASSIUM CLAV DICLOXACILLIN SODIUM DICLOXACILLIN SODIUM PENICILLIN V POTASSIUM PENICILLIN V POTASSIUM PENICILLIN V POTASSIUM PENICILLIN V POTASSIUM CIPROFLOXACIN HCL CIPROFLOXACIN HCL CIPROFLOXACIN HCL LEVOFLOXACIN LEVOFLOXACIN LEVOFLOXACIN SULFAMETHOXAZOLE/TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM SULFAMETHOXAZOLE/TRIMETHOPRIM SULFASALAZINE DOXYCYCLINE HYCLATE DOXYCYCLINE HYCLATE DOXYCYCLINE HYCLATE DOXYCYCLINE MONOHYDRATE DOXYCYCLINE MONOHYDRATE DOXYCYCLINE MONOHYDRATE DOXYCYCLINE MONOHYDRATE MINOCYCLINE HCL MINOCYCLINE HCL MINOCYCLINE HCL MINOCYCLINE HCL MINOCYCLINE HCL MINOCYCLINE HCL CLINDAMYCIN HCL CLINDAMYCIN HCL TERBINAFINE HCL FLUCONAZOLE FLUCONAZOLE FLUCONAZOLE FLUCONAZOLE FLUCONAZOLE NYSTATIN Generic Dose Form SUSP RECON SUSP RECON SUSP RECON SUSP RECON TAB CHEW TAB ER 12H TABLET TABLET TABLET CAPSULE CAPSULE SOLN RECON SOLN RECON TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET ORAL SUSP ORAL SUSP TABLET TABLET TABLET CAPSULE CAPSULE TABLET CAPSULE CAPSULE CAPSULE TABLET CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET CAPSULE CAPSULE TABLET SUSP RECON TABLET TABLET TABLET TABLET ORAL SUSP Dose Strength Description Name 200-28.5/5 250-62.5/5 400-57MG/5 600-42.9/5 200-28.5MG 1000-62.5 250-125 MG 500-125 MG 875-125 MG 250 MG 500 MG 125 MG/5ML 250 MG/5ML 250 MG 500 MG 250 MG 500 MG 750 MG 250 MG 500 MG 750 MG 200-40MG/5 800-160/20 400MG-80MG 800-160 MG 500 MG 100 MG 50 MG 100 MG 100 MG 50 MG 75 MG 100 MG 100 MG 50 MG 75 MG 100 MG 50 MG 75 MG 150 MG 300 MG 250 MG 40 MG/ML 100 MG 150 MG 200 MG 50 MG 100000/ML Comments 2 0 Medical Access Program (MAP) Formulary- 2016 AHFS Classification 81428 POLYENES 81428 POLYENES 81428 POLYENES 81492 ANTIFUNGALS, MISCELLANEOUS 81492 ANTIFUNGALS, MISCELLANEOUS 81492 ANTIFUNGALS, MISCELLANEOUS 81492 ANTIFUNGALS, MISCELLANEOUS 81828 NEURAMINIDASE INHIBITORS 81828 NEURAMINIDASE INHIBITORS 81828 NEURAMINIDASE INHIBITORS 81828 NEURAMINIDASE INHIBITORS 81828 NEURAMINIDASE INHIBITORS 81832 NUCLEOSIDES AND NUCLEOTIDES 81832 NUCLEOSIDES AND NUCLEOTIDES 81832 NUCLEOSIDES AND NUCLEOTIDES 81832 NUCLEOSIDES AND NUCLEOTIDES 81832 NUCLEOSIDES AND NUCLEOTIDES 83008 ANTIMALARIALS 83092 ANTIPROTOZOALS, MISCELLANEOUS 83092 ANTIPROTOZOALS, MISCELLANEOUS 83600 URINARY ANTI-INFECTIVES 83600 URINARY ANTI-INFECTIVES 83600 URINARY ANTI-INFECTIVES 83600 URINARY ANTI-INFECTIVES 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840404 ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE) 840406 ANTIVIRALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name NYSTATIN PWD PADD 150MU NYSTATIN PWD PADD 50MU NYSTATIN TAB 500MU MUT 100@ GRISEOFULV OS 125/5ML Q/P 4OZ@ GRIFULVIN V TAB 500MG 100 GRIS-PEG TAB 125MG 100 GRIS-PEG TAB 250MG 100 TAMIFLU CAP 30MG BP 10 NR TAMIFLU CAP 45MG BP 10 NR TAMIFLU CAP 75MG BP 10 NR TAMIFLU O/S 6MG/ML 60ML NR RELENZA DSKHLR 5MG 5X4 ACYCLOVIR CAP 200MG UD AHP100@ ACYCLOVIR TAB 400MG UD AHP100@ ACYCLOVIR TB 800MG UD AVK 50 VALACYCL TAB 1GM UD AHP 30@ VALACYCLOVIR TAB 500MG CIP 30 HYDROXYCH TAB 200MG AVK 100 METRONID TAB 250MG UD AHP 100@ METRONID TAB 500MG WAT 50@ NITROFURAN OS 25MG CARA 5ML@ NITROFURAN CAP 100MG UDAHP100@ NITROFURAN CAP 50MG UD AHP100@ NITROFURAN CAP 100MG MYLN 100@ CLINDAMY PH VAG CRM GRE 40GM@ CLINDAMY GEL USP 1% FOUG 30GM@ CLINDAMY PH LOT 1% GRE 60ML@ CLINDAMY PHOS TS 1% ACTA30ML ERYTHR TOP SOL 2% FOUG 60ML METRONIDAZ CRM 0.75% PRAS45G@ METRONID GEL 0.75% PRAS 45GM@ METROGEL TOP GEL 1% 60GM METROGEL VAGINAL .75% TBE 70GM METROGEL 1% PUMP 55GM METRONIDAZ LOT 0.75% PRAS 2OZ@ MUPIROCIN OINT 2% PERR 22GM@ ACYCLOVIR 5% OINT ACT 30GM@ CICLOPIR GEL 0.77% GLEN 45GM@ CICLOPIR SHAM 1% TAR 120ML CICLOPIR TOP SOL 8% HARR 6.6ML CICLOPIR CRM 0.77% FOU 15GM CLOTRIMAZ+BETAM CRM ACTA 15GM@ CLOTRIMAZ+BETAM LOT TAR 30ML@ KETOCONAZOLE CRM 2% TAR 15GM@ KETOCONAZOLE SHAM 2% SAN 4OZ@ NYSTATIN CRM 100MU FOUG 30GM@ NYSTATIN OIN 100MU FOUG 15GM@ NYSTATIN TOP PWD X-G 15GM GenericName NYSTATIN NYSTATIN NYSTATIN GRISEOFULVIN MICROSIZE GRISEOFULVIN MICROSIZE GRISEOFULVIN ULTRAMICROSIZE GRISEOFULVIN ULTRAMICROSIZE OSELTAMIVIR PHOSPHATE OSELTAMIVIR PHOSPHATE OSELTAMIVIR PHOSPHATE OSELTAMIVIR PHOSPHATE ZANAMIVIR ACYCLOVIR ACYCLOVIR ACYCLOVIR VALACYCLOVIR HCL VALACYCLOVIR HCL HYDROXYCHLOROQUINE SULFATE METRONIDAZOLE METRONIDAZOLE NITROFURANTOIN NITROFURANTOIN MACROCRYSTAL NITROFURANTOIN MACROCRYSTAL NITROFURANTOIN MONOHYD/M-CRYST CLINDAMYCIN PHOSPHATE CLINDAMYCIN PHOSPHATE CLINDAMYCIN PHOSPHATE CLINDAMYCIN PHOSPHATE ERYTHROMYCIN BASE/ETHANOL METRONIDAZOLE METRONIDAZOLE METRONIDAZOLE METRONIDAZOLE METRONIDAZOLE METRONIDAZOLE MUPIROCIN ACYCLOVIR CICLOPIROX CICLOPIROX CICLOPIROX CICLOPIROX OLAMINE CLOTRIMAZOLE/BETAMETHASONE DIP CLOTRIMAZOLE/BETAMETHASONE DIP KETOCONAZOLE KETOCONAZOLE NYSTATIN NYSTATIN NYSTATIN Generic Dose Form POWDER(EA) POWDER(EA) TABLET ORAL SUSP TABLET TABLET TABLET CAPSULE CAPSULE CAPSULE SUSP RECON BLST W/DEV CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET ORAL SUSP CAPSULE CAPSULE CAPSULE CREAM/APPL GEL (GRAM) LOTION SOLUTION SOLUTION CREAM (G) GEL (GRAM) GEL (GRAM) GEL W/APPL GEL W/PUMP LOTION OINT. (G) OINT. (G) GEL (GRAM) SHAMPOO SOLUTION CREAM (G) CREAM (G) LOTION CREAM (G) SHAMPOO CREAM (G) OINT. (G) POWDER Dose Strength Description Name 150MM UNIT 50MM UNIT 500K UNIT 125 MG/5ML 500 MG 125 MG 250 MG 30 MG 45 MG 75 MG 6 MG/ML 5 MG 200 MG 400 MG 800 MG 1000 MG 500 MG 200 MG 250 MG 500 MG 25 MG/5 ML 100 MG 50 MG 100 MG 2% 1% 1% 1% 2% 0.75% 0.75% 1% 0.75% 1% 0.75% 2% 5% 0.77% 1% 8% 0.77% 1 %-0.05 % 1 %-0.05 % 2% 2% 100000/G 100000/G 100000/G Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840408 ANTIFUNGALS (SKIN & MUCOUS MEMBRANE) 840412 SCABICIDES AND PEDICULICIDES 840412 SCABICIDES AND PEDICULICIDES 840412 SCABICIDES AND PEDICULICIDES 840412 SCABICIDES AND PEDICULICIDES 840492 LOCAL ANTI-INFECTIVES, MISCELLANEOUS 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840600 ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS) 840800 ANTIPRURITICS AND LOCAL ANESTHETICS 840800 ANTIPRURITICS AND LOCAL ANESTHETICS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name NYSTAT+TRIAM CRM 0.1% ACTA15GM NYSTATIN+TRIAM OINT SAN 30GM@ TERCON CRM 0.4% WAT 45GM LINDANE LOTION 1% WOCK 60ML@ LINDANE SHAMPOO 1% WOCK 60ML@ PERMETHRIN CRM 5% PERR 60GM@ PERMETHRIN LOT 1% ALPH 59ML SILVADENE CRM 1%TUBE PFIZ25G BETAMET DIP CRM 0.05%TAR 15GM@ BETAMET DIP LO 0.05%FOUG 60ML@ BETAMET DIP OI 0.05%FOUG 45GM@ BETAMET VAL CR 0.1% FOUG 45GM@ BETAMET VAL LO 0.1% FOUG 60ML@ BETAMET VAL OI 0.1% FOUG 15GM@ BETAMET DIP AU 0.05% SAN 15GM BETAMET DIP AU 0.05%FOUG 15GM@ CLOBETASOL CRM .05% ACT 30GM@ CLOBETASOL LOT 0.05% TAR 59ML CLOBETAS PR OI 0.05% FOU 60GM@ CLOBETAS T/S 0.05% ACTA 50ML CLOBETAS EM CR 0.05% FOU 15GM@ DESONIDE CRM 0.05% G&W 15GM@ DESONIDE OIN 0.05% PERR 15GM@ FLUOCINOL AC BDY.01%AMN118ML@ FLUOCIN SCLP OIL 0.01% SET 4Z@ FLUOCINON CRM 0.05% ACTA 15GM@ FLUOCINON GEL 0.05% TEV 60GM FLUOCINON ONT 0.05% TEV 15GM@ FLUOCINO TS 0.05% COUN 20ML@ HYDROCORT CRM 2.5% TAR 28.35GM PROCTOZ HC CRM 2.5% RIS 30GM HYDROCORT LOT 2.5% FOUG 2OZ@ HYDROCORT OINT 2.5% PERR454GM@ CORTIFOAM 15GM GRX HICORT SUPP 25MG GER 12 TRIAMCIN CRM 0.025% FOUG 15GM@ TRIAMCINOL CRM Q/P 30GM/0.1%@ TRIAMCIN CRM 0.5% FOUG 15GM@ TRIAMCIN LOT 0.025% MOR 2OZ@ TRIAMCIN LOT 0.1% Q/P 60ML@ TRIAMCIN OINT .025% FOUG 80GM@ TRIAMCIN OINT 0.05% CMP 430GM TRIAMCIN OINT 0.1% FOUG 15GM@ TRIAMCIN OINT 0.5% PERR 15GM@ PHENAZ TAB 100MG ECI 100@ PHENAZ TAB 200MG ECI 100@ TRETINOIN CRM .025%SPEA45GM@ TRETIN CREAM 0.05% SPEA 20GM@ GenericName NYSTATIN/TRIAMCIN NYSTATIN/TRIAMCIN TERCONAZOLE LINDANE LINDANE PERMETHRIN PERMETHRIN SILVER SULFADIAZINE BETAMETHASONE DIPROPIONATE BETAMETHASONE DIPROPIONATE BETAMETHASONE DIPROPIONATE BETAMETHASONE VALERATE BETAMETHASONE VALERATE BETAMETHASONE VALERATE BETAMETHASONE/PROPYLENE GLYC BETAMETHASONE/PROPYLENE GLYC CLOBETASOL PROPIONATE CLOBETASOL PROPIONATE CLOBETASOL PROPIONATE CLOBETASOL PROPIONATE CLOBETASOL PROPIONATE/EMOLL DESONIDE DESONIDE FLUOCINOLONE ACETONIDE FLUOCINOLONE/SHOWER CAP FLUOCINONIDE FLUOCINONIDE FLUOCINONIDE FLUOCINONIDE HYDROCORTISONE HYDROCORTISONE HYDROCORTISONE HYDROCORTISONE HYDROCORTISONE ACETATE HYDROCORTISONE ACETATE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE TRIAMCINOLONE ACETONIDE PHENAZOPYRIDINE HCL PHENAZOPYRIDINE HCL TRETINOIN TRETINOIN Generic Dose Form CREAM (G) OINT. (G) CREAM/APPL LOTION SHAMPOO CREAM (G) LIQUID CREAM (G) CREAM (G) LOTION OINT. (G) CREAM (G) LOTION OINT. (G) CREAM (G) OINT. (G) CREAM (G) LOTION OINT. (G) SOLUTION CREAM (G) CREAM (G) OINT. (G) OIL OIL CREAM (G) GEL (GRAM) OINT. (G) SOLUTION CREAM (G) CREAM/APPL LOTION OINT. (G) FOAM/APPL SUPP.RECT CREAM (G) CREAM (G) CREAM (G) LOTION LOTION OINT. (G) OINT. (G) OINT. (G) OINT. (G) TABLET TABLET CREAM (G) CREAM (G) Dose Strength Description Name 100000-0.1 100000-0.1 0.40% 1% 1% 5% 1% 1% 0.05% 0.05% 0.05% 0.10% 0.10% 0.10% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.01% 0.01% 0.05% 0.05% 0.05% 0.05% 2.50% 2.50% 2.50% 2.50% 10% 25 MG 0.03% 0.10% 0.50% 0.03% 0.10% 0.03% 0.05% 0.10% 0.50% 100 MG 200 MG 0.03% 0.05% Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 841600 CELL STIMULANTS AND PROLIFERANTS 842800 KERATOLYTIC AGENTS 842800 KERATOLYTIC AGENTS 845004 DEPIGMENTING AGENTS 848000 SUNSCREEN AGENTS 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 849200 SKIN AND MUCOUS MEMBRANE AGENTS, MISC. 861600 RESPIRATORY SMOOTH MUSCLE RELAXANTS 861600 RESPIRATORY SMOOTH MUSCLE RELAXANTS 881600 VITAMIN D 881600 VITAMIN D 881600 VITAMIN D 881600 VITAMIN D 881600 VITAMIN D 882400 VITAMIN K ACTIVITY 920400 ALCOHOL DETERRENTS 920800 5-ALPHA-REDUCTASE INHIBITORS 921600 ANTIGOUT AGENTS 921600 ANTIGOUT AGENTS 921600 ANTIGOUT AGENTS 922400 BONE RESORPTION INHIBITORS 922400 BONE RESORPTION INHIBITORS 922400 BONE RESORPTION INHIBITORS 922400 BONE RESORPTION INHIBITORS 922400 BONE RESORPTION INHIBITORS 922400 BONE RESORPTION INHIBITORS 923600 DISEASE-MODIFYING ANTIRHEUMATIC AGENTS 923600 DISEASE-MODIFYING ANTIRHEUMATIC AGENTS 924400 IMMUNOSUPPRESSIVE AGENTS 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name TRETINOIN CREAM .1% SPEA 45GM@ TRETIN GEL 0.01% SPEA 15GM@ TRETINOIN GEL 0.025% ROUS15GM@ TRETIN GEL MICR .04% SPEA20GM@ TRETIN GEL MICR .1% SPEA 20GM@ TRETIN GEL MICR .04% SPEA50GM@ TRETIN GEL MICR .1% SPEA 50GM@ TRETINOIN EMOL 0.05% SUNV 40GM BENZOYL GEL 5% MMP 1.5OZ@ CARB-O-PHILIC CRM 40% GER 3OZ MELPAQUE HP 4% CRM STRA 1OZ@ NUQUIN HP CRM 4% 1OZ AZELEX CREAM 20% 30GM CALCIPOTR CRM .005% PRAS 60G@ CALCIPOTR OINT 0.005% TAR60GM@ CALCIPOTR T/S 0.005% HI-T 60ML FLUOROUR CRM 5% TAR 40GM@ IMIQUIMOD CRM 5% PERR 12 ELIDEL CREAM 1% 100GM CONDYLOX GEL 0.5% 3.5GM PODOFIL T/S 0.5% WAT 3.5ML@ THEOPHY ER TAB 100MG AVK 90 THEOPHY ER TAB 300MG AVK 90 CALCITRIOL CP.25MCG UD AHP100 CALCITRIOL 0.5MCG CAP GOLD 100 VIT D CAP 5000IU MMP 100 VIT D3 50,000 IU NIVA 12 VITAMIN D CAP 1.25MG STR 100 MEPHYTON TAB 5MG 100 DISULFIR TAB 250MG ROX 30 FINASTER TAB 5MG MYLN 30@ ALLOPURINOL 100MG TAB GOLD 90 ALLOPURINOL TAB 300MG 30 NSTR COLCHICINE TB 0.6MG PRAS 100@ ALENDRONAT TB 10MG UD UDL 20@ ALENDRONATE 35MG VIRT 4 @ ALENDRONAT TB 5MG TEV 30@ ALENDRONAT SOD TB 70MG SUN 4@ RISEDRONATE SOD 35MG TAB ACT 4 RISEDRONATE TAB 5MG TEVA 30@ LEFLUNOM TAB 10MG TRIG 30@ LEFLUNOM TAB 20MG TRIG 30@ AZATHIOPRIN TAB 50MG AMN 100@ TRUECONTROL G/S LVL0 M5H01-83 TRUECONTROL G/S LVL1 M5H01-80 TRUE TEST CONT L2 3ML E5H01-81 TRUERESULT METER E4H01-81 AEROCHAMBER+MASK SML 013535 GenericName TRETINOIN TRETINOIN TRETINOIN TRETINOIN MICROSPHERES TRETINOIN MICROSPHERES TRETINOIN MICROSPHERES TRETINOIN MICROSPHERES TRETINOIN/EMOLLIENT BASE BENZOYL PEROXIDE UREA HYDROQUINONE/FERRIC OXIDE DIOXYBENZONE/PDO/HYDROQUINONE AZELAIC ACID CALCIPOTRIENE CALCIPOTRIENE CALCIPOTRIENE FLUOROURACIL IMIQUIMOD PIMECROLIMUS PODOFILOX PODOFILOX THEOPHYLLINE ANHYDROUS THEOPHYLLINE ANHYDROUS CALCITRIOL CALCITRIOL CHOLECALCIFEROL (VITAMIN D3) CHOLECALCIFEROL (VITAMIN D3) ERGOCALCIFEROL (VITAMIN D2) PHYTONADIONE DISULFIRAM FINASTERIDE ALLOPURINOL ALLOPURINOL COLCHICINE ALENDRONATE SODIUM ALENDRONATE SODIUM ALENDRONATE SODIUM ALENDRONATE SODIUM RISEDRONATE SODIUM RISEDRONATE SODIUM LEFLUNOMIDE LEFLUNOMIDE AZATHIOPRINE BLOOD-GLUCOSE CONTROL HIGH BLOOD-GLUCOSE CONTROL LOW BLOOD-GLUCOSE CONTROL NORMAL BLOOD-GLUCOSE METER INHALER ASSIST DEVICES Generic Dose Form CREAM (G) GEL (GRAM) GEL (GRAM) GEL (GRAM) GEL (GRAM) GEL W/PUMP GEL W/PUMP CREAM (G) GEL (GRAM) CREAM (G) CREAM (G) CREAM (G) CREAM (G) CREAM (G) OINT. (G) SOLUTION CREAM (G) CREAM PACK CREAM (G) GEL (GRAM) SOLUTION TAB ER 12H TAB ER 12H CAPSULE CAPSULE CAPSULE CAPSULE CAPSULE TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET TABLET EACH EACH EACH KIT SPACER Dose Strength Description Name 0.10% 0.01% 0.03% 0.04% 0.10% 0.04% 0.10% 0.05% 5% 40% 4% 3%-5%-4% 20% 0.01% 0.01% 0.01% 5% 5% 1% 0.50% 0.50% 100 MG 300 MG 0.25 MCG 0.5 MCG 5000 UNIT 50000 UNIT 50000 UNIT 5 MG 250 MG 5 MG 100 MG 300 MG 0.6 MG 10 MG 35 MG 5 MG 70 MG 35 MG 5 MG 10 MG 20 MG 50 MG Comments Medical Access Program (MAP) Formulary- 2016 AHFS Classification 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES 940000 DEVICES Formulary? FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY FORMULARY Brand Name OPTICHAMB LGE MASK HS81311-010 LANCET MPD ULT THIN 26GA BX100 TRUEPLUS SFTY LANCET 28G 100 TRUEPLUS LANCET 30G 100 TRUEPLUS LANCET 33G M/COLR 100 TRUEPLUS LANCING DEVICE PEN NDL NOVOTWIST 30G 8MM 100 PEN NEEDL PIC IN 30G 8MM 100 PEN NDL NOVOTWIST 32G 5MM 100 PEN NDL NOVOFINE 32G 4MM 100 PEN NDL NOVOFINE 32G 6MM 100 PEN NDL ESY-T 32GX3/16 100 PEN NEEDL PIC IN 32G 8MM 100 PEAK FLOW METER PF9940 UNIFINE PENTP 12MM 1/2X29G 100 UNIFINE PENTP 6MM 31G 30 UNIFINE PENTP 5MM 31G 30 UNIFINE PENTP 8MM 31G 100 UNIFINE PENTP 4MM 32G 30 NOVOFINE AUTOCVR 30G 100 TRUEPLUS SYR .3CC 29G CT100 SYR INS S/C 3/10CC 30GX1/2 100 TRUEPLUS SYR .3CC 30G CT100 TRUEPLUS SYR .3CC 31G CT100 INS SYRNGE D/G 28GX1/2CC DS100 TRUEPLUS SYR .5CC 28G CT100 TRUEPLUS SYR .5CC 29G CT100 INS SYRINGE D/P 29GX1/2CCDS100 INS SYRNGE YEL 30GX1/2CC DS100 SYR INS S/C 1/2CC 30GX1/2 100 SYR INS MIS 0.5/30G BX100 TRUEPLUS SYR .5CC 30G CT100 TRUEPLUS SYR .5CC 31G CT100 SYR INS THNP 1/2CC 31GX3/8 100 SYR INS 1ML 27GX5/8 100 INS SYRINGE BLU 28GX1CC DS100 TRUEPLUS SYR 1CC 28G CT100 TRUEPLUS SYR 1CC 29G CT100 INS SYRINGE RED 29GX1CC DS100 INS SYRINGE PINK 30GX1CC DS100 SYR INS S/C 1CC 30GX1/2 100 TRUEPLUS SYR 1CC 30G CT100 TRUEPLUS SYR 1CC 31G CT100 SYR INS THNP 1CC 31GX3/8 CT100 GenericName INHALER ASSIST DEVICE ACCESORY LANCETS LANCETS LANCETS LANCETS LANCING DEVICE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE NEEDLES INSULIN DISPOSABLE PEAK FLOW METER PEN NEEDLE DIABETIC PEN NEEDLE DIABETIC PEN NEEDLE DIABETIC PEN NEEDLE DIABETIC PEN NEEDLE DIABETIC PEN NEEDLE DIABETIC SAFETY SYRING W-NDL DISP INSUL 0.3 ML SYRING W-NDL DISP INSUL 0.3 ML SYRING W-NDL DISP INSUL 0.3 ML SYRING W-NDL DISP INSUL 0.3 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRING W-NDL DISP INSUL 0.5 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML SYRINGE & NEEDLE INSULIN 1 ML Generic Dose Form EACH EACH EACH EACH EACH EACH DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE EACH DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DIS NEEDLE DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN DISP SYRIN Dose Strength Description Name 26 GAUGE 28 GAUGE 30 GAUGE 33 GAUGE 30GX1/3" 30GX5/16" 32 GX 1/5" 32 GX 1/6" 32G X 1/4" 32GX3/16" 32GX5/16" 29 G X1/2" 31 G X1/4" 31 GX3/16" 31 GX5/16" 32GX 5/32" 30GX1/3" 29 G X1/2" 30GX1/2" 30GX5/16" 31 GX5/16" 28 GAUGE 28GX1/2" 29 G X1/2" 29 GAUGE 30 GAUGE 30GX1/2" 30GX3/8" 30GX5/16" 31 GX5/16" 31GX3/8" 27GX5/8" 28 GAUGE 28GX1/2" 29 G X1/2" 29 GAUGE 30 GAUGE 30GX1/2" 30GX5/16" 31 GX5/16" 31GX3/8" Comments MEDICATION OVERRIDE REQUEST FORM To: MAP Pharmacy staff Request date: FAX: 512-901-9763 Telephone: 512-978-8139 Number of pages: From: Prescribing Physician/Provider Telephone number Office Contact Person Fax number Instructions: 1. Complete the Medication Override Request Form to request evaluation for nonformulary medications and interim fill 2. Use a separate form for each request. Please attached any additional supporting documentation. 3. Pharmacy staff will send a fax disposition back to the Office Contact Person. MEMBER INFORMATION Member ID: DOB: Last Name: First name: PREVIOUS MEDICATION THERAPIES FOR CONDITION (include notes and supporting documentation). 1. Medication name: Reason for change: 2. Medication name: Reason for change: 3. Medication name: Reason for change: REQUESTED MEDICATION INFORMATION Medication name: Dose: Duration: Diagnosis: Medical Necessity: D Non-Formulary Medication D Interim Fill D Other If other describe here: FOR INTERNAL USE ONLY APPROVAL: D YES D NO rev: 01-07-2016 12. COMMUNITY CARE WOMEN’S HEALTH CENTER Women’s Health Center FAX Transmittal -MAP Patients 1313 Red River, Suite 320, Austin, TX 78701 Fax- 512-279-7367 From Cli nic: Fax: Con tac t Nam e: Con tac t Phon e: Pages (i ncluding fax tra nsmi tt al) Re: NOTE: Appointment information will be faxed to the PCP clinic within 72 business hours of receiving a completed referral with all pertinent documentation. The PCP clinic is responsible for notifying the patient of the specialty appointment. Comments: The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the entity named above. If the reader of this transmission is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this transmission is strictly prohibited. If you received this transmission in error, please immediately notify us by telephone to arrange for return of the original documents. CommUnityCare Women’s Health Center Professional Office Building 1313 Red River, 3rd Floor, Suite 320 (512) 978-8870 □ From the 2nd Floor of the Parking Garage, pass the parking garage elevators and turn right. Go down a short hallway until you get to the automatic doors. When you enter through the automatic doors, you will be located on the 2nd Floor of the Professional Office Building. Take the elevador to the 3rd Floor. As you come out of the elevator, turn right and then at the corner turn right again to get to the CommUnityCare Women’s Health Center (Suite 320). Enter through the door and sign in at the check-in desk. □ □ □ □ □ Elevator Clinical Education Center (CEC) University Medical Center Labor & Delivery Brackenridge Employee Elevators Chapel Public Elevator Public Elevator Information Desk Gift Shop Second Floor Coffee Shop Parking Garage W A L K W A Y Professional Office Building CommUnityCare Women’s Health Center Suite 320 YOU ARE HERE nd 2 Floor Parking Garage Elevators ENTER ON 2nd Floor 3rd Floor Elevator Go up to Restroom 3rd Floor CommUnityCare Centro de Salud para Mujeres Edificio de Oficinas Profesionales 1313 Red River, Piso 3, Sala 320 (512) 978-8870 □ Desde Piso 2 del Estacionamiento, pase los elevadores del estacionamiento, y dase una vuelta a la derecha. □ Camine hasta que llega a la puerta automática. □ Cuando entre por la puerta automática, usted estará en el Piso 2 del Edificio de Oficinas Profesionales. □ Tome el elevador hasta Piso 3. □ Saliendo del elevador, dase una vuelta a la derecha y en la esquina otra vez a la derecha para llegar a la Clinica de Embarazo y Ginecologia (Sala 320). □ Entre por la puerta y presentese a la ventana de recepción. Elevador Centro de Educación Clinica (CEC) Centro Universitario de Medicina Brackenridge Sala de Parto Elevadores de Empleados Capilla Elevador Público Elevador Público Información Tienda de Regalos Segundo Piso Cafeteria Estacionamiento P U E N T E Edificio de Oficinas Profesionales CommUnityCare Women’s Health Sala 320 USTED ESTA AQUi PISO 2 Elevadores del Estacionamiento ENTRE EN Piso 2 Piso 3 Elevador CommUnityCare Women’s Health Brackenridge Professional Office Building CommUnityCare — Women’s Health Brackenridge Professional Office Building Table of Contents Clinic Rotation Schedule_______________________________________________________3 Genetic Counseling ___________________________________________________________4 Gynecology Clinic _____________________________________________________________5 Gynecology Clinic Worksheet ___________________________________________________6 Gyn Procedures - LEEPs & Colpos _______________________________________________9 Obstetrics Clinic _____________________________________________________________10 Guidelines for Diabetes in Pregnancy ____________________________________________18 Appendix A _________________________________________________________________22 Appendix B _____23 Appendix C _____24 Ultrasounds — Level II _____25 Pg. 2 CommUnityCare — Women’s Health Brackenridge Professional Office Building Clinic Rotation Schedule Pg. 3 CommUnityCare — Women’s Health Brackenridge Professional Office Building Genetic Counseling Scope □ Genetic Risk Assessment and Testing □ Candidates for amniocentesis must be ≤ 20 weeks gestation on the day of their genetic clinic appointment Appropriate patients for referral include: □ Advanced Maternal Age (AMA): maternal age D 35 years old at delivery and patient consents to an amnio; must watch video; see below. □ Abnormal TAST screening test; amnio may or may not be indicated □ Family history of birth defects, mental retardation, or genetic diseases □ Personal history of birth defects, mental retardation, or genetic disease □ Exposure to teratogens such as alcohol, drugs, and medications for maternal diseases (e.g. Insulin-dependent diabetes). Patient may prefer to call Texas Teratogen Information Service for free pregnancy exposure/risk counseling at 1-800-733-4727. □ Abnormal ultrasound findings (fetal abnormalities) □ Recurrent Pregnancy Loss (D 2 SAB) □ Consanguineous matings IMPORTANT! Before scheduling an appointment for genetic counseling, patient must watch video titled, “Prenatal Diagnosis of Birth Defects: Amniocentesis”. Documentation required for scheduling an appointment: □ □ □ □ Completed referral form Pertinent Lab results (TAST, hemoglobin electrophoresis, blood type, etc.) Ultrasound report(s) Title V Screening Document, if eligible NOTE: Instruct patient to report to specialty clinic appointment no earlier than 15-30 minutes prior to appointment time. Pg. 4 CommUnityCare — Women’s Health Brackenridge Professional Office Building Gynecology Clinic Scope: □ To evaluate moderate to highly complex gynecologic problems, and pre- & post- surgical patients. Appropriate patients for referral include: □ □ □ □ □ □ □ □ Post-menopausal bleeding Pelvic pain Endometriosis Missed AB & Threatened AB Abnormal gynecological diagnoses Pelvic Mass Menometrorrhagia Pelvic prolapse/urinary incontinence Please do NOT refer the following patients to the Gyn clinic: □ Desire for sterilization — Refer patient to AWH at 322-2100 for work-up and scheduling. □ Infertility Documentation required for scheduling an appointment: □ Completed referral form □ Copy of recent documentation (i.e. chart notes) □ Recently drawn labs, pap smear and gyn probe results See worksheet on next page for more information. Pg. 5 CommUnityCare — Women’s Health Brackenridge Professional Office Building Gynecology Clinic Worksheet 1. Abnormal Pap/Colposcopy/LEEP— a. ASCUS +HPV or higher (ASC-H, LGSIL, HGSIL, AGUS, CIS regardless of HPV) b. Except: □ If patient is 20 years or younger: o ASC-US, LGSIL (regardless of HPV)—repeat Pap in 1 year o If the repeat pap is ASC-US, LGSIL—repeat Pap again in 1 year o If third pap has any abnormality, refer for colposcopy □ Pregnancy o We will now start deferring colpo on LGSIL and ASCUS paps until 8 weeks Postpartum o Refer ASC-H, AGUS, HGSIL, CIS at any time c. Requires: □ Results of Pap generating referral □ Results of any previous abnormal paps, colposcopies and biopsies □ Date of last known menstrual period □ Last GC/CT (within the last year) 2. Abortion (Miscarriage)— a. Threatened, incomplete, complete, missed, etc b. Requires: □ Type and Screen, CBC, Ultrasound, all known quant HCGs, last Pap and GC/CT (within 1 year) 3. C-section staple removal— a. For Pfannensteil skin incisions, the staples should be removed prior to hospital discharge. If not, will be overbooked in next gyn clinic day. b. For vertical skin incisions, these should be booked in the resident’s continuity clinic 7-10 days after the surgery was done. BOTH OF THESE APPOINTMENTS SHOULD BE MADE BY THE RESIDENT AND PLACED ON THE CHART PRIOR TO THE PATIENT’S DISCHARGE FROM THE HOSPITAL. c. If this is being generated by an outside source, requires: □ Patient name and contact information □ Location, date and type of surgery (C-section with or without BTL) 4. Ectopic pregnancy— a. Call L&D attending cell phone for further direction 450-3775 Pg. 6 CommUnityCare — Women’s Health Brackenridge Professional Office Building G yn ec ol o g y C li n i c W o r ks h e et ( c o n ti n ue d) 5. Foley catheter following gyn surgery done at Brackenridge— a. Should be scheduled by resident surgeon into resident’s continuity clinic prior to patient’s discharge from hospital b. If not, then should be scheduled into continuity clinic of the resident who did the surgery c. If this is being generated by an outside source, requires: □ Patient name and contact information, □ Date, location of surgery, and type of surgery (as best can be determined) 6. Infertility— a. We cannot accept patients for this referral. b. Patients can be referred to Texas Fertility Center 7. IUD insertion— a. We cannot accept patients for this referral. b. Patients should be referred to primary care provider. 8. IUD removal— a. Can be scheduled in gyn clinic; b. If unable to be removed in gyn clinic, will require internal referral via Dr. Held for treatment/removal at AWH. c. Requires: D Last note documenting reason for referral, last Pap and GC/CT, ultrasound if done (i.e., if there are not strings noted so that intrauterine placement can be determined) 9. Molar Pregnancy— a. Call L&D attending cell phone for further direction 450-3775 10. Post-Op D&Cs— a. Should be scheduled in resident surgeon’s continuity clinic by the resident. b. If not, is scheduled in resident surgeon’s continuity clinic c. Requires (if referral from outside): □ Patient name and contact information, □ Date and location of surgery Pg. 7 CommUnityCare — Women’s Health Brackenridge Professional Office Building G yn ec ol o g y C li n i c W o r ks h e et ( c o n ti n ue d) 11. Postmenopausal Bleeding— a. Vaginal bleeding after 6 months or more of amenorrhea b. Requires: □ Last Pap and GC/CT (within last year), □ pelvic ultrasound, □ CBC, TSH, □ clinic notes discussing issue/referral 12. Pelvic Pain— a. Requires: □ Last Pap and GC/CT (within last year), □ All clinic notes addressing this issue 13. Endometriosis— a. Requires: □ Last Pap and GC/CT (within last year), □ All clinic notes addressing this issue 14. Pelvic Mass— a. Requires: □ Last Pap and GC/CT (within last year), □ Copies of any imaging studies done, □ All clinic notes addressing this issue 15. Menometrorrhagia— a. Requires: □ Last Pap and GC/CT (within last year), □ CBC, TSH, □ All clinic notes addressing this issue 16. Pelvic Prolapse/Urinary Incontinence— a. Requires: □ Last Pap and GC/CT (within last year), □ UA with C/S, □ Clinic notes addressing this issue 17. Sterilization— a. We do not accept referrals for this; refer these patients to AWH 322-2100 Pg. 8 CommUnityCare — Women’s Health Brackenridge Professional Office Building Gyn Procedures - LEEPs & Colpos Scope □ To perform LEEPs and Colpos. Appropriate patients for referral into Gyn Procedures include: □ Abnormal PAP results □ Cervical Dysplasia Documentation required for scheduling an appointment: □ □ □ □ Pap results Biopsy results Gen probe Colpo Target Sheet or NextGen GYN Colposcopy document (needed for LEEPs only) NOTE: Instruct patient to report to specialty clinic appointment no earlier than 15-30 minutes prior to appointment time. Pg. 9 CommUnityCare — Women’s Health Brackenridge Professional Office Building Obstetrics Clinic (OB High Risk, OB Diabetes and OB Testing) Scope: □ To evaluate high-risk obstetric patients. Appropriate patients for referral include: □ Hypertension (Chronic or Pregnancy Induced) □ Diabetes — refer to OB Diabetic Clinic on Mondays if diabetes management is desired. Nutrition counseling without diabetic management is also available. □ History of spontaneous abortions or premature births □ Placenta Previa / Preterm Labor: o If Suspected — refer to USG Clinic o If Diagnosed w/ previous USG — refer to OB High Risk Clinic □ Late Entry into Care (No prenatal care prior to 30 weeks gestation) □ Multiple Gestation □ Previous C-section □ Large/small for dates — refer only after evaluated by an OB physician. □ Post Date — refer to OB Testing Clinic □ Cholestasis of pregnancy □ Breech > 36 weeks □ Medical disorders complicating pregnancy including: o AIDs/HIV positive o Thyroid Disorder o Renal Disorder o Drug Dependence o Lupus o Seizure Disorder Documentation required for scheduling an appointment: □ Completed referral form □ ACOG (IOB) Forms □ Results of recent labs and pathology results (i.e. pap smears and biopsies) NOTE: Instruct patient to report to specialty clinic appointment no earlier than 15-30 minutes prior to appointment time. See worksheet on next page for more information Pg. 10 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t 1. Abnormal TAST— a. Needs an ultrasound to confirm dates □ If dates confirmed, then referral is to genetics to discuss amniocentesis □ Genetics can only be scheduled if gestation is <20 weeks b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ results of abnormal TAST, □ copy of ultrasound confirming dates 2. Amniocentesis—(For AMA or other genetics reasons, requires genetics referral) a. Genetics can only be scheduled if gestation is <20 weeks b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including TAST if done), □ Pap and GC/CT, □ copy of ultrasound (if done) 3. C-section scheduling—(if does not meet dating criteria) a. Previous C-section-b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of any ultrasounds 4. Anatomy scan (Level II Ultrasound or Targeted Ultrasound)— a. Reserved for patients with concerns on routine scan done at NE, HROB, or at a radiology facility (ie ARA) b. If for AMA, patient should see genetics first, and must be sent before 20 weeks gestation. c. Requires: □ IOB and master EMR coy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of ultrasound generating referral Pg. 11 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 5. Diabetes (pregnant)— a. See Guidelines for Diabetes in Pregnancj at end of Obstetrics Clinic Worksheet. b. Known diagnosis of diabetes prior to pregnancy (please send information on how long patient has been a diabetic, pre-pregnancy medications and treatment, pre-pregnancy diabetes complications, and last hemoglobin A1C (done within the last 3 months) c. Requires: □ IOB □ all prenatal labs □ copy of ultrasound (to document viability or if before viability, all quantitative HCGs) □ results of GTT testing, hemoglobin A1C, with information as noted below in Guidelines for Diabetes in Pregnancy □ if known diabetic, 24 hour urine for protein and creatinine clearance, TSH, free T4, TAST (if appropriate) 6. Genetics— a. AMA; abnormal TAST; family history of birth defects, mental retardation, or genetic diseases; personal history of birth defects, mental retardation or genetic disease; exposure to teratogens, abnormal ultrasound findings, recurrent pregnancy loss (2 or more), consanguineous mating b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including TAST, hemoglobin electrophoresis, Pap, GC/CT), □ documentation of specific reason for referral and all supporting information, □ copy of any ultrasounds done 7. NST— a. Postdates pregnancy (41 wks) or A1 (diet controlled) GDM (40 weeks) b. Done on Mon, Tues, Thurs and Fri (Mon, Thurs, Fri preferred) c. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs including Pap, GC/CT, GBS and date of its collection, □ copy of all ultrasounds 8. Pregnancy and Hypertension (Chronic or Pregnancy Induced)— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ Prenatal labs (including Pap and GC/CT), TSH, Free T4, 24 hour urine for creatinine clearance and total protein Pg. 12 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 9. History of 2 or more spontaneous abortions (<14 wks)— a. Genetics referral (see above); b. Send Lupus Anticoagulant and Anticardiolipin Antibodies; if abnormal, then refer. c. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), □ abnormal lab results as above 10. Pregnancy and history of previous second trimester loss (14-24 weeks)— a. Send Lupus Anticoagulant and Anticardiolipin Antibodies, Protein C, Protein S, Factor V Leiden, Antithrombin III, MTHFR mutation b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), lab results as above 11. Pregnancy and history of premature birth (24-36 weeks)— a. Provide protection against recurrent preterm birth b. Requires: □ Singleton pregnancy 15-24 weeks with a documented previous delivery prior to 37 weeks. □ No multiple gestations known fetal anomaly, progesterone or heparin use in this pregnancy, current or planned cervical cerclage, CHTN requiring medication, seizure disorder, delivery planned outside of Brackenridge or AWH. □ Ultrasound required between 14 and 20-6/7 weeks to confirm dating and identify major fetal abnormalities. □ Must sign release of information to obtain records from previous pregnancy ending in preterm delivery (singleton between 20 and 36-6/7 weeks gestation due to spontaneous preterm labor or PPROM). □ Patient must be willing to attend weekly appointments at HROB and receive weekly progesterone shots from 24-37 weeks of pregnancy □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), □ copy of all ultrasounds Pg. 13 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 1. Placenta Previa— a. Confirmed by ultrasound between 24-28 weeks of gestation b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), □ copies of all ultrasounds; □ DO NOT COLLECT PAP AND GC/CT IF NOT DONE PRIOR TO 24-28 WEEK DIAGNOSIS 2. Multiple gestation— a. Confirmed by ultrasound (we must have a copy of this ultrasound) b. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), □ copies of all ultrasounds 3. Large/small for dates— a. Only refer once confirmed by OB physician; Fundal height must be more than 3 cm off of gestational age b. Requires: □ OB and master EMR copy (which includes all prenatal visits and info to date), □ prenatal labs (including Pap and GC/CT), □ ultrasound done (either by ARA or NE) confirming <10% EFW for gestational age, >90% EFW for gestational age, AFI<5cm or AFI >25cm 4. Cholestasis of pregnancy— a. Pruritis without skin changes; Elevated liver function tests; Elevated fasting bile acids b. Requires: □ Pruritis without skin changes with either (or both) elevated liver function tests or elevated fasting bile acids □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copies of abnormal labs, □ copies of any ultrasounds 5. Breech >36 weeks— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copies of any ultrasounds Pg. 14 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 6. HIV/AIDS and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ most recent viral load and CD4 count, □ Hepatitis C antibody, □ any ultrasounds, □ copies of last clinic notes detailing disease diagnosis, co-morbid conditions or defining illnesses and treatment 7. Thyroid disorder and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), TSH, Free T4, □ any ultrasounds, □ copies of last clinic notes detailing thyroid disease diagnosis and duration of disease and treatment, □ copy of last endocrine consultation if done. 8. Renal disorder and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of any ultrasounds done (pregnancy or renal), □ copies of last clinic notes detailing renal disorder/diagnosis, duration of disease and treatment, □ copy of last renal consultation if done, □ 24 hour urine protein for creatinine clearance and total protein, CMP (complete metabolic panel) with calcium and phosphorus 9. Drug Dependence and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ urine and serum drug screen results, □ copy of any ultrasounds done, □ copies of last clinic notes outlining drugs of use/abuse and duration as well as past treatment Pg. 15 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 10. Lupus and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ 24 hour urine for creatinine clearance and total protein, □ ANA, anti-Ro and anti-La antibodies, CMP (complete metabolic panel) with calcium and phosphorus, □ copy of any ultrasounds done, □ copy of last clinic notes detailing diagnosis, duration of disease, manifestations, treatment, □ copy of last rheumatology consult if done 11. Seizure disorder and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of last CT scan and EEG if done, □ copy of last neurology consult if done, copy of any ultrasounds done a. At time of recognition of need for referral, start patient on 4mg folic acid daily 12. Mental illness and pregnancy— a. We do not accept referrals for this diagnosis. Please refer to MHMR or private psychiatry. If there are any questions regarding the safety of psychiatric medications in pregnancy, please call the L&D cell phone (450-3775), and the appropriate follow-up can be arranged. Patient may prefer to call Texas Teratogen Jnformation Service for free pregnancy exposure/risk counseling at 1800-733-4727. 13. Cardiac disease and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of any ultrasounds done, □ last EKG if done, □ last echo if done, □ last cardiology consultation if done, □ last clinic notes detailing diagnosis and treatment Pg. 16 CommUnityCare — Women’s Health Brackenridge Professional Office Building O b s te tr ics C li ni c W o r k s h ee t (c o n ti n ue d) 14. Hepatic disease and pregnancy— a. Requires: □ IOB and master EMR copy (which includes all prenatal visits and info to date), □ all prenatal labs (including Pap and GC/CT), □ copy of any ultrasounds done, liver function tests, coagulation tests (PT, PTT, INR), hepatitis panel, □ last GI consultation if done, □ last abdominal ultrasound if done, □ last clinic notes detailing diagnosis and treatment Pg. 17 CommUnityCare — Women’s Health Brackenridge Professional Office Building Guidelines for Diabetes in Pregnancy Effective Date 7/1/11 *This document does not define a standard of care, nor is it intended to dictate an exclusive course of management. There are other accepted strategies for the management of diabetes in pregnancy. I. Screening for gestational diabetes mellitus (GDM) (from Metzger BE, et al. Diabetes Care 2010, 33:676-681) A. Universal screening at 24-28 weeks. If pregestational diabetes is present by history, then screening is not necessary. Management will be with insulin. Further assessment as described in Appendix A. B. Selected screening early in pregnancy should be performed at the first prenatal visit. 1. Indications for select early screening: a. History of gestational diabetes in a prior pregnancy b. Previous macrosomic infant (>4000 gm) c. Family history of diabetes in first degree relative d. Obesity (BMI > 30) e. Unexplained stillbirth in previous pregnancy f. Maternal age at delivery to be > 35 2. Diagnostic Criteria for overt diabetes (to be measured on high risk women described as above) First prenatal visit Measure AIC (this is the preferred method; others listed below) To diagnose overt diabetes in pregnancy Measure of glycemia FPG‡ A1C‡ Random plasma glucose Consensus threshold >7.0 mmol/l (126 mg/dl) >6.5% (DCCT/UKPDS standardized) >11.1 mmol/l (200 mg/dl) + confirmations * ‡One of these must be met to identify the patient as having overt diabetes in pregnancy. sIf a random plasma glucose is the initial measure, the tentative diagnosis of overt diabetes in pregnancy should be confirmed by FPG or A1C using DCCT/UKPDSstandardized assay 3. If overt diabetes is diagnosed, then treatment and follow-up as for preexisting diabetes. Refer to High Risk OB (HROB). 4. If results are not diagnostic of overt diabetes and fasting plasma glucose >5.1 mmol/l(92 mg/dl) but <7.0 mmol/l (126 mg/dl), then diagnose as GDM. Management as described in section II and III of this document. It the fasting plasma glucose is <5.1 mmol/l (92 mg/dl), test for GDM from 24 to 28 weeks’ gestation with a 75-g OGTT Pg. 18 CommUnityCare — Women’s Health Brackenridge Professional Office Building G uid e li ne s f o r D ia b e tes i n P r e g na nc y (C o nti n u e d) C. If the early screen at first prenatal visit is negative (<5.1 mmol/1 or <92 mg/dl), then repeat at 24-28 weeks. Screen with a 2hr 75gm oral glucose tolerance test (75gm OGTT) D. Screen with 75 gm oral glucose tolerance test: 1. Diagnostic Criteria: 1. Positive screen when any one or more values is elevated 2. Method: 1. At least 8 hours of fasting prior to 75gm glucose screen 1. Fasting blood glucose followed by a 2 hour 75gm oral glucose tolerance test 2. Plasma glucose at 1, and 2 hours after ingestion of glucose 3. Diagnosis of gestational diabetes: at least one abnormal value: Fasting > 92 mg/dl 1 hour > 180 mg/dl 2 hour > 153 mg/dl 4. Diagnosis of overt diabetes if fasting plasma glucose is > 126 mg/dl. Refer to HROB. Management with insulin and further assessment as described in Appendix A. II. Management A. Refer to Diabetes Education (see Appendix B for summary of education) B. Diet 1. Arrange Nutritional counseling 2. IDEAL body weight (IDBW): 5 ft= 100lb. + 5lb. for every inch >5 ft. 3. Caloric intake: 30K cal/kg/day if body weight is IDBW +/- 20%. This may be adjusted by dietician depending on body weight. 4. CHO, 40%; Protein, 20%- 30%; fat, 20%-30%. 5. 3 Meals and 2- 3 snacks daily. C. Glucose monitoring four times daily: Fasting and 2hr glucose after breakfast, lunch and dinner D. Issue Glucometer and give education. A glucose log must be kept by patients. Check fasting glucose and 2 hours after main meals (2 hr pc); four times daily. Record mean fasting and mean 2 hr pc values each visit in the progress note. E. If the mean fasting glucose is greater than 92 mg/dl, or the mean 2 hour post prandial glucose is greater than 120 mg/dl, refer the patient to the High Risk Obstetrics clinic within one week. F. If the mean fasting glucose is greater than 120 mg/dl or if 2 hour glucose mean is greater than 200 mg/dl then, this patient needs immediate evaluation. Consult with the UMCB faculty at 512-450-3775. Pg. 19 CommUnityCare — Women’s Health Brackenridge Professional Office Building G uid e li ne s f o r D ia b e tes i n P r e g na nc j ( C o nti n ue d) III. Therapy — women needing therapy other than diet should be referred to HROB. A. Insulin (Humulin) Initial calculation for total dose: .8 units/kg/IBW daily — first trimester .9 units/kg/IBW daily — second trimester 1.0 units/kg/IBW daily — third trimester 2/3 AM (3/4 NPH, ¼ Humalog) — @ breakfast 1/3 PM (1/2 NPH, ½ Humalog) — Humalog @ supper; NPH @ bedtime snack B. Oral Agent Therapy — see Appendix C. In general this is reserved for gestational diabetes only. Overt or pre- existing diabetes should be managed with insulin in almost all cases. IV. V. Antenatal Testing A. A1 diabetes Fetal movement chart at 36 weeks NST twice weekly at 40 weeks B. A2 diabetes (uncomplicated) Fetal movement chart at 28 weeks NST weekly at 32 weeks; twice weekly at 36 weeks C. Pregestational or overt diabetes (uncomplicated) Fetal movement chart at 28weeks NST twice weekly at 32 weeks D. Diabetes complicated by hypertension, other evidence of vascular disease, renal or eye involvement, or other significant medial or obstetric complications. Fetal movement chart at 28 weeks NST twice weekly at 28 weeks E. Other interventions and testing as indicated by clinical finding Delivery A. Al diabetes at 4l weeks B. Medically managed or insulin dependent diabetes 38.5 to 40 weeks depending on control and patient reliability C. Delivery prior to 38.5 week may require amniocentesis for pulmonary maturity, unless an absolute indication for delivery based on maternal or fetal condition exists. There is considerable controversy surrounding this issue. Pg. 20 CommUnityCare — Women’s Health Brackenridge Professional Office Building A p p e nd ix A Early Assessment (< 20 weeks) - Overt or Pregestational Diabetes MATERNAL Physical Exam Evaluate for: Possible Tests Recommendation HTN Retinopathy EKG Retinal evaluation Goiter Nephropathy T4, TSH 24 hr urine Collection for Cr. Cl. Ophthalmology Consult Consult with appropriate Medical or MFM consult if and total protein, and required urine culture Obesity Glucometer (test 4 times daily) Glycemic Control Nutritional Counseling Nutritional Counseling regarding obesity Hb A1C Diabetic Counseling Dietician consult FETA L Gestational Age Assessment Physical Exam Early ultrasound if possible Anatomic Assessment Appropriate fetal screening MFM Consult in all cases (1st or 2nd trimester ultrasound for dating) MS-AFP at 15 0/7 (even if they had a 1st trimester screening) This is valid through 20 0/7 weeks Targeted ultrasound at 18 -22 weeks for anatomy Fetal echocardiogram at 24 weeks Pg. 21 CommUnityCare — Women’s Health Brackenridge Professional Office Building A p p e nd ix B Guidelines for Diabetes Education 1. Patients new to the OB Diabetic Clinic are provided education on Mondays, in a class setting. Education is provided in the client’s primary language. The template is for 3 classes of 4 patients each at 8:30am, 10:00 am and 11:30 am. Patients are instructed on importance of good control of blood sugar during pregnancy, as well as possible complication with poor control. Patients are encouraged to walk for exercise, unless medically prohibited. They are also instructed on exercise precautions. They are instructed on use of the glucose log, timing of testing for fasting and 2 hours after meals, and glucose logs. MAP patients are provided with a Contour Meter and instructed in its use as well as in the use of the control solution. Documentation is recorded in NextGen. 2. Patients are counseled on a 2000 calorie Gestational Diabetes meal plan of 3 meals and 3 snacks. Reference materials are provided for the meal plan, food safety, risk reduction of Type 2 Diabetes (when applicable) and healthy food habits for infants and children. Food models are used to demonstrate sample meals, snacks and food portion sizes and patients are evaluated on their knowledge of foods high in carbohydrates. Patients are also provided with a 1 week food log to record their intake and are asked to return it at their next clinic visit. The dietitian will review the food log with the patient and provide feedback. Documentation is recorded in NextGen. 3. Tuesdays, the dietitian and nurse educator are available in the clinic to follow up on patients taught the previous week in class, to teach patient needing Glyburide or insulin and to see any patients referred by the physician. We like to follow up with any patients who have been discharged from the hospital. 4. Please order insulin dose in increments of 2. We try to teach all patients needing insulin on the 1 cc insulin syringes which are marked only in 2’s, so even numbers of insulin can confusing to our clients. Pg. 22 CommUnityCare — Women’s Health Brackenridge Professional Office Building A p p e nd ix C Oral Agent Therapy for Gestational Diabetes (NEJM 2OOO: 343:1134-8) Hyperglycemia Not Controlled by Diet and requiring Therapy Physician review. Decision to start Glyburide Start Glyburide 2.5 mg q. a.m. Follow up in One Week Patient Experiencing Hypoglycemia Yes Consider decreasing oral agent and change food plan No Blood Glucose Improving as expected Yes Patients remains on oral agent. No Increase Oral Agent (Glyburide) Recommended Dose Adjustments (mg) Increase once weekly Up to 6 week period Start a.m. Next a.m. Next am-pm Next am-pm Max am-pm 2.5 mg 5 mg 5mg/lOmg lOmg/5mg lOmg/lOmg am = before breakfast pm = bedtime Pg. 23 Glucose control achieved? Yes No Continue dose Switch to insulin CommUnityCare — Women’s Health Brackenridge Professional Office Building Ultrasounds — Level II Scope: □ To perform Level II Targeted Ultrasounds for high-risk OB patients. Appropriate patients for referral into include: □ Rh disease □ Fetal anomaly identified on a prior scan □ Targeted anatomy scan for diseases and situations where there is a known risk of increased incidence of fetal abnormalities (e.g. seizure disorder, Class B Diabetes, Congenital Heart Disease) □ Targeted anatomy scan for history of a prior infant with an abnormality □ Abnormal TAST and only if they want Genetic Counseling □ AMA (Advance Maternal Age) only if they want Genetic Counseling □ Targeted scan for known twins □ Growth scans for known twins □ Suspected pelvic mass □ Suspected uterine anomaly Please do NOT refer the following patients to our clinic: □ □ □ □ Level I (routine) Ultrasounds Dating/Unsure of last menstrual period Size greater/less than dates Fetal Presentation Documentation required for scheduling an appointment: □ Completed referral form □ ACOG □ Any completed USG results NOTE: Instruct patient to report to specialty clinic appointment no earlier than 15-30 minutes prior to appointment time. Pg. 24 GUIDELINES FOR DIABETES IN PREGNANCY EFFECTIVE DATE 7/1/11 *This document does not define a standard of care, nor is it intended to dictate an exclusive course of management. There are other accepted strategies for the management of diabetes in pregnancy. I. Screening for gestational diabetes mellitus (GDM) (from Metzger BE, et al. Diabetes Care 2010, 33:676-681) A. Universal screening at 24-28 weeks If pregestational diabetes is present by history, then screening is not necessary. Management will be with insulin. Further assessment as described in Appendix A. B. Selected screening early in pregnancy should be performed at the first prenatal visit. 1. Indications for select early screening: a. History of gestational diabetes in a prior pregnancy b. Previous macrosomic infant (>4000 gm) c. Family history of diabetes in first degree relative d. Obesity (BMI > 30) e. Unexplained stillbirth in previous pregnancy f. Maternal age at delivery to be > 35 2. Diagnostic Criteria for overt diabetes (to be measured on high risk women described as above) First prenatal visit Measure AIC (this is the preferred method; others listed below) To diagnose overt diabetes in pregnancy Measure of glycemia Consensus threshold FPG‡ >7.0 mmol/l (126 mg/dl) A1C‡ >6.5% (DCCT/UKPDS standardized) Random plasma glucose >11.1 mmol/l (200 mg/dl) + confirmation§ * ‡One of these must be met to identify the patient as having overt diabetes in pregnancy. §If a random plasma glucose is the initial measure, the tentative diagnosis of overt diabetes in pregnancy should be confirmed by FPG or A1C using DCCT/UKPDS-standardized assay . 3. If overt diabetes is diagnosed, then treatment and follow-up as for preexisting diabetes. Refer to High Risk OB (HROB). 4. If results are not diagnostic of overt diabetes and fasting plasma glucose >5.1 mmol/l (92 mg/dl) but <7.0 mmol/l (126 mg/dl), then diagnose as GDM. Management as described in section II and III of this document. It the fasting plasma glucose is <5.1 mmol/l (92 mg/dl), test for GDM from 24 to 28 weeks’ gestation with a 75-g OGTT Revised 6/24/11 C. If the early screen at first prenatal visit is negative (<5.1 mmol/1 or <92 mg/dl), then repeat at 24-28 weeks. Screen with a 2hr 75gm oral glucose tolerance test (75gm OGTT) D. Screen with 75 gm oral glucose tolerance test: 1. Diagnostic Criteria: 1. Positive screen when any one or more values is elevated 2. Method: 1. At least 8 hours of fasting prior to 75gm glucose screen 2. Fasting blood glucose followed by a 2 hour 75gm oral glucose tolerance test 3. Plasma glucose at 1, and 2 hours after ingestion of glucose 3. Diagnosis of gestational diabetes: at least one abnormal value: Fasting> 92 mg/dl 1 hour > 180 mg/dl 2 hour > 153 mg/dl 4. Diagnosis of overt diabetes if fasting plasma glucose is > 126 mg/dl. Refer to HROB. Management with insulin and further assessment as described in Appendix A. II. Management A. Refer to Diabetes Education (see Appendix B for summary of education) B. Diet 1. Arrange Nutritional counseling 2. IDEAL body weight (IDBW): 5 ft= 100lb. + 5lb. for every inch >5 ft. 3. Caloric intake: 30K cal/kg/day if body weight is IDBW +/- 20%. This may be adjusted by dietician depending on body weight. 4. CHO, 40%; Protein,20%- 30%; fat, 20%-30%. 5. 3 Meals and 2- 3 snacks daily. C. Glucose monitoring four times daily: Fasting and 2hr glucose after breakfast, lunch and dinner D. Issue Glucometer and give education. A glucose log must be kept by patients. Check fasting glucose and 2 hours after main meals (2 hr pc); four times daily. Record mean fasting and mean 2 hr pc values each visit in the progress note. E. If the mean fasting glucose is greater than 92 mg/dl, or the mean 2 hour post prandial glucose is greater than 120 mg/dl, refer the patient to the High Risk Obstetrics clinic within one week. Revised 6/24/11 F. If the mean fasting glucose is greater than 120 mg/dl or if 2 hour glucose mean is greater than 200 mg/dl then, this patient needs immediate evaluation. Consult with the UMCB faculty at 512-450-3775. III. Therapy — women needing therapy other than diet should be referred to HROB. A. Insulin (Humulin) Initial calculation for total dose: .8 units/kg/IBW daily — first trimester .9 units/kg/IBW daily — second trimester 1.0 units/kg/IBW daily — third trimester 2/3 AM (3/4 NPH, ¼ Humalog) — @ breakfast 1/3 PM (1/2 NPH, ½ Humalog) — Humalog @ supper; NPH @ bedtime snack B. Oral Agent Therapy — see Appendix C. In general this is reserved for gestational diabetes only. Overt or pre- existing diabetes should be managed with insulin in almost all cases. IV. V. Antenatal Testing A. A1 diabetes Fetal movement chart at 36 weeks NST twice weekly at 40 weeks B. A2 diabetes (uncomplicated) Fetal movement chart at 28 weeks NST weekly at 32 weeks; twice weekly at 36 weeks C. Pregestational or overt diabetes (uncomplicated) Fetal movement chart at 28weeks NST twice weekly at 32 weeks D. Diabetes complicated by hypertension, other evidence of vascular disease, renal or eye involvement, or other significant medial or obstetric complications. Fetal movement chart at 28 weeks NST twice weekly at 28 weeks E. Other interventions and testing as indicated by clinical finding Delivery A. A1 diabetes at 41 weeks B. Medically managed or insulin dependent diabetes 38.5 to 40 weeks depending on control and patient reliability C. Delivery prior to 38.5 week may require amniocentesis for pulmonary maturity, unless an absolute indication for delivery based on maternal or fetal condition exists. There is considerable controversy surrounding this issue. Revised 6/24/11 Appendix A Early Assessment (< 20 weeks) Overt or Pregestational Diabetes MATERNAL Physical Exam Possible Tests Recommendation EKG Retinal evaluation T4, TSH 24 hr urine Collection for Cr. Cl. and total protein, and urine culture Ophthalmology Consult Consult with appropriate Medical or MFM consult if required Evaluate for: HTN Retinopathy Goiter Nephropathy Obesity Glucometer (test 4 times daily) Glycemic Control Nutritional Counseling Nutritional Counseling regarding obesity Hb A1C Diabetic Counseling Dietician consult FETAL Gestational Age Assessment Physical Exam Early ultrasound if possible Anatomic Assessment MFM Consult in all cases Appropriate fetal st nd screening (1 or 2 trimester ultrasound for dating) MS-AFP at 15 0/7 (even if they had a 1st trimester screening) This is valid through 20 0/7 weeks Targeted ultrasound at 18 -22 weeks for anatomy Fetal echocardiogram at 24 weeks Revised 6/24/11 Appendix B CommUnityCare Diabetes and Pregnancy Clinic Guidelines for Diabetes Education 1. Patients new to the OB Diabetic Clinic are provided education on Mondays, in a class setting. Education is provided in the client’s primary language. The template is for 3 classes of 4 patients each at 9am, 10:30 am and 12 noon. Patients are instructed on importance of good control of blood sugar during pregnancy, as well as possible complication with poor control. Patients are encouraged to walk for exercise, unless medically prohibited. They are also instructed on exercise precautions. They are instructed on use of the glucose log, timing of testing for fasting and 2 hours after meals, and glucose logs. MAP patients are provided with a Contour Meter and instructed in its use as well as in the use of the control solution. Documentation is recorded in NextGen. 2. Patients are counseled on a 2000 calorie Gestational Diabetes meal plan of 3 meals and 3 snacks. Reference materials are provided for the meal plan, food safety, risk reduction of Type 2 Diabetes (when applicable) and healthy food habits for infants and children. Food models are used to demonstrate sample meals, snacks and food portion sizes and patients are evaluated on their knowledge of foods high in carbohydrates. Patients are also provided with a 1 week food log to record their intake and are asked to return it at their next clinic visit. The dietitian will review the food log with the patient and provide feedback. Documentation is recorded in NextGen. 3. Tuesdays, the dietitian and nurse educator are available in the clinic to follow up on patients taught the previous week in class, to teach patient needing Glyburide or insulin and to see any patients referred by the physician. We like to follow up with any patients who have been discharged from the hospital. 4. Please order insulin dose in increments of 2. We try to teach all patients needing insulin on the 1 cc insulin syringes which are marked only in 2’s, so even numbers of insulin can confusing to our clients. Thank you, Bea Guerra, RN and Dahlia Gamez, RN, CDE Revised 6/24/11 Appendix C Oral Agent Therapy for Gestational Diabetes (NEJM 2OOO: 343:11348) Hyperglycemia Not Controlled by Diet and requiring Therapy Physician review. Decision to start Glyburide Start Glyburide 2.5 mg q. a.m. Follow up in One Week Patient Experiencing Hypoglycemia Yes Consider decreasing or agent And change food plan No Blood Glucose Improving as expected Yes Patients remains on oral agent. No Increase Oral Agent (Glyburide) Recommended Dose Adjustments (mg) Increase once weekly Up to 6 week period Start Next Next Next Max a.m. a.m. am-pm am-pm am-pm Yes No 2.5 mg 5 mg 1Omg/1Omg Continue dose Switch to insulin 5mg/1Omg 1Omg/5mg am = before breakfast pm = bedtime Glucose control achieved? Effective date 7/1/11 13. QUICK REFERENCE: CONTACTS AND HELPFUL NUMBERS MAP Contact Information for Services Rendered On and After November 26, 2015 Department Benefits and Eligibility Verification Phone/Fax Online: www.medicaider.com/medicaid/mana ger/start.asp. Telephone: 512-978-8130 Case Management Telephone: 512-978-8300 Option 2 CCC Fax: 512-901-9787 Claims and/or Appeals (Electronic) Seton Health Plan/MediView: CCC MAP EDI Vendor ID: TCMAP Seton MAP EDI Vendor ID: SHMAP Claims and/or Appeals (Paper) Claims Customer Service CCC MAP Travis County MAP PO Box 14447 Austin, TX 78761 SHP MAP PO Box 14447 Austin, TX 78761 512-421-5664 Community Care Collaborative 1111 E. Cesar Chavez St. Austin, TX 78702 Telephone: 512-978-8300 Credentialing 512-324-3125 MAP Customer Service MAP Enrollment 512-978-8130 Health Service – authorization and medical management (UM) 512-324-3135 Secure Fax: 512-380-4253 Pharmacy Hotline Telephone: 512-978-8139 Fax: 512-901-9763 512-324-3125 Seton Health Plan Provider Relations Bus Service (Public Transportation) Capital Metro: 512-474-1200 CARTS: 512-478-7433 14. FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS MAP Enrollment Who may quality for MAP? o Travis County residents with family incomes at or below 100 percent of the Federal Poverty Index Guidelines (FPIG) and have no other health care coverage (such as Medicaid or Medicare). o Travis County residents who are disabled or elderly with incomes at or below 200 percent of the Federal Poverty Index Guidelines and have no other health care coverage (such as Medicaid or Medicare). o Travis County residents with Medicaid or Medicare will not qualify for MAP benefits. Persons who do not qualify for MAP may be eligible for other programs that offer health care services at reduced rates. What color is the MAP card? The MAP card is pink. What is the length of issuance for MAP coverage? The length of issuance for MAP coverage may range from one month to one year and is dependent on the enrollee’s circumstances as determined during the enrollment process. What if an enrollee lost her/his MAP card? An enrollee should be referred to the Customer Service Call Center at (512) 978-8130 to obtain a replacement MAP identification card. To verify coverage, visit the Provider Self Service website. What if an enrollee wants to report a change of address? An enrollee should be referred to the Customer Service Call Center at (512) 978-8130 to report a change of address. Coverage Verification How do I verify MAP coverage and co-payments? Providers can verify an enrollee’s MAP information on-line using the Provider Self-Service website using the below link: www.medicaider.com/medicaid/manager/start.asp You will find instructions on how to register for the Provider Self-Service, and reading the MAP ID card in this handbook. What if an enrollee has expired MAP coverage? Enrollees are encouraged to call the Customer Service Call Center at (512) 978-8130 two to three (2-3) weeks in advance of her or his MAP expiration date to schedule an enrollment/eligibility appointment. Pharmacy Services Which pharmacies are in the MAP network? The list of MAP network pharmacies is included in this handbook. For additional information contact the MAP Pharmacy hotline at (512) 9788139. What medications are covered by MAP? MAP covers most medications needed by enrollees. The MAP Formulary is included in this handbook. For additional information contact the MAP Pharmacy hotline at (512) 978-8139. What if the enrollee cannot tolerate generic or formulary medications? The provider may submit a Medication Override Request Form on the enrollee’s behalf. For additional information contact the MAP Pharmacy hotline at (512) 978-8139. Where can I get the Medication Override Request Form? The form is included in this handbook. For additional information contact the MAP Pharmacy hotline at (512) 978-8139. What can I do if I receive calls from enrollees about pharmacy services? All callers inquiring about pharmacy services should be directed to the MAP Pharmacy Hotline at (512) 978-8139. Compliments and Complaints What if the enrollee is not satisfied with treatment or medical care? Please encourage enrollees to discuss any concerns or questions about her or his treatment or medical care with his/her primary care provider. If the enrollee is unable to resolve issues with the primary care office, please give the enrollee our telephone number (512) 978-8150.